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ABSTRACT
Potential indications for human prolactin (hPRL) and human growth hormone
(hGH) are the support and sustainment of lactation and the enhancement or reconstitution
of the immune system when under dysregulation.

A prolactin receptor (PRLR)

antagonist, hPRL-G129R (G129R), and a PRLR and growth hormone receptor (GHR)
antagonist, hGH-G120R (G120R), have been developed which may be useful for the
treatment of breast cancer since PRLR is elevated in a majority of human breast tumors and
makes cancer cells highly sensitive to the mitogenic and anti-apoptotic activity of hPRL and
hGH.
As a single agent, G129R is more cytostatic than cytotoxic to human breast cancer
cells xenografted into nude mice; when combined with common chemotherapies (e.g.
Tamoxifen or Herceptin) G129R has additive effects. In Chapter 2, we propose to enhance the
cytotoxicity of G129R by fusing it to a toxin that potently inhibits protein synthesis. We
demonstrate that the fusion protein specifically targets the PRLR and drastically enhances the
cytotoxicity of G129R in vitro and that it can be administered safely to mice in vivo.
The low molecular weight of hPRL and G129R make it difficult to maintain
therapeutic levels in the plasma. To increase the plasma half-life we conjugated hPRL and
G129R with hydroxyethyl starch (HES); unfortunately, the ligands lost their intrinsic activities.
In Chapter 3, we propose to increase the plasma half-life of hPRL, hGH, and their respective
antagonists by fusing them to a small serum albumin binding peptide. We demonstrate that the
serum albumin binding peptide extends the plasma half-life of the ligands and enhances
the bioactivity of hPRL and hGH in vivo.
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In Chapter 4, we propose to increase the plasma half-life and make hPRL and hGH
more amendable to chemical modifications such as HESylation by fusing two molecules of
hPRL and hGH in tandem (PRL-PRL and GH-GH). We demonstrate that their intrinsic
activity is unaffected and that the plasma half-life of PRL-PRL is extended. We also fused two
molecules of G129R or G120R in tandem (G129R-G129R and G120R-G120R) and
unexpectedly ended up with agonists. This indicates that the PRLR is flexible and that the
receptor binding sites on PRL-PRL and GH-GH can potentially interact with receptors in three
different ways, reducing the probability that chemical modifications will affect their crucial
receptor binding sites.
hGH can mediate its effects via a PRLR homodimer or a GHR homodimer and there is
no reason to believe it might not also mediate its effects via a PRLR/GHR heterodimer.
Unfortunately, there is no easy way to discern which receptor hGH exploits. In Chapter 5, we
extend the findings of Chapter 4 (i.e. that the fusion of two antagonists together results in an
agonist) and propose to make two unique ligands that are only capable of binding to a
PRLR/GHR heterodimer. We confirm that PRLR/GHR heterodimers either pre-exist or can be
induced, something which has previously only been shown to occur in rudiments. Also we
made a GHR agonist, characterized it, and confirmed that it is a pure GHR agonist. This
molecule can be used in place of hGH if one only wants to observe somatogenic effects in
human cell lines.
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CHAPTER ONE
LITERATURE REVIEW
Background on Prolactin, Growth Hormone, and Chorionic Somatomammotropin
Human prolactin (PRL), growth hormone (GH), chorionic somatomammotropin
(CS) and chorionic somatomammotropin-like hormone (CS-L) are members of the
cytokine protein superfamily. Although closely related, variations between these peptide
hormones are evident at the genetic level, transcriptional level, site of expression and in
their biological properties such as receptor specificity.
Gene Structure
The genes encoding these peptide hormones are composed of five exons which
are separated by four introns. The site of the introns has remained conserved while the
length of the introns has not. PRL is encoded by a single gene (PRL) located on
chromosome 6 (Owerbach et al., 1981) and the genes encoding GH (GH1, GH2), CS
(CSH1, CSH2) and CS-L (CSHL1) are closely linked on chromosome 17 (Chen et al.,
1989; Cooke and Liebhaber, 1995). GH1 encodes normal GH (GH-N), GH2 encodes a
placental GH variant (GH-V) which differs by 13 amino acids, and CSH1 and CSH2 give
rise to identical CSs often referred to as placental lactogen (PL).
Gene Transcription
In the pituitary, transcription of the PRL and GH1 genes is mediated via the
tissue-specific transcription factor Pit-1. In extrapituitary cells, transcription of the PRL
gene occurs from a promoter located 5.8 kb upstream of the promoter used in the
pituitary. Although the regulation of PRL transcription differs the translation and signal
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sequence cleavage are identical, resulting in a single PRL isoform.

In contrast,

differential splicing of the messenger ribonucleic acid (mRNA) precursor of GH1 gives
rise to five isoforms; GH2 and CSHL1, four isoforms; and CSH1 and CSH2, three
isoforms. Translation of these altered transcripts into protein may serve as a means of
further specialization (Lewis, 1984). For example, a 20 kD isoform of GH lacking amino
acid residues 32–46 of GH-N (Lewis et al., 1980; Cooke et al., 1988) is commonly
expressed (Ishikawa et al., 1999) that exhibits identical agonism for growth hormone
receptors (GHRs) (Wada et al., 1997) but weaker agonism for prolactin receptors
(PRLRs) (Tsunekawa et al., 1999).
Site of Expression
PRL and GH-N are synthesized in the anterior lobe of the pituitary gland, are
stored in granules, and are released in a pulsatile manner in response to hypothalamic
neuropeptides and growth factors. Secretion of PRL from lactotrophs is directly under
the stimulatory and strong inhibitory control of thyrotropin releasing hormone (TRH) and
dopamine, respectively; whereas, secretion of GH-N from somatotropes is directly under
the stimulatory and inhibitory control of growth hormone releasing hormone (GHRH)
and somatostatin, respectively. Alternative promoter usage for PRL and GH1 results in
extrapituitary secretion of PRL (Gellersen et al., 1994; Sinha, 1995) and GH (Wu et al.,
1996; Liu et al., 1997). Extrapituitary production of PRL has been reported in the uterus
(decidualized endometrial stroma, myometrial layer), immune system cells (peripheral
blood lymphocytes, thymocytes, hematopoetic system cells), and more recently in the
mammary gland and breast cancers (Ben-Jonathan et al., 1996). This extrapituitary PRL
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is not stored in granules and its secretion is not regulated by neuropeptides. GH-V, CS-L
and the CSs are transcribed and secreted almost exclusively in the placenta during
pregnancy (Barrera-Saldana et al., 1983; Baumann et al., 1991).
Physiology
Physiologically, PRL, GH and PL are intimately involved in modulating
reproductive functions. Evidence suggests that these ligands induce signaling in different
compartments (Gallego et al., 2001) and that the PRLR and GHR do not have an
instructive role, but rather provide tissue specificity (Brisken et al., 2002). These ligands
regulate ovarian, mammary gland and immune functions and adjust maternal metabolism
during pregnancy and lactation. In addition, PRL, GH and PL activity is often observed
in tissues exhibiting pathology which are normally targets during the establishment of
pregnancy. PRL primarily controls mammary gland development (Horseman et al.,
1997; Ormandy et al., 1997a).

PL mimics the action of PRL on mammary gland

development, maintenance of the corpus luteum of pregnancy, and promotion of luteal
progesterone synthesis during pregnancy (Handwerger and Freemark, 1987). In addition,
PL appears to substitute for GH-N in regulating IGF-I and stimulates growth of the fetus
during pregnancy. GH-V has also been reported to replace GH-N during pregnancy
(Frankenne et al., 1988; Eriksson et al., 1989) and to modulate maternal IGF-I levels
(Hall et al., 1984).
Hormone Structure
Structurally, PRL (Keeler et al., 2003; Teilum et al., 2005), GH (de Vos et al.,
1992; Chantalat et al., 1995; Clackson and Wells, 1995) and PL (Walsh and Kossiakoff,
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2006) are similar to one another. PL is more closely related to GH than PRL (Dietz et al.,
1992; Gootwine and Yossafi, 1998), sharing 93% and 42% sequence identity, respectively. Each

hormone contains between 190-199 amino acids which are arranged into four α-helical
segments that are connected via loops, allowing the helices to be bundled in an antiparallel (up-up-down-down) manner. The structural integrity of the four-helix bundle is
maintained by intra-chain disulfide bonds and non-covalent interactions between the
helices. Two receptor binding sites are located on the surface of these peptide hormones
that are structurally distinct.
Receptor Structure
The receptors to which PRL, PL, and GH bind belong to the class 1 cytokine
receptor family.

They are characterized as forming homodimers and as having no

intrinsic kinase activity. The full length GHR and PRLR are composed of 620 and 598
amino acids, respectively. Topologically, each receptor has an N-terminal extracellular
domain involved in hormone binding and receptor dimerization, a single-pass
transmembrane domain involved in membrane anchorage, and a C-terminal intracellular
domain involved in signal transduction. Although the PRLR and GHR exhibit little
overall sequence identity, they have highly conserved sequences in their extracellular and
intracellular domains.
The tertiary structure of the extracellular domain of the PRLR and GHR are
similar due to four positionally conserved Cys residues and a Trp-Ser-X-Trp-Ser
(WSXWS) motif which stabilize the cytokine recognition site (Somers et al., 1994).
They each have fibronectin-like type III subdomains (S1 and S2) which are connected via
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a hinge region.

The N-terminal S1 domain is involved in ligand binding and the

membrane proximal S2 domain plays more of a structural role. The PRLR appears to be
more promiscuous, binding PRL, GH and PL with high affinity; whereas, the GHR only
binds GH with high affinity. The membrane proximal region of the intracellular domains
of these receptors have a conserved Box 1 motif which is the binding site for an
intracellular non-receptor tyrosine kinase, Janus-activated kinase 2 (JAK2).
Hormone-Induced Receptor Dimerization
The two structurally distinct binding sites of GH (Cunningham et al., 1991; de
Vos et al., 1992; Clackson and Wells, 1995; Sundstrom et al., 1996) each interact with a
GHR to form a trimeric 1:2 ligand-receptor complex (Cunningham et al., 1989;
Cunningham et al., 1991; de Vos et al., 1992). Binding of GH occurs sequentially with
the higher affinity Site 1 interacting with the first receptor before lower affinity Site 2
interacts with a second receptor (Cunningham et al., 1991; Fuh et al., 1992; Ilondo et al.,
1994). In addition to binding to GHRs (Hughes and Friesen, 1985), GH also binds to
PRLRs (Kleinberg and Todd, 1980) in a sequential manner (Somers et al., 1994; Goffin
and Kelly, 1997) to form a trimeric 1:2 ligand-receptor complex (Wells et al., 1993). The
binding sites of GH for GHRs (Ultsch et al., 1994) and PRLRs (Somers et al., 1994)
overlap but are not identical (Cunningham and Wells, 1991; Kossiakoff et al., 1994).
Zinc influences the binding of GH to PRLRs but not to GHRs (Cunningham et al.,
1990b) and increases its bioactivity (Dattani et al., 1993; Fuh et al., 1993) by increasing
the affinity of Site 1 for the PRLR (Somers et al., 1994; Duda and Brooks, 2003).
Likewise, PL binds to PRLRs in a sequential manner (Fuh and Wells, 1995) and is
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influenced by zinc (Lowman et al., 1991). PRL also binds to PRLRs in a sequential
manner as illustrated in Fig. 1.1A (Fuh et al., 1993; Goffin et al., 1994). This sequential
binding process has been shown to be due to the functional coupling of the receptor
binding sites. The interaction of Site 1 with the first receptor induces conformational
changes in the ligand that create a functional Site 2 (Sivaprasad et al., 2004; Walsh et al.,
2004).
Receptor-Mediated Signal Transduction
Binding of GH to GHRs and binding of GH, PL or PRL to PRLRs induces the
formation of functional receptor homodimers, leading to the autophosphorylation of
receptor-associated JAK2 (Fig. 1.1A). Activation of JAK2 can lead to the stimulation of:
(1) signal transducer and activator of transcription (STAT) 1, 3, and 5 signaling; (2)
phosphoinositide 3-kinase (PI3K)/3-phosphoinositide-dependent protein kinase 1
(PDK1)/Akt signaling; (3) Ras/Raf/MEK/mitogen-activated protein kinases (MAPKs)
signaling by interacting with the Shc/Grb2/SOS complex; and (4) protein kinase C
(PKC)/MAPKs signaling by activating phospholipase C-gamma (PLC-γ).

These

signaling pathways ultimately affect cell motility, survival, proliferation, and adhesion
(Fig. 1.1B).
Using mutagenesis and by generating truncated forms of the PRLR, it has been
demonstrated that JAK2 is necessary for PRL-induced proliferation (Chang et al., 1998).
It has further been demonstrated that JAK2 is necessary for PRL-induced differentiation
of the mammary gland (Shillingford et al., 2002). PRL-induced JAK2 activation induces
both STAT5A signaling and Shc mediated MAPK signaling (Das and Vonderhaar, 1996).
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Fig. 1.1
Illustration of the signaling pathways activated as a result of the sequential
binding of PRL to PRLRs
(A) The higher affinity binding Site 1 of PRL (helices 1 & 4) interacts with the
first PRLR before the lower affinity binding Site 2 (helix 3) can interact with a second
receptor. Functional receptor dimerization leads to the autophosphorylation of a
receptor-associated tyrosine kinase, JAK2. (B) Activated JAK2 phosphorylates the
PRLR and associated proteins leading to the activation of JAK2/STAT signaling cascade,
the PI3K/PDK1/Akt signaling pathway, and the Ras/Raf/MEK/MAPKs signaling
pathway which are mainly associated with differentiation, survival, and proliferation,
respectively.
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PRL induced JAK2/STAT5A signaling has been shown induce the expression estrogen
receptor alpha (ERα) (Frasor et al., 2001) and receptor activator of nuclear factor kappaB
ligand (RANKL) in the mammary gland (Srivastava et al., 2003) via STAT5 binding
elements within their promoters; whereas, JAK2-Shc-MAPK signaling has been shown to
induce bcl-2 expression (Das and Vonderhaar, 1996).
STAT5 activatioin in mammary epithelial cells usually only occurs during
pregnancy and lactation. Constitutively active STAT5A delays the onset of involution; in
contrast, deletion of STAT5 during pregnancy, after the mammary epithelium has entered
STAT5-mediated differentiation, results in premature cell death (Cui et al., 2004). This
suggests the activation of STAT5 signaling by PRL not only serves as a proliferation and
differentiation signal during lactation but also as a survival signal at the end of lactation.
Similar to the mammary gland, the capacity of PRL to increase survival and proliferation
of early T-cell precursors has been shown to be related with its ability to induce lymphoid
differentiation (Carreno et al., 2005). These findings suggest that the multiple biological
effects of PRL (proliferation, differentiation, survival) are not separate events.
Breast Cancer and Hormones
There are numerous hypotheses to explain how a cell is transformed and
progresses to cancer. It is generally accepted that cancer is a multi-step process caused
by genetic alterations to a cell and the clonal expansion of the altered cell.
Carcinogenesis can be divided into three stages. The first stage of cancer is initiation,
when the DNA of a cell is permanently damaged by carcinogens (hormone, virus,
radiation, trauma) and the growth of the cell is altered. These alterations result from
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mutations in proto-oncogenes, tumor suppressor genes and stability (repair-mutator)
genes. The second stage of cancer is promotion, when non-mutagenic tumor promoters
expand the tumor cell population to the point where the benign tumor cell mass starts to
interfere with normal function. The third stage is progression, when the tumor becomes
malignant and invades surrounding tissue, blood vessels, lymphatics and metastasizes to
distant parts of the body.
Role of Proto-oncogenes, Tumor Suppressors, and Stability Genes
Proto-oncogenes are genes involved in the control of cell growth.

Upon

activation by mutation or overexpression due to gene amplification an oncogene product
can drive unconstrained proliferation. An oncoprotein may induce a cell to release
growth factors (e.g. EGF) into the local environment which are utilized by the cell,
alleviating the need for external stimuli to induce cell proliferation.

It may be an

overexpressed receptor (e.g. HER2) that hypersensitizes the cell to extremely low
concentrations of growth factor, convincing the cell to grow in response to subphysiological levels of growth factor. It may be an altered receptor (e.g. mutated EGFR)
that is constitutively active and sends growth promoting signals without the need for
growth factors. Or it may be a cytoplasmic protein (e.g. c-Src and Ras) or nuclear protein
(e.g. cylin D1) that is part of the signaling cascade downstream of the receptor that is
altered in a manner that prevents its signal from being turned off by regulatory proteins.
Tumor suppressor genes are genes that negatively regulate cell growth and
proliferation. There function is lost as a result of mutations or deletions to both alleles
and are often found in familial malignancies. Many tumor suppressors turn off signal
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transduction after it has been transmitted via a receptor (e.g. PTEN). Mutations in these
tumor suppressors can lead to constitutive activation or prolonged signal transduction
after stimulation, leading to uninhibited cell proliferation. Other tumor suppressors lie
downstream and control cell cycle progression (e.g. p16-INK4A), normally blocking the
activity of cyclin-dependent kinases (CDKs) and their interaction with cyclins.
Cells have to overcome many other hurdles in addition to altering growth factor
signaling to be able to proliferate indefinitely. During progression to cancer a variety of
phenotypic changes must occur, including: insensitivity to anti-growth factor signals;
evasion of programmed cell death; immortalization; the induction of blood vessel
formation; and eventually invasion and metastasis (Hanahan and Weinberg, 2000). It is
hard to envision all of these changes occurring without considering the last class of genes
that are mutated in cancers, the stability genes. Stability genes are tumor suppressor
genes involved in DNA repair whose loss of function increases the frequency of mutation
or chromosomal rearrangements that result in loss of heterozygosity (e.g. TP53, BRCA1,
and BRCA2). When DNA is damaged, p53 accumulates and halts the cell cycle until it
has been repaired so as to prevent the copying of mutated DNA; if the DNA is damaged
beyond repair, p53 induces programmed cell death. Loss of p53 allows damaged DNA to
be incorporated and passed along to descendent cells and has been shown to increase the
chance for gene amplifications. Aneuploidy, which is a change in the number or balance
of chromosomes, is a “hallmark” of all cancer cells and can alter the expression of
thousands of genes, providing an appealing explanation for the complexity of the
abnormal phenotypes observed in cancers.
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As mentioned above, a single mutation in anyone of these genes is unlikely to
turn a normal cell into a malignant cell as originally proposed in the one-molecule one-hit
hypothesis.

This is supported by epidemiological evidence which shows that the

relationship between cancer incidence and age is not linear and that the rates increase
sharply with age (American Cancer Society., 2007). This indicates that cancer is a long
process and likely involves at least six steps (Beckman and Loeb, 2005). The current
hypothesis is that cancer arises from the accumulation of multiple gene mutations within
a cell (Knudson, 1971) and that these genetic alterations sequentially give rise to
hyperplasia, dysplasia, carcinoma in situ, and eventually cancer (Wellings et al., 1975).
It has been hypothesized that the gene mutations must be in multiple oncogenes and at
least one tumor suppressor gene. It has also been hypothesized that the first step in
transformation and perhaps the most important genetic alteration is genetic instability (Li
et al., 2000). Mutations to genes that preserve chromosomal stability, such as the breast
cancer susceptibility gene (BRCA1), inevitably lead to initiation of cancer (Rosen et al.,
2005).
Role of Growth Promoting Agents
Carcinogens include not only agents that directly promote mutations (mutagens)
but also agents that facilitate the propagation of the affected cell. Growth promoting
agents further increase the chance of mutation. The more a cell replicates its DNA the
greater the chance of a spontaneous mutation occurring. In addition, mutagens are more
effective during DNA replication. This suggests that growth promoting agents may be
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carcinogenic, even though they are not mutagenic, by shortening the time necessary to
acquire the multiple mutations necessary for cancer.
Growth Promoting Hormones Involved in Breast Development
The mammary gland is one of the few organs to undergo substantial changes
postnatally, including cycles of growth, differentiation, apoptosis, regression, and
remodeling (Topper and Freeman, 1980; Richert et al., 2000; Wiseman and Werb, 2002;
Bissell et al., 2003). The prenatal gland primarily consists of a stromal fat pad and
simple ducts that are lined with epithelial cells and a small number of stem cells critical
for development.

Development of these ducts into a functional gland is controlled

primarily by steroid and peptide hormones produced by the ovary and pituitary,
respectively. During early puberty, systemic increases in GH and estrogen stimulate the
proliferation of the ductal epithelial cells and the formation of large buds at the termini of
the ducts. Proliferation of cap cells within these terminal end buds (TEBs) results in the
extension of the ducts throughout the fat pad. Later in puberty the TEBs regress as
progesterone and PRL induce ductal branching and the formation of lobular buds. By the
end of puberty, elaborately branched ducts lined with resting lobules extend throughout
the fat pad.
Proliferation within the lobules continues to occur in response to the release of
steroid hormones from ovarian follicles during normal menstrual cycling (Ramakrishnan
et al., 2002), with the highest proliferation occurring during diestrus. During pregnancy,
increases in the systemic levels of PRL, PL, and progesterone induce the lobular
epithelial cells to proliferate and form lobulo-alveolar-like structures. At parturition, PL
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and progesterone levels fall and the lobulo-alveolar epithelial cells terminally
differentiate and form functional alveoli that produce and secrete milk proteins in
response to PRL. Upon weaning the systemic levels of PRL fall and the mammary gland
undergoes involution, at which point inflammatory cells infiltrate the lobules, the alveoli
regress, and lobules with acinar similar to those observed before pregnancy are reformed
from progenitor cells.
The changes within the lobules throughout mammary gland development have
been categorized based on their degree of differentiation (i.e. average number of ductules
per lobular unit). After puberty the TEBs differentiate into Type 1 lobules; at sexual
maturity into Type 2 lobules; during pregnancy into Type 3 lobules, and during lactation
into Type 4 lobules (Russo et al., 2001). Childless women have 65-85% Type 1 lobules,
10-35% Type 2 lobules, and 0-5% Type 3 lobules; whereas, childbearing women have
70-90% Type 3 lobules (Russo et al., 2000). Proliferation within the lobules has been
correlated with estrogen receptor alpha (ERα) and progesterone receptor (PR) expression.
As the lobules become more differentiated there are fewer cells proliferating and
expressing both ERα and PR (Russo et al., 2000). This indicates that parity reduces the
population of cells capable of proliferating in response to ovarian hormones (i.e. the cells
have differentiated).

Parous women also have significantly shorter menstrual cycle

lengths, significantly lower estrogen levels (22%) (Bernstein et al., 1985; Hankinson et
al., 1995), and lower levels of PRL in the follicular phase than at mid-cycle or during the
luteal phase of the menstrual cycle.
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Growth Promoting Hormones in Breast Cancer
Since hormones from the ovaries and pituitary have an intimate role in normal
breast development, it’s not surprising that they may strongly influence the initiation and
promotion of breast cancer. Hormones from ovaries and pituitary glands are absolutely
essential for the proliferation and differentiation of mammary epithelial cells, which are
the predominant carcinogen-susceptible cell type in the mammary gland (Imagawa et al.,
1990; Nandi et al., 1995). They play a role in the development of both hormoneindependent and hormone-dependent mammary cancers (Nandi et al., 1995).

For

example, estrogen may stimulate ER positive cells to produce a growth factor (such as
PRL) which may stimulate theirself and neighboring ER negative cells to proliferate.
Hormone imbalances are one of the major risk factors for the development of
breast cancer. When the biochemical balance of estrogens is upset they can be potent
mitogens to mammary epithelial cells and can influence tumor development by
stimulating the local production of growth factors and their cognate receptors. Estrogens,
epidermal growth factor (EGF), and heregulin have all been implicated in mammary
carcinomas and evidence suggests other factors involved in mammary gland development
may have a role too.
Role of Ovarian Hormones in Breast Cancer
Several lines of evidence indicate that hormones associated with females are
involved in precancerous ductal and lobular carcinomas in situ. First, breast cancer is
rare in men, accounting for less than 1% of all cancer cases. Second, a majority of the
risk factors associated with breast cancer are specific to women. The risk of breast
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cancer in women increases with age and has been found to be higher in women who
experience early menarche (< 12 years old) or late menopause (> 55 years of age),
indicating that the greater number of menstrual cycles (i.e. exposure to estrogen)
increases the risk factor for breast cancer; whereas, later menarche and early menopause
have been found to have protective effects. Early pregnancy (< 30 years of age) reduces
the risk of developing breast cancer; whereas, late pregnancy (>30 years of age) or
nulliparity increases the risk of breast cancer. The protective effect of parity likely
reflects the reduction in the number of responsive cells to ovarian hormones and the longterm reduction in exposure to both estrogens and PRL. Breastfeeding also provides a
degree of protection against breast cancer development. Studies have correlated the
protective effects of lactation with the permanent lowering of circulatory levels of PRL;
however, it should also be noted that prolonged lactation reduces the number of
menstrual cycles. Third, removal of the ovaries reduces the risk of breast cancer and can
cause regression of some tumors as does the irradiation of the ovaries (2000a; Metcalfe et
al., 2004; Prowell and Davidson, 2004). Fourth, prevention studies using anti-estrogens,
tamoxifen or raloxifene, have shown that they reduce the risk of breast cancer by about
half (Dunn and Ford, 2000; Cauley et al., 2001; Fisher et al., 2005; Vogel et al., 2006).
The Link Between Estrogen and Prolactin
Estrogens have been shown to mediate there effects in part by regulating PRL
signaling.

Studies have shown that the overall pattern of serum PRL during the

menstrual cycle resembles that reported for circulating 17β-estradiol (Vekemans et al.,
1977).

Neuropeptides modulated by ovarian steroids during menstrual cycling and
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lactation reduce the inhibitory effects of the hypothalamus, permitting enhanced secretion
of PRL from the pituitary (Freeman et al., 2000; Takahashi, 2004). Estrogen-induced
increases in galanin cause the lactotrophs to proliferate and release PRL. Estrogenstimulated synthesis and release of vasoactive intestinal peptide (VIP) from the
hypothalamus regulates the release of hypothalamic oxytocin which in turn causes PRL
secretion. Antiserum to estradiol or oxytocin has been shown to block the proestrous
surge of PRL and antiserum to galanin has been shown to inhibit basal PRL secretion.
These findings suggest that estrogen’s effect on hypothalamic oxytocin or galanin may be
responsible for its regulation of pituitary PRL secretion (Arey and Freeman, 1989).
Estrogen can also promote PRL transcription by activating MAPK and by
interacting with multiple estrogen response elements within the PRL promoter. This
indicates that estrogen may induce the expression of PRL outside the pituitary in ER
positive cells. It has been suggested that one of the most important actions of estrogen is
to modulate growth factor secretion in human breast cancer and that this may be the
critical event in progression of cancer (Dickson and Lippman, 1986). Consistent with
this, PRL and estrogen have been shown to cross-talk with each other to synergistically
cause mammary gland proliferation. Both the ERα and the PRLR are co-expressed in
many breast tumors (Murphy et al., 1984; Ormandy et al., 1997b). Tamoxifen has been
shown to down-regulate PRLRs in breast cancer cells (de Castillo et al., 2004), which
may indicate that estrogen increases PRLR levels. Likewise, endogenous PRL has been
shown to increase ERα levels and the responsiveness of cells to estrogens, suggesting
that PRL acting via the PRLR amplifies the effects of estrogen (Gutzman et al., 2004).
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If PRL amplifies the effects of estrogen than it undoubtedly should be associated with
breast cancer and should increase the risk.
Prolactin and Breast Cancer
Several lines of evidence support the involvement of PRL in human breast cancer
(Vonderhaar, 1998, 1999; Llovera et al., 2000a). First, PRL interacts synergistically with
estrogen and progesterone to promote cancerous growth and the receptors of these
ligands are co-expressed in primary breast cancers and have been shown to be crossregulated in mammary tumor cell lines (Ormandy et al., 1997b). Second, approximately
80% of human breast cancer cell lines tested transcribe PRL and respond to its growth
stimulatory action in vitro (Ginsburg and Vonderhaar, 1995; Das and Vonderhaar, 1997;
Ginsburg et al., 1997). Addition of exogenous PRL has a proliferative effect upon human
breast cancer cell lines (Malarkey et al., 1983) and has been reported to increase DNA
synthesis, protein synthesis and serves as a chemoattractant (Maus et al., 1999). Similarly,
PRL mRNA and protein have been detected in both normal and cancerous human
mammary tissue (Purnell et al., 1982; Fields et al., 1993) and has been shown to originate
primarily from the mammary epithelium (Clevenger et al., 1995). Third, biopsies have
revealed that a majority of human breast tumors have higher PRLR mRNA and protein
levels than surrounding and normal mammary tissue (Reynolds et al., 1997; Touraine et
al., 1998). Both PRL and the PRLR are expressed in the epithelium of a majority (>90%)
of benign and malignant human breast tissue samples (Reynolds et al., 1997), indicating
that PRL may be acting in an autocrine/paracrine manner (Clevenger et al., 1995).
Together, these observations support the hypothesis that: 1) estrogen elevates PRLRs in

17

malignant breast tissue making these cells highly sensitive to stimulation by PRL; 2) that
PRL released from the epithelial cells acts locally via the PRLR in an autocrine/paracrine
loop; and 3) that the mitogenic effects of PRL play a role in the progression to
malignancy (Fig. 1.2).
Several lines of evidence support the proposed role of PRL in tumor progression.
Sufferers of Parkinson's disease, a dopamine deficient population, have been shown to
have lower rates of breast cancer and other types of malignancies (Lalonde and
Myslobodsky, 2003). In contrast, dopamine antagonists, which increase the release of
PRL, slightly but significantly increase the risk of breast cancer (Wang et al., 2002). In a
study of 424 women, PRL levels above the median value were associated with a 2.1-fold
increase in the risk of breast cancer and a 1.7-fold increase in risk for women with benign
epithelial hyperplasia (Ingram et al., 1990). A large study showed that postmenopausal
women with high levels of PRL had an increased risk of breast cancer regardless of ER status
(Hankinson et al., 1999). A highly significant correlation was found between tumor size
and plasma PRL levels in premenopausal patients with breast cancer (Olsson et al.,
1985). The least favorable prognosis based on nodal status, tumor size and histological
grade was significantly associated with the highest PRL levels (Wang et al., 1986). High
PRL levels before surgery or high PRL levels post-mastectomy were also significantly
related to shorter disease-specific survival in postmenopausal women (Wang et al., 1995).
These findings clearly show that PRL levels are associated with breast cancer risk and
progression.

18

1

PRLR expression
PRL

5

Unknown
Kinase
Jak2Jak2

PP
PRL

PP

Jak2Jak2

PP

P
P
P Jak2Jak2 P

Jak2 Jak2

P
P

P
P

2

PP

PRL autocrine
loop

PP

PP

PRL

ase
ki n
pS

Ub

PP

Mitogenic
Signaling

PP

PP

PP
Jak2Jak2

PP
PRL

Jak2 Jak2

kinase
kinase

PRL
PRL

PP
PRL

PRL

P
P

pY
pY
pY
pY
pY

P
P

P
P
P Jak2Jak2 P

pY
pY
pY
pY
pY

P
P

K K Grb2 P

Jak2

P

P
P

P
P
P Jak2Jak2 P

32
PRL

PRL

ErbB family
receptors

4 Changes In PRLR

PRL

3 Crosstalk

Isoform Ratios

Fig. 1.2

Mechanisms exploited by breast cancer cells to sustain PRLR activation

(1) Overexpresion of PRLR may hypersensitize cells to low levels of PRL; (2)
autocrine/paracrine action of PRL can lead to constitutive activation of the PRLR; (3)
activated PRLR can exploit ErbB2 via Grb2 to sustain MAPK activation; (4) modulation
the PRLR isoforms can expand and intensify signaling; and (5) reducing the level or
activity of an unidentified kinase reduces the degradation of the PRLR after activation
leading to sustained signaling.
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Further supporting a role for PRL are rodent models. PRL has been shown to
contribute to the formation of chemical carcinogen-induced mammary carcinomas and to
accelerate tumor progression in rodents (Manni et al., 1977; Welsch et al., 1977; Welsch
and Nagasawa, 1977; Mershon et al., 1995; Tomblyn et al., 2005). Transgenic mice
expressing rat PRL or human GH were shown to have a higher incidence of breast cancer
due to signaling mediated via the PRLR (Bartke et al., 1994; Cecim et al., 1994; Wennbo
et al., 1997).
Growth Hormone and Breast Cancer
In humans, GH can mediate its effects via PRLRs in addition to GHRs. For this
reason it is not possible to discriminate between GHR and PRLR mediated effects in the
mammary gland. Like PRL, expression of GH has been detected in the mammary gland
(Mol et al., 1995) and breast cancer cell lines (Decouvelaere et al., 1995) and its
transcription is independent of Pit-1 (Lantinga-van Leeuwen et al., 1999). In situ RTPCR and in situ hybridization revealed that GH mRNA is predominantly expressed in the
epithelial and myoepithelial ductal cells of the normal human mammary gland (Raccurt et
al., 2002). In comparison to normal surrounding tissue, the expression of GH was found
to be elevated in intraductal and invasive ductal carcinomas and was even higher in
metastatic mammary carcinoma cells, occurring not only in proliferative epithelial cells
but also stromal cells (Raccurt et al., 2002). Similarly the levels of GH protein have been
shown to be elevated in carcinomas in comparison to normal tissue of the mammary
gland (Mol et al., 1995; Raccurt et al., 2002) and are elevated in breast cancer patients
(Emerman et al., 1985). Conditions which increase GH increase the risk of malignancy
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including breast cancer (Nabarro, 1987).

Intramuscular injection of GH prior to

chemotherapy in patients with advanced breast cancer induced a 2-fold increase in the
proliferative activity of the tumor cells (Baldini et al., 1994). The changes in the local
concentration of GH are thought to be pivotal to determine the effects on the behavior of
the mammary epithelial cells.
The receptors for GH are expressed in normal human mammary tissue (Sobrier et
al., 1993; Lincoln et al., 1998) and in breast cancers (Decouvelaere et al., 1995; Reynolds
et al., 1997; Lincoln et al., 1998; Mertani et al., 1998; Gebre-Medhin et al., 2001).
Contrary to some reports (Emerman et al., 1985; Mertani et al., 1998), the expression of
the GHR appears to be up-regulated in breast cancers in comparison to adjacent normal
mammary tissue (Gebre-Medhin et al., 2001). The GHR is also up-regulated in stroma
cells of the breast carcinomas (Gebre-Medhin et al., 2001).
Transfection of MCF-7 human breast cancer cells with the hGH gene resulted in a
hyperproliferative state (Kaulsay et al., 1999) due to increased mitogenesis and decreased
apoptosis (Kaulsay et al., 2001). GH-induced mitogenesis was mediated in part by
increased expression of HOXA1 (Zhang et al., 2003), which increases the expression of
cyclin D1 which is necessary for cell cycle progression and the up-regulation of the antiapoptotic factor bcl-2 (Graichen et al., 2002; Zhang et al., 2003). Autocrine hGH also
inhibits apoptosis by suppressing the expression of a positive regulator of the TGF-β
pathway (PTGF-β) (Graichen et al., 2002) and inducing a negative regulator, c-ski, which
associates with Smads to repress TGF-β inducible genes (Mertani et al., 2001). CHOP
also appears to be upregulated by autocrine hGH and appears to protect the cells from
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apoptosis too (Mertani et al., 2001). Stimulation with hGH resulted in reorganization of
both the microfilament (Goh et al., 1997) and microtubule networks (Goh et al., 1998)
and dramatically increased the rate of human mammary carcinoma cell spreading on a
collagen substrate (Kaulsay et al., 2000). Autocrine production of hGH by MCF-7 cells
alters the cellular morphology (loss of cell-cell contact, formation of multiple cellular
protrusions, flattening of the cells) and was found to involve the downregulation
(occludin, γ-catenin) or relocalization (E-cadherin) of epithelial markers and acquisition
of mesenchymal markers (fibronectin, vimentin) which stimulated cell migration and
invasion via enhanced matrix metalloproteinase (MMP-2 and MMP-9) activity (Mukhina
et al., 2004).
Similarly, transfection of immortalized but otherwise normal MCF-10A human
mammary epithelial cells with the hGH gene caused a change in the morphology of the
cells from epithelial to mesenchmyal spindle-shaped phenotype.

Autocrine hGH

significantly increased mitogenesis and abrogated apoptotic cell death. When cultured in
Matrigel the organization of cells resembled that of aggressive mammary carcinoma cell
lines and supported anchorage-independent proliferation in the soft agar colony formation
assay reminiscent of oncogenic transformation, this was not observed for exogenous hGH
(Zhu et al., 2005).

This oncogenic transformation of immortalized MCF-10A cells

induced by autocrine hGH was mediated primarily via the up-regulation of HOXA1 and
involves Bcl-2 (Zhang et al., 2003). These drastic changes provide solid evidence that
the acquisition of hGH production can lead to transformation of mammary epithelial cells
and and tumor cell progression.
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Current Therapies for Breast Cancer
Breast cancer predominantly occurs in women between 45 to 50 years of age and
is the most common cause of death among women 18-54 years of age, primarily due to
their tendency to metastasize (Baselga and Norton, 2002). The mortality rate for this
disease is highest in the U.S. and the American Cancer Society projects the incidences of
breast cancer within the U.S. will continue to rise while deaths associated with the
disease will continue to decline. These trends have primarily been attributed to earlier
detection of breast disease by mammograms and treatment of the disease with tamoxifen
and/or chemotherapy.
Standard post-operative therapy for post-menopausal women with early-stage,
hormone-receptor-positive breast cancers is five years of tamoxifen therapy rather than
cytotoxic chemotherapy. Tamoxifen is an anti-estrogen that blocks mammary epithelial
proliferation induced by natural estrogen cycling. It has been shown to significantly
decrease the recurrence of breast cancers and to reduce the incidence of ER positive
tumors in women with extremely high risk of breast cancer.

Like chemotherapy,

tamoxifen has some potentially serious side effects that include an increased risk of
uterine cancer, thromboembolism, hot flashes, sexual dysfunction and cataracts (Fabian
and Kimler, 2001). In addition, tamoxifen has proven ineffective for the prevention or
treatment of ER negative tumors, which represent approximately 30% of all breast
cancers and result in 12,000-15,000 deaths each year (Fabian and Kimler, 2001). The
short comings of tamoxifen, the failure of conventional chemotherapy against advanced
invasive disease, and the projection of over 178,480 new cases of breast cancer and
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40,910 deaths this year alone (American Cancer Society., 2006), suggests new
approaches to control and prevent breast cancer are needed. The major challenges facing
investigators of breast cancer are to develop alternative therapies that have fewer side
effects, and to develop drugs that act independently of ER status (Arun and Hortobagyi,
2002).
To address the short comings of tamoxifen, numerous therapeutic agents are
under development to prevent the cyclic production of estrogens and progesterone by the
ovary (aromatase inhibitors, gonadotrophin-releaseing hormone agonists) and to block
the receptor mediated effects of estrogen (selective estrogen receptor modulators) and
progesterone (von Minckwitz and Kaufmann, 1998). These endocrine agents may one
day replace tamoxifen as the primary therapy for prevention of cancer reoccurrence in
postmenopausal women since they appear to be more potent, have few if any agonistic
effects on other organs, and show considerably fewer side effects than tamoxifen.
Numerous targets other than estrogen production and signaling are being explored
for the development of therapeutics with potentially broader application since they may
prove more useful for premenopausal women and may be effective on ER negative
cancers. Potential targets include proteases, tyrosine kinases, receptors, and ligands
which are aberrantly expressed and / or activated within cancerous tissues. Utilizing a
variety of recombinant techniques and strategies, therapies have been developed which
interfere with angiogenesis, modulate an immune response, induce apoptosis or necrosis,
interfere with signal-transduction pathways, downregulate proto-oncogenes, block
processes involved in metastasis and invasion, or a combination of the above.
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The most widely explored therapies to date are ligand-based.

Ligand-based

therapies utilize ligands (peptides, growth factors, or steroids) that bind to receptors or
antibodies that bind to antigens on the surface of target cells. Ideally, the receptor or
antigen to be targeted is uniformly expressed within the target cell population; present at
high levels on the surface of the target cells; and is not released or down-regulated. The
use of ligand-based therapies overcomes many of the limitations of traditional
chemotherapeutics by reducing the exposure of the normal tissues to the drug while
increasing the dose achieved within the targeted cancerous tissue.
Monoclonal antibodies have proven more effective than small molecule tyrosine
kinase inhibitors at disrupting growth factor signaling via the human epidermal growth
factor receptor (HER) family of receptors. Strategies to modulate an immune response
against breast cancer are being explored using adjuvants (non-specific immunotherapy);
tumor vaccines (specific immunotherapy); interleukins (cytokine immunotherapy); and
humanized Abs (passive immunotherapy). To interfere with angiogenesis and invasion
the use of inhibitors of the action of vascular endothelial growth factor (anti-VEGF
antibodies, soluble VEGF receptors, dominant-negative VEGF receptors, tyrosine kinase
inhibitors, ribozymes, antisense); endogenous inhibitors of endothelial cells (endostatin,
angiostatin, anti-angiogenic antithrombin); and inhibitors of matrix-metalloproteases
(small molecules) are currently being explored. Strategies targeting the extracellular
portion of the receptors have run into fewer issues.
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Fig. 1.3
Representation of PRLR gene expression in 25 tumors and normal
contiguous breast tissues
Results are presented from lowest to highest level of PRLR gene expression in
tumors. Note that a majority of breast cancers express elevated levels of PRLR in
comparison to adjacent normal tissue. Adapted from Touraine et al., (Touraine et al.,
1998).
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Targeting Prolactin and Growth Hormone Receptor Signaling
At first glance there may appear to be no need to develop drugs that prevent the
activation of the GHR and PRLR because the secretion of GH and PRL from the pituitary
is under the inhibitory control of somatostatin and dopamine, respectively. Octapeptide,
which mimics the activity of somatostatin, has been used to prevent GH secretion and to
shrink pituitary tumors (e.g. pituitary adenomas) and treat disorders associated with these
tumors (e.g. acromegaly). Similarly, bromocriptine and cabergoline, which mimic the
activity of dopamine, have been used to prevent PRL secretion and to treat pituitary
tumors (e.g. prolactinomas) and disorders associated with hyperprolactinaemia (e.g.
amenorrhoea and infertility).
In rodents, significant inhibition of tumor progression has been achieved by
removing their pituitary gland or by inhibiting the release of PRL from the pituitary using
bromocriptine. In contrast, these approaches have had little success in humans. Removal
of the pituitary gland has been reported to reduce the circulating levels of PRL by only
50-70% while other pituitary hormones were undetectable (Lachelin et al., 1977),
indicating that extrapituitary production of PRL occurs in humans. Drugs that inhibit the
release of PRL from the pituitary are ineffective against PRL secreted from extrapituitary
sources such as the mammary epithelium.
Since biologically active PRL may be produced locally by human breast cancer
cells (Ginsburg and Vonderhaar, 1995) and acts in an autocrine/paracrine manner within
the mammary gland (Clevenger et al., 1995), therapeutics should be designed that
directly antagonize PRL/PRLR signaling rather than PRL production or release from the
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pituitary. In addition, some disorders may not be due to hyperprolactinaemia but rather
to elevated levels of the PRLR which may increase the sensitivity of cells to normal
levels of PRL. Elevation of PRLR occurs in a majority of breast cancers (Fig. 1.3) providing
a strong argument in support of the development of a PRLR targeting antagonist.
No therapeutic agents are on the market that disrupt PRLR mediated signaling. Since
both PRL and the PRLR are expressed widely in breast cancer, it was postulated that targeted
inhibition of signaling via the PRLR would have potential as a therapy for breast cancer
(Reynolds et al., 1997). Drugs that target the PRLR represent a new class of therapeutics
for disrupting the effects of autocrine/paracrine PRL or hypersensitivity to pituitary PRL
due to over-expression of the PRLR.
In vitro, anti-hPRL antibodies and anti-sense RNA directed against the hPRL gene
have been used to successfully inhibit T-47Dco cell proliferation (Ginsburg and Vonderhaar,
1995; Ginsburg et al., 1997) as have antibodies against PRLR in multiple breast cancer cell
lines (Fuh and Wells, 1995). An antibody raised against the PRLR has also been shown to
reduce the incidence of carcinogen induced breast cancers in vivo in mice (Sissom et al., 1988).
These findings validate PRL/PRLR signaling as a target for the development of breast cancer
therapeutics.
Development of a Growth Hormone Receptor Antagonist
PRL and GH share approximately 40% amino acid sequence identity and a similar
tertiary structure as do the extracellular regions of the receptors to which they bind
(Forsyth and Wallis, 2002). Two separate receptor binding sites have been identified in
these hormones, each of which interacts with one receptor to form a one ligand two
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receptor complex that activates signal transduction. Because of differences in affinity
between the two binding sites, binding occurs sequentially with the higher affinity site
interacting with the first receptor before the lower affinity site can interact with the
second receptor (Cunningham et al., 1990b; Goffin et al., 1992; Fuh and Wells, 1995).
Even with the limited identity among these hormones, hGH can bind to both GHR and
PRLR with high affinity and the introduction of as few as eight amino acid mutations to hPRL
confers the ability to bind to GHR with high affinity (Cunningham et al., 1990a). These
findings suggest the few amino acid residues that are conserved among these hormones are
involved in receptor binding and/or the maintenance of the overall confirmation of their fourhelix bundle, which made them a good starting point for the development of an antagonist.
While studying the effect of mutations on the growth promoting activity of bovine
GH, it was discovered that mutations in its third α-helix either enhanced or suppressed
growth without affecting the binding affinity of GH towards GHR (Chen et al., 1990;
Chen et al., 1991a; Chen et al., 1991c; Chen et al., 1991b; Chen et al., 1994; Chen et al.,
1995). It was further elucidated that Gly 119 of bovine GH (Chen et al., 1991b) or Gly
120 of human GH (Chen et al., 1994; Xu et al., 1995) is critical for retaining this growth
promoting activity. Substitution of this Gly residue with an Arg residue results in a GH
analog, hGH-G120R, which behaves as an antagonist (Fuh et al., 1992; Chen et al.,
1994). In vitro, GH has been shown to induce the tyrosine phosphorylation of STAT5
(Silva et al., 1993), hGH-G120R does not (Chen et al., 1994), and hGH-G120R
competitively inhibits this GH-induced tyrosine phosphorylation (Silva et al., 1993).
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In vivo, hGH-G120R transgenic mice have a dwarf phenotype, indicating that hGHG120R inhibits the binding of endogenous GH to GHRs (Chen et al., 1994).
It was originally proposed that hGH-G120R inhibits signal transduction by
preventing the dimerization of GHRs (Fuh et al., 1992; Silva et al., 1993). However, in
contrast to the sequential dimerization due to differential affinity model, hGH-G120R
does not appear to block dimerization or affect internalization of porcine GHRs in mouse
L-cells but rather leads to the formation of dimeric complexes which are non-functional
(Harding et al., 1996).
Since hGH binds to PRLR in addition to GHR, it is not surprising that the hGHG120R antagonist also inhibited GH and PRL responses mediated through the PRLR
(Fuh et al., 1993; Fuh and Wells, 1995). However, it did not appear to always behave as
an antagonist in species other than human. At about 25 to 50-fold higher concentrations
than GH, it promoted the growth in hypophysectomized rats possibly via PRLRs (Mode
et al., 1996) and stimulated the proliferation of rat Nb2 cells which are responsive to
lactogens (Dattani et al., 1995).

Evidence suggests that these effects were species

specific, reflecting different affinities towards rat PRLRs (Goffin et al., 1996).
A pure GHR antagonist, B2036, was developed which combines an amino acid
substitution at position 120 of hGH with an additional eight amino acid substitutions to
improve the affinity of binding Site 1 towards the GHR (Thorner et al., 1999) and reduce
its affinity towards the PRLR (Goffin et al., 1999). A poly(ethyene glycol) modified
form of B2036 (PEG-B2036) known as Somavert™ has recently been approved by FDA
for the treatment of acromegaly (Trainer et al., 2000; Muller et al., 2001; Goffin and
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Touraine, 2002). Another potential use for this pure GHR antagonist is the treatment of
breast cancer (Kaulsay et al., 2001). However, it remains to be determined if GH
mediates its effects primarily via GHRs or PRLRs in breast cancer.
Development of a Prolactin Receptor Antagonist
The Gly residue mutated in hGH was found to be conserved in both hPL and
hPRL. Using an approach similar to the one used to develop hGH-G120R, the equivalent
mutation was introduced in to hPL. hPL-G120R was found to antagonize the PRLR;
however, it had a lower affinity than hGH-G120R for the receptor (Fuh and Wells, 1995).
To develop a high affinity antagonist specific for the PRLR, an equivalent Gly at position
129 of hPRL was converted to an Arg (Fig. 1.4). This single mutation altered the
structure of binding Site 2, greatly reducing the binding affinity of hPRL-G129R for a
second receptor, resulting in an analog that behaves as a PRLR antagonist (Fig. 1.5).
hPRL-G129R was found to selectively bind to PRLRs on cell surfaces with high affinity,
where it blocked the binding of PRL, and thus interfered with PRL signal transduction
(Goffin et al., 1996; Ramamoorthy et al., 2001).
It has been demonstrated that hPRL-G129R inhibits cell proliferation in human
breast cancer cell lines in a dose-dependent manner by inducing apoptosis (Fig. 1.6)
(Chen et al., 1999). It has also been shown that hPRL-G129R competitively blocks
hPRL-induced JAK2/STAT signal transduction (Cataldo et al., 2000) and by doing so upregulates tumor suppressors such as TGF-β and the down-regulates proto-oncogenes such
TGF-α (Chen et al., 1999) and bcl-2 (Beck et al., 2002; Peirce and Chen, 2004); leading
to the arrest of cell cycle progression and in some circumstances the induction of
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apoptosis (Chen et al., 1999). In vivo, hPRL-G129R appears to be more cytostatic than
cytotoxic in human breast cancer xenograft-bearing nude mice (Fig. 1.7) (Chen et al.,
2002).
Potential Indications for Prolactin Receptor Antagonists
The most apparent indication for a PRLR antagonist is the treatment of breast
cancer. It may also have utility for the treatment of immune diseases such as rheumatoid
arthritis (Figueroa et al., 1997), systemic lupus erythematosus (McMurray et al., 1995;
Peeva et al., 2004), and Reiter's syndrome (Bravo et al., 1992). PRL has been associated
with these diseases, has been shown to function as a cytokine in lymphocytes, and may
be produced by immune system cells (peripheral blood lymphocytes, thymocytes,
hematopoetic system cells) where it can act in an autocrine manner.
Potential Indications for Prolactin Receptor Agonists
There are many circumstances where the growth promoting effects of PRL and
GH may be beneficial. They may have utility for restoring the immune system in
immunocompromised patients. PRLR agonists may have potential agricultural uses to
maintain milk yields in dairy animals or overcome lactation insufficiencies in humans.
Similar to how GH increases insulin-like growth factor (IGF)- I levels, PRL increases
IGF-II levels in the mammary gland. In addition, PRL represses the production of IGF
binding protein 5 (IGFBP-5), a protein associated with involution. The induction of IGFII and repression of IGFBP-5 by PRL suggests a coordinate regulation of IGF-II
bioavailability during pregnancy and lactation stages.
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A

Arginine

Glycine

B

hPRL

G129R

Fig. 1.4
Model of hPRL and G129R complexes with the extracellular domain of
the human PRLR
The G129R substitution (yellow) in helix 3 of hPRL disrupts the integrity of
binding Site 2 without destabilizing the 3rd α-helix (A). The G129R mutation (yellow)
fills the crevice between the 1st and 3rd helices and prevents functional receptor
dimerization from occurring (B). Generated using Swiss Modeler
(http://www.expasy.ch/swissmod/SWISS-MODEL.html).
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Fig. 1.5
Schematic representation of G129R competitively inhibiting the binding
of hPRL to PRLRs
The high affinity binding Site 1 of G129R (helices 1 and 4) readily binds to a
PRLR; however, its altered binding Site 2 (X) prevents it from interacting with a second
receptor in a manner that will induce signal transduction. Bound G129R prevents hPRL
from occupying the PRLR homodimers and therefore behaves as an antagonist of PRL,
GH or PL signaling via PRLRs.
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Control
(Untreated)

G129R
(500 ng/ml/24hr)

MDA-MB-134

T-47D

BT-474

MCF-7

Fig. 1.6
Apoptotic response of four PRLR-positive human breast cancer cell lines
to G129R treatment
Apoptosis was measured using the TUNEL assay. Cells treated with 500 ng/ml of
hPRL showed results similar to the control cells (not shown). The green fluorescence
staining represents cells undergoing apoptosis (DNA fragmentation). Adapted from
Chen et al. (Chen et al., 1999), with modifications
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Fig. 1.7
Effects of hPRL and G129R on T-47D human breast cancer cell xenograft
growth in nude mice
Thirty 6-7 week old Nuj/Nude mice (Jackson Laboratory) pre-implanted s.c. with
slow-releasing E2 pellets (0.72 mg/60 day, Innovative Research of America, Inc.) were
6
injected with T-47D cells (5 x 10 ) pre-mixed with Matrigel (BD Biosciences; San Diego,
CA) into the mammary fat pad. One week after tumor cell inoculation, the mice were
randomized into three groups and treated 5 times per week with either Matrigel, 200μg
hPRL in Matrigel or 200μg G129R in Matrigel for seven consecutive weeks. The hPRL
treated mice exhibited enhanced tumor growth (mean tumor volume = 202 + 62 mm3
versus 124 + 31 mm3 in the control mice). Mice treated with the G129R showed
inhibition of tumor growth (mean tumor volume was 79 + 32 mm3). The final tumor
weight in the three groups was also significantly different (p<0.05), (control, 100 mg + 2
mg; PRL, 121 mg + 5 mg, G129R, 65 mg + 16 mg). Adapted from Chen et al. (Chen et
al., 2002).
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CHAPTER TWO
DEVELOPMENT OF A PROLACTIN RECEPTOR TARGETING
FUSION TOXIN USING A PROLACTIN RECEPTOR ANTAGONIST
AND A RECOMBINANT FORM OF PSEUDOMONAS
EXOTOXIN A
Abstract
Human (h) prolactin (PRL) promotes the proliferation and differentiation of
mammary epithelial cells during mammary gland development and has been linked to
breast tumor development. The receptor for PRL (PRLR) is elevated in a majority of
human breast tumors, making cancer cells highly sensitive to the mitogenic and antiapoptotic activity of hPRL. These findings provide the rationale for the development of
PRLR targeted breast cancer therapeutics.

Previously, a hPRL receptor antagonist,

G129R, was developed that competitively binds to the PRLR resulting in growth
inhibition and the induction of apoptosis in certain types of breast cancer cells. To
further increase the potency of G129R, we fused G129R to a truncated form of
Pseudomonas exotoxin A, PE40, which lacks the cell recognition domain of the toxin but
retains the domains necessary for it to translocate into the cytosol and inhibit protein
synthesis. We postulated that the fusion of G129R to PE40-KDEL would (1) deliver the
recombinant toxin to breast cancer cells where the PRLR is overexpressed; (2) block PRL
signaling via the G129R moiety; and (3) inhibit protein synthesis via the PE40-KDEL
moiety. We demonstrate that the fusion toxin competitively binds to PRLR on T-47D
human breast cancer cells and inhibits signal transducers and activators of transcription 5
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(STAT5) phosphorylation induced by hPRL. In addition, we show that G129R-PE40KDEL is selectively cytotoxic to breast cancer cell lines expressing the PRLR and that
cell death is associated with the inhibition of protein synthesis and does not involve
caspase mediated apoptosis.
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Introduction
Human (h) prolactin (PRL) promotes the proliferation and differentiation of
mammary epithelial cells during mammary gland development and is necessary for the
stimulation of lactogenesis. The receptor for PRL (PRLR) is up regulated in mammary
tissue during development and studies have shown that a majority of human breast
tumors have higher PRLR levels than surrounding normal mammary tissue (Clevenger et
al., 1995; Reynolds et al., 1997; Touraine et al., 1998). It has also been shown that PRL
mRNA and protein are present in both normal and cancerous human mammary tissue
(Purnell et al., 1982; Fields et al., 1993) and that it originates primarily from the
mammary epithelium (Clevenger et al., 1995). Based on these observations, it has been
hypothesized (1) that elevated PRLR levels in malignant breast tissue make these cells
highly sensitive to the mitogenic and anti-apoptotic activity of PRL; (2) that PRL
released from the epithelial cells acts locally via the PRLR in an autocrine/paracrine
manner; and (3) that alterations in PRL signaling may play a role in malignant
transformation and/or tumor development.
Since both PRL and PRLR are expressed widely in breast cancers, it was
proposed that targeted inhibition of signaling via the PRLR would have potential as a
therapy for breast cancers (Reynolds et al., 1997). In vitro, anti-hPRL antibodies and
anti-sense RNA directed against the hPRL gene have been used to successfully inhibit T47Dco cell proliferation (Ginsburg and Vonderhaar, 1995; Ginsburg et al., 1997) as have
antibodies against hPRLR in multiple breast cancer cell lines (Fuh and Wells, 1995). An
antibody raised against the PRLR has also been shown to reduce the incidence of
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carcinogen induced breast cancers in vivo in mice (Sissom et al., 1988). These findings
validate PRL/PRLR signaling as a target for the development of breast cancer
therapeutics.
A PRLR antagonist, G129R, was developed by substituting a single glycine residue at
position 129 of hPRL with a bulky arginine residue (Goffin et al., 1996; Chen et al., 1999).
This amino acid substitution disrupts the structural integrity of the lower affinity binding site of
hPRL so that it retains the ability to bind to the first receptor with high affinity but can no
longer interact with a second receptor to initiate signal transduction (Chen et al., 1999; Llovera
et al., 2000b). It has been demonstrated that G129R binds to the PRLR with similar affinity as
hPRL and is able to competitively antagonize the effects of hPRL on hormone responsive
human breast cancer cell lines (Chen et al., 1999). It has further been demonstrated that the
antagonist competitively blocks hPRL-induced Janus-activated kinase 2/signal transducers
and activators of transcription (JAK2/STAT) signaling and by doing so results in the upregulation of a tumor suppressor (TGF-β) and the down-regulation of a proto-oncogene (bcl-2);
leading to the arrest of cell cycle progression and in some circumstances the induction of
apoptosis (Cataldo et al., 2000; Ramamoorthy et al., 2001; Beck et al., 2002; Peirce and Chen,
2004). Since the blocking of PRL signaling by G129R appears to be more cytostatic than
cytotoxic to breast cancer cells in vitro and in vivo using mouse xenografts (Chen et al., 2002),
we proposed to enhance the cytotoxicity of G129R by fusing it to a toxin that potently inhibits
protein synthesis.
Pseudomonas exotoxin A (PE) is a bacterial toxin with three structurally and
functionally different domains (Allured et al., 1986; Hwang et al., 1987). Domain I is
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responsible for cell recognition, domain II for translocation, and domain III for inhibition
of protein synthesis (Fig. 2.1). PE binds to the membrane-associated heavy chain of α2macroglobulin receptor and undergoes receptor-mediated endocytosis (Fig. 2.2) (Morris
et al., 1983; Kounnas et al., 1992; Zdanovsky et al., 1996). Within the endosome PE is
acidified and processed (Jinno et al., 1988; Ogata et al., 1990; Siegall et al., 1991; Fryling
et al., 1992); the low pH induces conformational changes in PE necessary for
translocation (Idziorek et al., 1990) and for processing by furan (Chiron et al., 1994; Gu
et al., 1996), which cleaves PE between arginine 279 and glycine 280 (Ogata et al.,
1992). The mechanism by which the 37 kDa C-terminal fragment of PE translocates to
the cytosol remains unclear; however, both the N-terminal (Theuer et al., 1993;
Zdanovsky et al., 1993) and C-terminal regions of PE37 are necessary for translocation.
The C-terminal five amino acids, REDLK, resemble an endoplasmic reticulum retention
signal (Chaudhary et al., 1990) and are necessary for cytotoxicity (Theuer et al., 1993).
After removal of the C-terminal lysine, this C-terminal fragment is thought to exploit the
KDEL receptor retrieval system by binding to KDEL receptors present in the Golgi,
which retrograde transport the toxin to the lumen of the endoplasmic reticulum (Hessler
and Kreitman, 1997; Jackson et al., 1999). In the endoplasmic reticulum, PE may be
reduced, unfolded and reverse translocated across the membrane into the cytosol where it
can inactivate elongation factor 2 (EF-2), thereby inhibiting protein synthesis and ultimately
causing cell death.
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Fig. 2.1

Structural domains of Pseudomonas exotoxin A

Receptor binding domain Ia (red), cytoplasm translocation domain II (blue),
linker domain Ib (yellow), and ADP-ribosyl transferase domain III (green).
Crystallographic structure from Wedekind et al. (Wedekind et al., 2001).
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Diagram of intoxification by exotoxin A

The toxin is internalized by receptor-mediated endocytosis. In the endosome the
toxin is cleaved by furan and the cytoplasmic translocation domain of the toxin is
activated. The activated toxin is retrograde transported through the Golgi to the
endoplasmic reticulum and enters the cytosol where it binds to and irreversibly ADPribosylates elongation factor 2 (EF2). Inactivation of EF2 prevents protein synthesis
from occuring and results in cell death.
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Here we describe the development of a fusion toxin intended to specifically target
and kill PRLR-positive breast cancers using G129R and a recombinant form of
Pseudomonas exotoxin A that lacks the cell recognition domain (Fig. 2.3). Our data
demonstrates that G129R-PE40-KDEL drastically increases the potency of G129R even though
it has a lower affinity for the PRLR when fused with PE40-KDEL. We show that G129R-PE40KDEL has the attributes of a dual function protein; it retains the ability to antagonize the PRLR
by partially inhibiting hPRL-induced STAT5 phosphorylation and it drastically reduces the
viability of PRLR-positive human breast cancer cells by inhibiting protein synthesis.
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Diagram of G129R-PE40KDEL

The receptor binding domain of exotoxin A was replaced with G129R to target the
toxin to the PRLR. The C-terminal five amino acids (REDLK) of exotoxin A were replaced
with a more acitive endoplasmic reticulum retention signal (KDEL) to enhance the
retrograde transport of the toxin via the KDEL receptor retrieval system.
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Materials and Methods
Cell Lines and Reagents
The human breast cancer cell lines T-47D, MCF-7, BT-474, BT-483, MDA-MB134, MDA-MB-453, MDA-MB-231 and the murine breast cancer cell line 4T1 were
purchased from the American Type Culture Collection (Manassas, VA) and were
maintained in medium containing 10 μg/ml gentamicin at 37°C with humidity and 5%
CO2 unless otherwise mentioned. All media and supplements were purchased from
Invitrogen (Carlsbad, CA) unless otherwise mentioned. T-47D and MCF-7 cells were
maintained in RPMI Medium 1640 supplemented with 10% fetal bovine serum (FBS).
BT-474 cells were maintained in RPMI Medium 1640 supplemented with 10% FBS, 1
mM sodium pyruvate, and 10 μg/ml insulin (Sigma, St. Louis, MO). BT-483 cells were
maintained in RPMI Medium 1640 supplemented with 20% FBS, 2.5 mg/ml glucose
(Sigma), 10 mM HEPES, 1 mM sodium pyruvate, and 10 μg/ml insulin. MDA-MB-134
cells were maintained in Leibovitz’s L-15 Medium supplemented with 20% FBS without
CO2. MDA-MB-453 and MDA-MB-231 cells were maintained in Leibovitz’s L-15
Medium supplemented with 10% FBS without CO2. 4T1 cells were maintained in RPMI
Medium 1640 supplemented with 10% FBS, 2.5 mg/ml glucose, 10 mM HEPES, and
36.4 ml of 7.5% (w/v) sodium bicarbonate per liter of medium.
Pseudomonas exotoxin A was purchased from List Biological Laboratories
(Campbell, CA). PE40, which retains the enzymatic activity of the toxin but has low
cytotoxicity due to the lack of the cell recognition domain Ia (Seetharam et al., 1991),
was prepared and purified as described previously from the periplasmic fraction (Kondo
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et al., 1988). Recombinant hPRL and G129R were prepared in house as previously
described (Chen et al., 2002). Cbz-Val-Ala-Asp-(Ome)-fluoromethyl ketone (zVADfmk) was purchased from Enzyme Systems Products (Livermore, CA) and dissolved in
DMSO (Fisher Scientific, Pittsburgh, PA) to a final concentration of 50 mM, aliquoted,
and stored at -20ºC. Working solutions were made in culture medium immediately
before use.
Construction of PRL-PE40-KDEL and G129R-PE40-KDEL Expression Vectors
Previously, hPRL and G129R were cloned by inserting their cDNAs between the
Nde I and Xho I sites of the expression vector pET22b(+) obtained from Novagen
(Madison, WI).

Plasmid JH8, which encodes a recombinant form of Pseudomonas

exotoxin A (PE40), was obtained from the American Type Culture Collection.

All

oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, IA), all
restriction and modifying enzymes were purchased from New England BioLabs (Beverly,
MA), and all PCR reactions were performed using the Advantage-HF™ Kit (BD
Biosciences, Palo Alto, CA). Internal BamH I and Xho I sites were removed from the
DNA encoding PE40 using the QuickChange® XL Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA). The C-terminal codons of hPRL, G129R, and PE40 were
modified and restriction sites were added by PCR using oligonucleotides; the stop codons
of hPRL and G129R were replaced with codons encoding Gly-Gly-Gly-Gly-Ser (G4S)
and the codons of PE40 encoding REDLK were replaced with codons encoding KDEL
since it has been shown to significantly increase the cytotoxicity of PE and its derivatives
(Seetharam et al., 1991). The PCR products were ligated with pCR2.1 T/A cloning
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vector and transformed into E. coli TOP10 cells obtained from Invitrogen. Positive
clones were identified by plating the cells on Luria-Bertani (LB) agar plates containing
100 µg/ml ampicillin and 80 µg/ml 5-bromo-4-chloro-3-indolyl-bD-galactoside. The
plasmids were isolated using the QIAprep® Spin Miniprep Kit (Qiagen, Valencia, CA)
and the Nde I-PRL-G4S-BamH I, Nde I-G129R-G4S-BamH I, and BamH I-PE40-KDELXho I DNA fragments were isolated by restriction digestion, separated by electrophoresis,
purified from the agarose gel using the QIAquick® Gel Extraction Kit (Qiagen), and
ligated with Nde I and Xho I cut pET22b(+) to create pET22b-PRL-PE40-KDEL and
pET22b-G129R-PE40-KDEL.

Various oligonucleotides linkers were inserted at the

BamH I site located between G129R and PE40-KDEL to increase the distance between
the two moieties.
Production and Purification of Fusion Toxins
Chemically competent E. coli BL21 (DE3) Star cells (Invitrogen) were
transformed with pET22b-PRL-PE40-KDEL or pET22b–G129R-PE40-KDEL and
propagated overnight at 37°C with agitation in LB broth containing 100 µg/ml ampicillin.
The next morning 160 ml of each of the starter cultures was used to inoculate four liters
of LB broth and the cultures were grown to an O.D.600 of 0.9 before induction of protein
production with 1 mM isopropyl β-thiogalactoside (Alexis Biochemicals, San Diego,
CA). After 5 h of induction the cells were harvested by centrifugation at 5,000 x g for 5
min and resuspended in Solution 1 (0.2M NaPO4; 10 mM EDTA, pH 8.0; 0.5% Triton X100; pH adjusted to 8.0) to which 0.1 mg/ml lysozyme was added. The cells were
incubated at room temperature for 1 h to weaken the cell membranes before the cells
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were sheared on ice with five 1-min ultrasonic pulses (30% duty at setting 7) using a 550
Sonic Dismembrator (Fisher Scientific). The insoluble fraction containing the inclusion
bodies was recovered by centrifugation at 12,000 x g for 30 min at 4ºC and resuspended
in Solution 2 (0.2M NaPO4; 10 mM EDTA, pH 8; 0.5% Triton X-100; 1 M urea; pH
adjusted to 7.0). The inclusion bodies were collected by centrifugation at 12,000 x g for
30 min at 4ºC and were solubilized and denatured in Solution 3 (0.2M NaPO4; 8 M urea;
1% v/v β-mercaptoethanol; pH adjusted to 8.0). The proteins were refolded by dialysis against
baths of 20 mM Tris·HCl, pH 8.0 containing decreasing amounts of urea (4M urea, 2 M urea, 0
M urea, 0 M urea). The refolded fusion toxins were filtered through 0.45 μm filters and
purified by anion-exchange chromatography using a 5 ml HiTrap Q Sepharose XL column
(Amersham Biosciences, Piscataway, NJ) on an ÄKTA fast protein liquid chromatography
system (Amersham Biosciences). The purified fusion toxins were separated by reducing SDSPAGE along with BSA standards (Pierce, Rockford, IL) and stained with SYPRO® Orange
(Molecular Probes, Eugene, OR) to determine the concentration and purity of the fusion
toxins. The identity of the fusion toxins were confirmed by Western blotting.
Western Blot Analysis
PE, G129R, and G129R-PE40-KDEL were separated on a 12% polyacrylamide gel
by reducing SDS-PAGE. The proteins were transferred by Western blot to a Hybond™
enhanced chemiluminescence (ECL) nitrocellulose membrane (Amersham Biosciences)
at 16 W for 1 h. The nitrocellulose membrane was incubated in a blocking solution
containing TBS with 0.05% Tween 20 (TBS-T) and 5% milk for 1 h at room temperature.
The membrane was incubated overnight at 4°C with agitation in blocking solution
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containing a 1:2000 dilution of anti-exotoxin A (List Biological Laboratories). The blots
were washed three times with TBS-T, and incubated for 2 h at room temperature with
agitation in blocking solution containing a 1:2000 dilution of swine anti-goat horseradish
peroxidase (HRP) conjugate (Roche, Indianapolis, IN). Blots were washed three times
with TBS-T and incubated for 1 min with ECL™ Western Blotting Detection Reagents
(Amersham Biosciences). Blots were exposed to Biomax MR film (Kodak, Rochester,
NY) and the film was developed with a Konica SRX-101A processor (Konica Minolta
Medical Imagining, Wayne, NJ). The membrane was stripped and re-probed with a
1:4000 dilution of rabbit anti-hPRL antiserum (National Hormone and Pituitary Program,
NIH, Bethesda, MD) and 1:2000 dilution of goat anti-rabbit conjugated HRP (Bio-Rad,
Hercules, CA).
Radio-Receptor Binding Assay
One million cells per well of T-47D human breast cancer cells were seeded in sixwell tissue culture plates and grown to confluency. Cells were starved in serum-free
RPMI Medium 1640 for 1 h, and incubated for 2 h at room temperature in serum-free
medium containing 5 x 104 cpm of 125I-labeled hPRL (specific activity, 40 µCI/µg; NEN
Perkin-Elmer, Boston, MA) with or without various concentrations of hPRL, G129R, or
G129R-PE40-KDEL. Cells were washed three times with serum-free RPMI Medium
1640 and were lysed in 0.5 ml of 0.1 N NaOH/1% SDS. Bound radioactivity was
determined using a Beckman LS6500 Liquid Scintillation Counter calibrated to detect
125

I using a wide spectrometer window.

The percentage of specific binding was

calculated and compared among the samples.
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STAT5 Phosphorylation Assay
T-47D cells were grown to 90% confluency in six-well plates in RPMI Medium
1640 supplemented with 10% (v/v) charcoal-stripped fetal bovine serum (CSS; HyClone,
Logan, UT) and 10 μg/ml gentamycin. The cells were depleted for 1 h in RPMI Medium
1640 supplemented with 0.5% CSS and then treated for 20 min with various
concentrations and combinations of hPRL, G129R, PRL-PE40-KDEL, and G129R-PE40KDEL. The cells were washed with ice cold phosphate buffered saline (PBS) and lysed
in 200 μl of Lysis Buffer (20 mM Tris⋅HCl, pH 7.4; 1% Igepal CA630; 6 mM
deoxycholic acid; 150 mM NaCl; 1 mM EDTA, pH 8.0) containing protease inhibitors (1
µg/ml aprotinin; 1 µg/ml leupeptin; 170 µg/ml PMSF; 180 µg/ml sodium orthovanadate).
The lysates were agitated for 10 min on an orbital shaker, transferred to 1.5 ml tubes,
passed six times through 21-gauge needles, and incubated on ice for 20 minutes. The
lysates were clarified by centrifugation for 10 min at 12,000 x g at 4ºC and 30 µl of the
supernatants were used for Western blot analysis as described previously using 4-15%
polyacrylamide gels.

Blots were performed with 1.5 µg/ml mouse anti-phosphate

STAT5A/B antibody (Upstate, Lake Placid, NY) and a 1:2000 dilution of goat antimouse-HRP conjugate (Bio-Rad). The membranes were re-probed with 3 µg/ml rabbit
anti-STAT5 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and a
1:2000 dilution of goat ant-rabbit HRP conjugate (Bio-Rad).

51

Protein Synthesis Inhibition Assay
Approximately 1 x 105 cells were seeded in each well of a 24-well plate in a final
volume of 0.5 ml of appropriate growth medium and the cells were incubated overnight.
The medium was replaced with 0.5 ml of appropriate treatments and incubated for 44 h
after which each well was supplemented with 1 µCi of

3

H-leucine (Amersham

Biosciences) in 100 µl of medium and incubated an additional 4 h. The monolayers were
washed with 1 ml PBS and the protein was precipitated with 0.5 ml of 26%
trichloroacetic acid (TCA) overnight at -20 °C. The monolayers were solubilized with
0.5 ml of 0.2 nM NaOH and loaded onto GF/C glass fiber filters (Whatman, Clifton, NJ)
pre-rinsed with 1 ml of 10% TCA. The filters were washed twice with 1 ml of 10% TCA
and once with 3 ml of 95% ethanol and dried by vacuum. The dried filters were placed in
scintillation vials and aqueous scintillation cocktail was added before counting with a
liquid scintillation counter. The amount of 3H-leucine incorporated into precipitable
protein was determined and expressed as a percent of control.
Cell Proliferation Assay
The various cell lines to be assayed were seeded in 96-well culture plates at a
density of 5,000 cells per well in 200 µl of appropriate culture medium and grown as
recommended. After incubation for 24 h, the medium was discarded and replaced with
200 µl of medium containing various concentrations of PE, G129R, or G129R-PE40KDEL and the cells were incubated for an additional 48 h. The culture medium was
discarded

and

replaced

with

100

µl
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of

3-(4,5-dimethylthiazol-2-yl)-5-(3-

carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium/phenazine

methosulfate

(MTS/PMS) solution diluted in PBS at a 1:6 ratio (CellTiter 96 AQueous non-radioactive
cell proliferation kit; Promega, Madison, WI). The relative viability of the cells was
determined by colorimetric measurement of the reduction of MTS by the living cells
using a Benchmark microplate reader (Bio-Rad) measuring absorbance at 490 nM. All
assays were performed in quadruplicate and the relative cell viability was calculated as a
percentage of control treatments.
Poly-(ADP-Ribose)-Polymerase (PARP) Cleavage Assay
Approximately 3 x 105 MCF-7 cells were resuspended in 5 ml of RPMI Medium
1640 supplemented with 10% CSS and seeded into T-25 flasks and allowed to grow 24 h.
For experiments that included zVAD-fmk, 50 μM of the peptide was added 1 h prior to
treatment with 1 µg/ml of PE, hPRL, G129R, or G129R-PE40-KDEL.

After 24 h

treatment, the medium and cells were collected and transferred to 5 ml Falcon tubes and
centrifuged at 5,000 x g.

The pellets were washed once with ice-cold PBS and

resuspended in 100 μl of Lysis Buffer with inhibitors and lysed for 30 min at 4ºC. The
lysates were clarified by centrifugation for 10 min at 12,000 x g at 4ºC and the protein
content of the lysates were assayed using the Coomassie Plus Protein Assay Reagent
(Pierce). Thirty micrograms of the lysates were resolved on a 10% gel by reducing SDSPAGE and were Western blotted as previously described using a blocking solution
containing 10% milk.

A 1:2000 dilution of rabbit anti-PARP (Roche) and 1:2000

dilution of goat anti-rabbit HRP conjugate (Bio-Rad) were used.
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Bax Translocation and Cytochrome C Release Assay
MCF-7 cells were resuspended in RPMI Medium 1640 supplemented with 10%
CSS at a concentration of 1 x 106 cells/ml. Two milliliters of the suspension was used to
seed each well of a six-well culture plate. After 24 h incubation, the medium was
replaced with medium containing 1 µg/ml G129R, PE, G129R-PE40-KDEL, or TNF-α.
After 24 h, the cells were washed with PBS, collected in microcentrifuge tubes, and
permeabilized in 200 µl of ice cold Digitonin Lysis Buffer (75 mM KCl, 1 mM
NaH2PO4, 8 mM Na2HPO4, 250 mM sucrose, 190 µg/ml digitonin). After 5 min on ice,
the cells were centrifuged for 5 min at 16,000 x g at 4°C and the supernatants were
transferred to new microcentrifuge tubes. Laemmli buffer was added to the supernatants
containing the cytosolic fraction and to the pellets containing the membrane fractions and
the samples were heated at 98°C for 5 min before being separated by reducing SDSPAGE using a 15% polyacrylamide gel.

Western blot analysis was performed as

described previously. A 1:200 dilution of rabbit anti-Cytochrome C (Cell Signaling
Technology, Danvers, MA), a 1:200 dilution of rabbit anti-BAX (Santa Cruz) and a
1:2000 dilution of goat anti-rabbit HRP conjugate (Bio-Rad) were used.
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Fig. 2.4
in E. coli

Schematic representation of plasmid used to produce G129R-PE40-KDEL

The cDNA encoding G129R was fused to the DNA encoding an enzymatically
active form of PE (PE40-KDEL) with a BamH I site separating the two. In an effort to
increase the activity of the fusion toxin, linkers of increasing length were inserted at the
BamH I site between G129R and PE40-KDEL to decrease steric hindrance caused by their
close proximity. The diagram above shows the amino acids encoded by the linkers
inserted between G129R and PE40-KDEL. The fusion toxin used for all studies is shown
highlighted. The selection was based on its superior potency at inhibiting protein
synthesis.
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Results
Construction, Expression, and Purification of PRL-PE40-KDEL
and G129R-PE40-KDEL
To target the PE40 toxin to the PRLR, we fused cDNA encoding hPRL or G129R
to the N-terminus of DNA encoding PE40 and replaced the DNA sequence encoding the
native endoplasmic reticulum retention sequence (REDLK) of the toxin with a sequence
encoding KDEL to increase its cytotoxicity (Fig. 2.4). Linkers of increasing length were
inserted between hPRL or G129R and PE40-KDEL since the fusion toxins had little
cytotoxicity with the G4S linker (Fig. 2.4). For all studies we used the fusion toxins
containing the Gly-Gly-Gly-Gly-Ser-Thr-Leu-Arg-Asp-Leu-Phe-Asp-Arg-Ala-Val-ValLeu-Ser-His-Tyr-Ile-His-Asn-Leu-Ser-Ser-Glu-Met-Phe-Ser-Glu-Gly-Ser (helix1) linker
since they showed greater potency.

PRL-PE40-KDEL and G129R-PE40-KDEL were

produced in E. coli and found to accumulate in the insoluble fraction as inclusion bodies.
The inclusion bodies were isolated and denatured and the fusion toxins were refolded and
purified by anion-exchange chromatography to yield preparations of greater than 90% purity.
Purified G129R-PE40-KDEL was analyzed by reducing SDS-PAGE and was found to have a
size corresponding to the predicted molecular mass of 66 kDa (Fig. 2.5A). Western blots with
antibodies that detect the G129R and PE40-KDEL moieties confirmed the identity of purified
protein to be G129R-PE40-KDEL (Fig. 2.5, B and C).
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WB w/ anti-hPRL
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Fig. 2.5
Reducing SDS-PAGE (A) and Western blot analysis (B and C) of purified
PE (66 kD), G129R (23 kD), and G129R-PE40-KDEL (66 kD) in lanes 1 thru 3,
respectively
The purity of G129R-PE40-KDEL was confirmed after reducing SDS-PAGE by
staining with SYPRO® Orange (A). The identity of the protein was confirmed by
Western blotting with antibodies that detect the G129R (B) and PE40-KDEL moieties (C)
as indicated by arrows.
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Fig. 2.6
Binding of hPRL, G129R, and G129R-PE40-KDEL to PRLRs on the
surface of T-47D human breast cancer cells
The ability of hPRL, G129R and G129R-PE40-KDEL to bind to PRLRs was
determined by measuring their ability to compete with 125I-labeled hPRL for binding to
the surface of the cells. Each data point represents the mean + SD of at least three
independent experiments.
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G129R-PE40-KDEL Binds to Prolactin Receptor
The ability of G129R and G129R-PE40-KDEL to specifically bind to PRLRs
expressed on the surface of T-47D human breast cancer cells was demonstrated using a
radio-receptor binding assay. Figure 2.6 shows that increasing doses of hPRL, G129R, or
G129R-PE40-KDEL were able to competitively reduce the binding of

125

I-hPRL to

PRLRs. This confirmed that G129R-PE40-KDEL retains the ability to bind to PRLRs;
however, the higher percent specific binding of

125

I-hPRL suggests that G129R-PE40-

KDEL has a reduced affinity for PRLRs in comparison to hPRL and G129R. The EC50s
for hPRL, G129R and G129R-PE40-KDEL were determined to be 2.7 nM, 6.3 nM, and
76.5 nM, respectively.
PRL-PE40-KDEL Activates STAT5 and G129R-PE40-KDEL Inhibits STAT5
Phosphorylation
Human PRL induces PRLR dimerization and leads to the phosphorylation of
STAT5 via receptor associated JAK2. The PRL-PE40-KDEL fusion toxin retained the
ability of the hPRL moiety to bind to PRLRs on T-47D human breast cancer cells and
activate STAT5 phosphorylation (Fig. 2.7), albeit with only a fraction (1/10th) of the
activity of hPRL. The ability of this fusion toxin to activate STAT5 suggested that
G129R-PE40-KDEL should be able to bind to and antagonize the PRLR. Like G129R,
G129R-PE40-KDEL did not activate STAT5 (Fig. 2.8A) and was able to compete with
hPRL for occupancy of the PRLR as shown by its ability to partially block STAT5
phosphorylation (Fig. 2.8B). G129R-PE40-KDEL was unable to completely block the
action of hPRL at a ratio of 1:100 and had antagonistic activity less than 1/10th that of
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G129R, which corresponds with the reduced activity observed for PRL-PE40-KDEL.
These findings are consistent with the fusion toxins retaining the ability to bind to PRLR
but with a reduced affinity.
The PE40-KDEL Moiety of G129R-PE40-KDEL Retains the Ability to Cleave PARP
Having confirmed that the G129R moiety retains its ability to bind and block
receptor activation, we wanted to determine if the PE40-KDEL moiety retained its
activity. Previously, it has been shown that treatment of MCF-7 cells with PE results in
the activation of caspases that cleave PARP into 89 kDa and 24 kDa fragments (KepplerHafkemeyer et al., 1998). Figure 2.9A shows that PE cleaved this DNA repair enzyme
and that this cleavage was inhibited by treating the cells with the broad spectrum caspase
inhibitor, zVAD-fmk. Neither hPRL nor G129R caused cleavage of PARP, confirming
that the ability of G129R-PE40-KDEL to cleave PARP is due the PE40-KDEL moiety of
the fusion toxin (Fig. 2.9A).
A cell proliferation assay was used to examine the cytotoxic effects of PE and
G129R-PE40-KDEL on MCF-7 cells in the presence or absence of zVAD-fmk. Both PE
and G129R-PE40-KDEL were found to have cytotoxic effects, confirming that at least a
portion of the fusion toxin was taken up and processed correctly by MCF-7 cells (Fig.
2.9B). Interestingly, pretreatment with zVAD-fmk had little effect on the viability of the
cells, indicating that caspase mediated apoptosis does not play a major role in cell death
associated with protein synthesis inhibition (Fig. 2.9B).
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Fig. 2.7
Stimulation of STAT5 phosphorylation by hPRL and PRL-PE40-KDEL
using T-47D human breast cancer cells
The ability of hPRL and PRL-PE40-KDEL to bind to PRLRs and activate STAT5
was determined by treatment of the cells with 4 nM of hPRL or increasing concentrations
of PRL-PE40-KDEL. Phosphorylated STAT5 (p-STAT5) was detected by Western blot
using an anti-phospho STAT5 antibody and is indicated by the arrow.
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Fig. 2.8
Competitive inhibition of STAT5 phosphorylation by G129R and G129RPE40-KDEL in T-47D human breast cancer cells
The inability of G129R and G129R-PE40-KDEL to activate STAT5 (A) and their
ability to competitively block hPRL-induced STAT5 activation (B) was determined by
Western blot with antibodies against phosphorylated STAT5 (p-STAT5) and STAT5.

62

A
50 µM zVAD-fmk

-

(-)

+

-

PE

PRL
+

+

G129R
+

G129R-PE40KDEL
+

24 kDa PARP
fragment

Relative Cell Viability
(% of Control)

B
no zVAD-fmk

50 µM zVAD-fmk

100
80
60
40
20
0
Control

PE

G129R-PE40-KDEL

Fig. 2.9
Examination of PARP cleavage and the effect of zVAD-fmk on the
viability of MCF-7 breast cancer cells treated with PE, hPRL, G129R, or G129R-PE40KDEL
Cells were treated for 24 h with 1 µg/ml of PE, hPRL, G129R, or G129R-PE40KDEL in the absence or presence of a broad spectrum caspase inhibitor, zVAD-fmk (A
and B). The cell lysate was separated by reducing SDS-PAGE, and immunblotted with
anti-PARP antibody. The caspase mediated cleavage of PARP is indicated by the
presence of a 24 kDa PARP fragment as shown by the arrow (A). The role of activated
caspases in cytotoxicity caused by PE or G129R-PE40-KDEL was examined by
measuring the reduction of MTS by living cells in the absence or presence of zVAD-fmk
(B). Data presented is representative of the mean + SD from assays performed in
quadruplicate on two separate occasions.
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G129R-PE40-KDEL Triggers Bax Translocation to the Mitochondria and Induces
Cytochrome C Release
Cytochrome C release is an indicator of mitochondrial damage and is regulated in
part by the translocation of Bax from the cytosol to the mitochondria. To assess Bax
translocation to the mitochondria and cytochrome C release from the mitochondria we
examined their levels in the cytosolic and membrane fractions of MCF-7 cells treated
with G129R, PE, G129R-PE40-KDEL, or TNF-α (Fig. 2.10). Densitometric analysis of
the Western blots revealed no difference in the total amount (cytosolic fraction +
membrane fraction) of Cytochrome C and Bax between treatments, but a difference in
their subcellular location. Cytochrome C was undetectable in the cytosolic fraction of
untreated or G129R treated cells. Consistent with Cytochrome C release, treatment with
PE or G129R-PE40-KDEL increased cytosolic levels while reducing mitochondrial levels
of Cytochrome C. Consistent with Bax translocation, an increase in mitochondrial levels
and a reduction in cytosolic levels of Bax were observed in PE and G129R-PE40-KDEL
treated cells.
G129R-PE40-KDEL Inhibits Protein Synthesis and Decreases the Viability of Breast
Cancer Cell Lines Expressing PRLR
Human breast cancer cell lines expressing various levels of PRLR were treated for
48 h with increasing doses of G129R-PE40KDEL and the inhibition of protein synthesis
(Fig. 2.11A) and its effect on the relative viability of the cells (Fig. 2.11B) was
determined by measuring the incorporation of 3H-leucine into perceptible protein and by
colorimetrically measuring the reduction of MTS by living cells, respectively.
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Fig. 2.10
The effect of G129R, PE, and G129R-PE40-KDEL on the subcellular
location of Bax and Cytochrome C in MCF-7 human breast cancer cells
Cells were treated for 24 h with 1 µg/ml of G129R, PE, G129R-PE40-KDEL, or
TNF-α. The membrane fractions containing the mitochondria and the cytosolic fractions
were separated by reducing SDS-PAGE and immunblotted with antibodies against Cyt C
and Bax. A reduction in the membrane fraction of Cyt C with an increase in the cytosolic
fraction of Cyt C is in accordance with Cytochrome C release. A reduction in the
cytosolic fraction of Bax with an increase in the membrane fraction of Bax is in
accordance with Bax translocation.
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Fig. 2.11
The effect of G129R-PE40KDEL on protein synthesis and the relative
viability of human breast cancer cell lines expressing different levels of PRLR
Cells were treated for 48 h with increasing doses of G129R-PE40KDEL and the
inhibition of protein synthesis was determined by measuring the incorporation of 3Hleucine into perceptible protein (A). The relative number of viable cells was determined
colorimetrically by measuring the reduction of MTS by living cells (B). Data points
presented are representative of the mean + SD from three assays performed in
quadruplicate.
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Cells expressing PRLRs were markedly more sensitive to G129R-PE40-KDEL than cell
lines such as MDA-MB231 and MDA-MB453 which lack or have few PRLRs (Fig. 2.11,
A and B).
The Inhibitory Effect of G129R-PE40-KDEL is Mediated via the G129R Moiety and
is Due to the Inhibition of Protein Synthesis by the PE40-KDEL Moiety
Previously, we have shown that G129R can inhibit the proliferation of breast
cancer cells. At the concentrations used, G129R appeared to be cytostatic and did not
decrease the viability of T-47D, MCF-7, or BT-474 breast cancer cells which have
elevated levels of the PRLR (Fig. 2.12). Even with the greater than ten-fold reduced
receptor binding affinity and reduced antagonistic activity as indicated by STAT5
phosphorylation, G129R-PE40-KDEL was extremely cytotoxic in comparison to G129R.
Fusion of G129R with PE40-KDEL drastically decreased the relative number of viable
cells at concentrations well below those observed for G129R, suggesting that the
increased cytotoxicity was due to the PE40-KDEL moiety of the fusion toxin.
To confirm that the killing observed with G129R-PE40-KDEL was not due to nonspecific binding and to confirm that it was due to the inhibition of protein synthesis by
the PE40-KDEL moiety, we measured the incorporation of 3H-leucine into perceptible
protein and the relative cell viability in response to G129R-PE40-KDEL in the absence or
presence of competitors (Fig. 2.13, A and B). Treatment of T-47D cells with increasing
doses of G129R-PE40-KDEL decreased protein synthesis (Fig. 2.13A); this inhibition was
reduced by co-treatment of the cells with excessive amounts of G129R, suggesting that the
cytotoxic effects of the toxin rely heavily on cell binding. Similarly, cells co-treated with anti-
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PE had no reduction in protein synthesis, indicating that the PE40-KDEL moiety was
responsible for the inhibition of protein synthesis.

Treatment of T-47D cells with

increasing doses of G129R-PE40-KDEL also decreased the relative number of viable cells
(Fig. 2.13B). Co-treatment of the cells with G129R-PE40-KDEL and G129R or hPRL
revealed that the relative number of viable cells was increased by G129R and hPRL.
This confirmed that the inhibition of protein synthesis was mediated through the PRLR
and that the decreased viability was due to the PE40-KDEL moiety. We also examined the
non-specific effects of G129R-PE40-KDEL in mouse 4T1 cells which are extremely
sensitive to PE and the non-specific effects of PE40; G129R-PE40-KDEL was found to
have lower cytotoxicity than PE40 by itself, consistent with the fusion toxin having lower
non-specific cytotoxicity than PE40 alone (Fig. 2.14).
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Fig. 2.12
Comparison of the response of human breast cancer cells to G129R (),
G129R-PE40-KDEL ( ), and PE (U)
The relative viability of three cell lines was examined after 48 h treatment by
measuring the reduction of MTS by living cells. Data points presented are representative
of the mean + SD from assays performed in quadruplicate on three separate occasions.
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Fig. 2.13
Prevention of G129R-PE40-KDEL-induced protein synthesis inhibition
and cytotoxicity by hPRL, G129R, and anti-PE
The ability of G129R-PE40-KDEL to inhibit protein synthesis and decrease the
relative number of viable T-47D cells in the absence or presence of competitors, G129R
(4 μM), PRL (4 μM) or anti-PE antibody (5 μL) was determined by measuring the
incorporation of 3H-leucine into precipitable protein (A) and by measuring the reduction
of MTS by living cells (B). Data points presented in (B) are representative of the mean +
SD from assays performed in quadruplicate on two separate occasions.
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Discussion
Most growth factors and hormones are taken up by receptor-mediated
endocytosis, a broadly named process that can involve a variety of different
internalization pathways. For this reason, the ligand chosen for making a fusion toxin is
not only important for determining its host-range, but also the ability of the toxin to be
properly internalized and processed. Numerous fusion toxins have been constructed by gene
fusion or conjugation of PE40 with cytokines, growth factors, hormones, or antibodies. Most of
these fusion toxins have proven to be cytotoxic to the targeted cells in the picomolar range.
Based on the potency of PE based fusion toxins we wanted to examine the potential of a fusion
toxin that targets the PRLR. Studies have shown that a majority of human breast carcinomas
express higher levels of PRLR than normal mammary tissue (Clevenger et al., 1995;
Reynolds et al., 1997; Touraine et al., 1998) and that their expression patterns differ
markedly (Gill et al., 2001). These observations suggest a relationship between PRLR
overexpression and the pathology of breast carcinomas and were our justification for
making G129R-PE40-KDEL.
Previous studies have reported the mechanism by which hPRL and G129R bind to
the PRLR and activate or inhibit signal transduction, respectively (Goffin et al., 1996;
Chen et al., 1999; Llovera et al., 2000b). We have constructed G129R-interleukin 2 and
G129R-endostatin fusion proteins and showed that their G129R moieties retain the ability
to bind to the PRLR and competitively block hPRL-induced signal transduction (Zhang et
al., 2002; Beck et al., 2003). In these studies we also demonstrated that the interleukin 2
and endostatin portions of the fusion proteins retain the ability to bind to and activate
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receptors on T-cells and endothelial cells, respectively. The intracellular fate of these
fusion proteins remains unknown and is inconsequential since their functions are believed
to be served solely on the surface of the cells. Unlike G129R-interleukin 2 and G129Rendostatin, the fusion of G129R to PE40-KDEL would require PRLR mediated
internalization and processing of the toxin to enter the cytoplasm and inhibit protein
synthesis.
Little is known of the intracellular fate of hPRL and even less is known of the fate
of G129R. In rat liver cells it has been demonstrated that PRL undergoes receptor
mediated endocytosis and accumulates intact in the Golgi region (Josefsberg et al., 1979;
Posner et al., 1982) before degradation occurs (Bergeron et al., 1983). In lactating rat
mammary epithelial cells PRL has been shown to avoid degradation in lysosomes by
undergoing transcytosis; possibly via the fusion of the vesicles in the Golgi region with
secretory vacuoles (Seddiki et al., 2002). In addition to remaining in endosomes or
undergoing degradation, PRL has also been shown to undergo nuclear retrotranslocation
in rat Nb2 lymphoma cells (Clevenger et al., 1990b; Clevenger et al., 1990a; Rao et al.,
1993). This nuclear PRL has been shown to have nuclear actions (Clevenger et al., 1991;
Rao et al., 1995) and can modulate transcriptional events in part by interacting with
chaperones such as cyclophilin B (Rycyzyn et al., 2000; Rycyzyn and Clevenger, 2002).
In rat pituitary mammotrophs PRL was observed in all of these locations except
lysosomes (Giss and Walker, 1985). The presence of PRL in the Golgi apparatus,
secretory vesicles, and the nucleus suggest multiple intracellular fates for PRL in addition
to endosome/lysosomes, the organelle PE exploits to gain access to the cytoplasm.
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Fig. 2.14
Examination of non-specific cytotoxicity in 4T1 mouse breast cancer cells
in response to G129R, PE40, and G129R-PE40-KDEL
The consequence of fusing G129R to PE40-KDEL was examined to determine the
effect on non-specific cytotoxicity. Cells were treated with PE, PE40, G129R-PE40KDEL, or G129R and the relative number of viable cells was examined after 48 h by
measuring the reduction of MTS. Data points presented are representative of the mean +
SD from assays performed in quadruplicate on two separate occasions.
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Table 2.1
Extrapolated concentrations of G129R-PE40-KDEL necessary for 50%
inhibition of protein synthesis and 50% reduction in the relative number of viable cells in
various breast cancer cell lines

Cell Line

PRL
Cell
Protein
Synthesis Cytotoxicity Binding*
IC50 (nM)
IC50 (nM)

MCF-7

0.9

4.75

++

BT-474

2.1

4.8

++

BT-134

6

22.7

ND

T-47D

8.2

12.5

+++

MDA-MB-453

29.6

>100

+

MDA-MB-231

>33

>100

+/-

*Ormandy et al. 1997. J Clin Endo & Metab. 82:3692-3699.
Shiu et al., 1987. Recent Prog Horm Res. 43:277-303.
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In this study we demonstrate that G129R-PE40-KDEL is able to inhibit protein
synthesis and cell proliferation in multiple human breast cancer cell lines that express the
PRLR (Fig. 2.11). We did not anticipate that the inhibitory concentrations for G129R-PE40KDEL would be in the nanomolar range rather than the picomolar range (Table 2.1). To
further examine this, we utilized T-47D breast cancer cells since they are hPRL responsive
and express relatively high levels of PRLR (Shiu et al., 1987). We demonstrate that the
inhibitory effects of G129R-PE40-KDEL can be reduced drastically by treatment with excess
amounts of G129R or antibody against PE (Fig. 2.13), suggesting that the cytotoxic effects of
the fusion toxin rely heavily on cell binding and are mediated via the toxin moiety. We also
examined the ability of G129R-PE40-KDEL to compete with 125I-labeled hPRL for binding to
T-47D cells and confirmed that G129R-PE40-KDEL is able to bind to the PRLR with an
approximately 28-fold lower affinity than hPRL and approximately eleven-fold lower
affinity than G129R (Fig. 2.6).
The lower receptor binding affinity of G129R-PE40-KDEL may be due its size
and a conformational change in the G129R moiety which make it less accessible to PRLR
than G129R.

The lower binding affinity of G129R-PE40-KDEL provides a logical

explanation for its poor inhibitory effects on STAT5 activation by hPRL (Fig. 2.8B). The
reduced affinity of G129R-PE40-KDEL for the PRLR may also account for the necessity
to use nanomolar concentrations to inhibit protein synthesis and cause cell death. To
ensure that the cytotoxicity observed in the nanomolar range was not due to non-specific
binding, we examined the effects on mouse 4T1 cells which are extremely sensitive to the
specific and non-specific effects of PE and PE40, respectively. We observed that fusion
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of G129R to PE40-KDEL actually reduced the non-specific side effects associated with
PE40 (Fig. 2.14), indicating that G129R-PE40-KDEL may actually decrease the nonspecific cytotoxicity associated with the PE40 moiety.

To further ensure that the

cytotoxicity observed was due to specific binding, we examined the effects on cell lines
that express the PRLR. The concentrations of G129R-PE40-KDEL necessary to reduce
the relative number of viable cells were orders of magnitude lower than the concentrations of
G129R needed to show any affect (Fig. 2.12); similarly, treatment of the human breast cancer
cell lines with PE40 alone resulted in little or no killing of the cells (data not shown). This
suggests that the cytotoxic effects observed are mediated via the PRLR and only occur if
G129R is fused with PE40-KDEL.
We evaluated the relationship between sensitivity to G129R-PE40-KDEL and
PRLR mRNA expression level based on two studies that quantified the expression of the
long isoform of PRLR mRNA in human breast cancer cell lines using Northern blot
analysis (Ormandy et al., 1997b) and real-time PCR (Peirce et al., 2001). Both studies
identified T-47D, MDA-MB-134, MDA-MB-483, and BT-474 cells as having high
PRLR levels; MCF-7 cells as having moderate levels; and MDA-MB-453 and MDAMB-231 cells as having little or no expression. All of the cell lines reported to express
high levels of PRLR were more sensitive than the cell lines reported to have few or no
PRLR (Fig. 2.11). We also noticed that MCF-7 cells, reported to have modest PRLR
levels, were more sensitive than all of the cell lines with high PRLR expression levels
(Fig. 2.11). The most obvious reason for the discrepancy would be that the mRNA levels
don’t necessarily correlate with actual PRLR levels; however, this would not explain why
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T-47D cells are not the most sensitive to G129R-PE40-KDEL since studies have shown
they have the highest PRLR binding activity (Shiu et al., 1987; Ormandy et al., 1997b).
Differences in the rate at which the PE40 moiety is processed and translocated may affect
the sensitivity of the cells.

As controls for all of the cell proliferation assays we

examined the sensitivity of the cell lines to PE. All of the cell lines showed various
degrees of sensitivity to PE, with MCF-7 cells being the most sensitive. This suggests
that processing of PE is the rate limiting step in intoxification and that sensitivity may not
necessarily reflect PRLR expression levels.
Another explanation for the lack of a clear correlation between long isoform of PRLR
mRNA expression level and sensitivity to G129R-PE40-KDEL may be explained by the
complexity of PRLR expression. Multiple promoters (Hu et al., 2002) and multiple PRLR
isoforms have been identified that arise from alternative splicing in humans (Clevenger et al.,
2003). In addition to the long isoform of PRLR which activates all known PRL signaling
pathways, isoforms displaying differences in the extracellular or cytoplasmic domains have
been identified that may have roles in the development and function of normal human
mammary tissue and breast carcinomas. A transcript that would result in a soluble form of
PRLR has been found to be lower in human breast carcinomas than in normal mammary
tissue and may modulate the expression of the long isoform of PRLR (Laud et al., 2000).
An isoform of PRLR with an extracellular truncation has also been identified in normal
and malignant human breast tissue that has reduced binding affinity for PRL (Kline et al.,
2002).

Isoforms of PRLR with truncations in the cytoplasmic domain have also been

identified that may affect intracellular signaling and the internalization rates. An intermediate
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isoform was identified in human breast cancer biopsies (Clevenger et al., 1995) that lacks
STAT5 motifs and has diminished ability to activate Fyn (Kline et al., 1999) and two short
isoforms have been identified that are incapable of activating JAK2/STAT5 signaling (Hu et
al., 2001). These short isoforms are expressed widely in human tissues and may modulate PRL
signaling through the long isoform by acting in a dominant negative manner (Hu et al., 2001;
Trott et al., 2003). Recently, it has been observed that the ratio of short forms to long forms
appears to be lower in human breast carcinomas and breast cancer cell lines than in normal
samples (Meng et al., 2004). The short forms of the rodent and bovine PRLR have been
shown to have a slower internalization rate than the long isoform (Lu et al., 2002). The
presence of multiple PRLR isoforms with variations in expression level; the potential of
these PRLRs to form homodimers and heterodimers with differences in binding affinity
and internalization rates; and the lack of data concerning the trafficking and degradation of
these various PRLR isoforms make it difficult to predict the potential effectiveness of
G129R-PE40-KDEL based solely on PRLR mRNA expression levels.
Studies regarding the status of PRLR in human breast cancer patients are limited
in contrast to the estrogen receptor status. From the relatively small numbers of clinical
studies it appears that the PRLR levels are elevated in a majority of primary human breast
cancers (Clevenger et al., 1995; Reynolds et al., 1997; Touraine et al., 1998). The high
levels of PRLR in the malignant breast tissue provide an opportunity to design targeted
therapeutics such as ligand directed toxin in this case. We show that G129R-PE40-KDEL
binds to the PRLR with 28-fold reduced affinity compared to that of hPRL and retains
one-tenth of the ability of G129R to inhibit PRL-induced STAT5 phosphorylation yet
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drastically increases the specific cytotoxicity.

In addition, we show that it can be

administered safely to mice in vivo (Table 2.2). The clinical potential of this ligand
targeted toxin will largely depend upon improving the binding affinity of the fusion toxin
towards the PRLR.
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Table 2.2 Toxicity of PE and G129R-PE40-KDEL to mice

Protein

µg/mouse

Mortality

Single Dose
PE66

10

4/4

G129R-PE40-KDEL

50

0/4

G129R-PE40-KDEL

100

3/4

Daily Dose
G129R-PE40-KDEL

15

0/4

Mice were injected i.p. with a single dose or five times a week for
two weeks. The number of dead mice was determined 72 h after
administration.
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CHAPTER THREE
IMPROVING THE PHARMACOKINETIC PROPERTIES OF
PROLACTIN AND GROWTH HORMONE RECEPTOR
AGONISTS AND ANTAGONISTS BY FUSION TO A
SYNTHETIC ALBUMIN BINDING PEPTIDE
Abstract
Human growth hormone (hGH) must be administered daily in order to achieve
therapeutic effects due to its short circulation half-life. Human prolactin (hPRL), with
similar molecular size as hGH, shares a similar pharmacokinetic profile.

Prolactin

receptor (PRLR) and growth hormone receptor (GHR) antagonists, G129R and G120R,
developed by introducing amino acid substitutions into hPRL and hGH, respectively,
suffer a similar fate in vivo. To prolong the circulation half-life, and therefore reduce the
frequency of injection of these potential therapeutics, we examined the effects of fusing a
serum albumin binding peptide, SA20 (Dennis et al., 2002), to the N-terminus or Cterminus of hPRL, hGH, and their respective antagonists. Fusion of the SA20 peptide to
the N-terminus of the ligands was less detrimental upon the intrinsic activities of the
ligands, i.e. the ability to induce or inhibit signal transduction or rat Nb2 cell
proliferation, than when fused to the C-terminus. For pharmacokinetic studies, SA20hPRL (4 mg/kg) and hPRL-SA20 (4 mg/kg) exhibited a 4-fold prolonged plasma half-life
compared to hPRL (3.59 mg/kg) and their clearance was reduced approximately 9.5-fold
and 7-fold, respectively, after intraperiotneal (i.p.) administration of a single dose to
mice. Based upon the signaling results in vitro and the pharmacokinetic profiles in vivo,
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only the fusion proteins with SA20 fused to the N-terminus were further used for
pharmacodynamic studies. SA20-hPRL (4 mg/kg), hPRL (3.59 mg/kg), or PBS was i.p.
administered to 8-week-old female mice daily, every two days, or every third day over a
12-day period. The number of lobulo-alveolar-like structures in mammary glands was
greater in the three groups of mice treated with SA20-hPRL in comparison to hPRL.
SA20-hGH (8 mg/kg), hGH (7.15 mg/kg), or PBS were i.p. administered to 23-day-old
female mice daily over a 40-day period. The weight gain, body length, and number of
lobulo-alveolar-like structures in the mammary glands were greater in the mice treated
with SA20-hGH than hGH. These findings indicate that SA20-hPRL and SA20-hGH are
biologically active, that the serum albumin binding peptide improves the pharmacokinetic
properties of otherwise short lived hPRL and hGH, and that it enhances the efficacy of
hPRL and hGH in vivo by reducing their clearance from plasma.
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Introduction
Human prolactin (hPRL) and human growth hormone (hGH) are members of the
somatotropin/prolactin family of four-helical cytokines which regulate the survival,
proliferation and differentiation of cells in a variety of tissues and endocrine glands.
hPRL mediates its effects via prolactin receptors (PRLRs); whereas, hGH mediates its
effects via PRLRs or growth hormone receptors (GHRs). Because hPRL and hGH have a
low molecular weight (23 kDa and 22 kDa, respectively) and are protein in nature, they
are rapidly removed from circulation via renal clearance and by proteolytic degradation
within responsive tissues. For these reasons recombinant (r) hPRL and hGH must be
administered subcutaneously on a daily basis to maintain physiologically relevant plasma
concentrations in humans (Kastrup et al., 1983; MacGillivray et al., 1996; 2000b).
To the best of our knowledge, no long-acting formulations of rhPRL are under
development that would reduce the frequency of administration by sustaining its release
or by extending its plasma half-life. Sustained release of rhPRL could be achieved by
encapsulating it in microspheres of biodegradable polymers such as poly(D,L-lactide-coglycolide) or by creating hydrogels using poly(ethylene glycol) (PEG) modified with
fluorocarbon end groups, these strategies have proven effective for rhGH (Johnson et al.,
1996; Brodbeck et al., 1999; Tae et al., 2005). The pharmacokinetic properties of rhPRL
and rhGH may also be enhanced by expanding their absorptional half-life and reducing
their elimination half-life. This has been achieved for rhGH by covalently attaching one
or more PEG chains to the N-terminus and/or amino groups of lysine residues within
rhGH (Clark et al., 1996), allowing the hydrophilic regions of PEG to interact with water
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molecules and effectively increase the size of the conjugated protein above the limit of
filtration by the kidney. Thus, PEGylation enhances the mean residence time by reducing
the glomerulus filtration rate. The greater the degree of PEGylation, the higher the mean
residence time in the bloodstream; unfortunately, the degree of PEGylation is also
correlated with a reduction in potency (Clark et al., 1996). This random conjugation of
PEG to lysine residues decreases the accessibility of the ligands for receptor-binding.
Recently, site-specific PEGylation has been achieved by introducing an unpaired cysteine
residue into a non-essential site of rhGH followed by modification with a cysteinereactive PEG (Cox et al., 2007).
In this study, we examine another means to expand the absorptional half-life and
reduce the elimination half-life of rhPRL, rhGH, and their antagonists. We report that the
fusion of a small serum albumin binding peptide to the N-terminus of rhPRL or rhGH:
(1) results in minimal deleterious effects on their ability to induce signaling via the Janusactivated kinase 2 (JAK2)/signal transducer and activator of transcription 5 (STAT5) and
Ras/Raf/MEK/mitogen-activated protein kinases (MAPKs) signaling cascades; (2)
induces proliferation of Nb2 cells in a manner similar to that of unmodified rhPRL and
rhGH in vitro; (3) increases their mean residence time by reducing glomerulus filtration;
and (4) enhances proliferation and differentiation of epithelial cells within the lobules of
mammary glands in vivo.
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Materials and Methods
Cell Lines and Reagents
T-47D human breast ductal carcinoma cells and IM-9 Epstein-Barr virustransformed human B-lymphoblastoid cells were obtained from the American Type
Culture Collection (Manassas, VA). Nb2-11 rat pre-T lymphoma cells (Nb2) were kindly
provided by Dr. Ameae Walker and are now commercially available from Sigma-Aldrich
(St. Louis, MI). All reagents were purchased from Invitrogen (Carlsbad, CA) unless
otherwise stated. T-47D cells were maintained in RPMI Medium 1640 supplemented
with 10% fetal bovine serum (FBS) and 10 µg/ml gentamicin. For IM-9 cells, the
medium was further supplemented with 10 mM HEPES and 1.0 mM sodium pyruvate.
Nb2 cells were maintained in RPMI Medium 1640 supplemented with 10% FBS, 10%
horse serum (HS), 10 µg/ml gentamicin, and 0.1 mM 2-mercaptoethanol. The cell lines
were incubated at 37°C with humidity and 5% CO2.
Construction of Plasmids for Expression of Albumin Binding Fusion Protein
Plasmids encoding the cDNAs for hPRL, hGH, G129R, and G120R were used as
DNA templates for the polymerase chain reaction (PCR). PCR was performed using the
Advantage-HF™ Kit (BD Biosciences, Palo Alto, CA).

All oligonucleotides were

synthesized by Integrated DNA Technologies (Coralville, IA) and are shown in Table
3.1.

Oligonucleotide primers for PCR were designed to incorporate restriction

endonuclease cleavage sites upstream and downstream of the gene of interest. The PCR
products were ligated with pCR2.1 T/A cloning vector and transformed into Escherichia
coli (E. coli) TOP10 cells obtained from Invitrogen. Positive clones were identified by
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Table 3.1 List of oligonucleotides used to construct DNA
encoding albumin-binding fusion proteins
Nde I-SA20-BamH I Linker (Cohesive Ends)
Nde I-SA20 for 1

5’-TATGCAGCGTCTGATTGAAGAT-3’

SA20 for 2

5’-ATTTGCCTGCCGCGTTGGGGCTG-3’

SA20-Bam H I for 3

5’-CCTGTGGGAAGATGATTTTG-3’

SA20-Bam HI rev 1

5-GATCCAAAATCATCTTCCCACAGGCAGCCCCA-3’

Nde I-SA20 rev 2

5’-ACGCGGCAGGCAAATATCTTCAATCAGACGCTGCA-3’
BamH I-SA20-stop-Xho I Linker (Cohesive Ends)

BamH I-SA20 for 1

5’-GATCCCAGCGTCTGATTGAAGAT-3’

SA20 for 2

5’-ATTTGCCTGCCGCGTTGGGGCTG-3’

SA20-Xho I for 3

5’-CCTGTGGGAAGATGATTTTTAAC-3’

SA20-Xho I rev 1

5’-TCGAGTTAAAAATCATCTTCCCACAGGCAGCCCCA-3

BamH I-SA20 rev 2

5’-ACGCGGCAGGCAAATATCTTCAATCAGACGCTGG-3’
Nde I-PRL-BamH I & Nde I-G129R-BamH I

Nde I-PRL for

5’-CATATGTTGCCCATCTGTCCCGGCGGGG-3’

PRL-BamH I rev

5’-CTGGGATCCGCCGCCGCAGTTGTTGTTGTG-3’

BamH I-PRL-stop-Xho I & BamH I-G129R-stop-Xho I
BamH I-PRL for

5’-GGATCCTTGCCCATCTGTCCCGGCGG-3’

PRL-stop-Xho I rev

5’-CTCGAGTTAGCAGTTGTTGTTGTGGA-3’
Nde I-GH-BamH I & Nde I-G120R-BamH I

Nde I-GH for

5’-CATATGTTCCCAACCATTCCCTTATCCAG-3’

GH-BamH I rev

5’-GGATCCGAAGCCACAGCTGCCCTCCACA-3’

BamH I-GH-stop-Xho I & BamH I-G120R-stop-Xho I
BamH I-GH for

5’-GGATCCTTCCCAACCATTCCCTTATCCAGG-3’

GH-stop-Xho I rev

5’-CTCGAGCTAGAAGCCACAGCTGCCCTCCAC-3’
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plating the cells on Luria-Bertani (LB) agar plates containing 100 µg/ml ampicillin and
80 µg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside. Plasmids were isolated
using the QIAprep® Spin Miniprep Kit (Qiagen, Valencia, CA), restriction endonuclease
digested, and the DNA fragments were separated by electrophoresis. The Nde I-PRLBamH I, Nde I-G129R-BamH I, Nde I-GH-BamH I, Nde I-G120R-BamH I and BamH IPRL-stop-Xho I, BamH I-G129R-stop-Xho I, BamH I-GH-stop-Xho I, and BamH IG120R-stop-Xho I DNA fragments were purified from the agarose gel using the
QIAquick® Gel Extraction Kit (Qiagen). Double stranded DNA encoding the serum
albumin binding peptide, SA20, was prepared by annealing five oligonucleotides together
that had been treated with T4 polynucleotide kinase. The oligonucleotides were designed
to create cohesive ends ready for ligation with restriction digested DNA utilizing optimal
codons for expression in E. coli. The DNA fragments were ligated with Nde I and Xho I
cut pET22b(+) (Novagen, Madison, WI) to create pET22b-SA20-hPRL, pET22b-hPRLSA20, pET22b-SA20-G129R, pET22b-G129R-SA20, pET22b-SA20-hGH, pET22bhGH-SA20, pET22b-SA20-G120R, and pET22b-G120R-SA20.

All restriction and

modifying enzymes were purchased from New England BioLabs (Beverly, MA).
Production and Purification of Albumin Binding Fusion Proteins
To understand the nomenclature, SA20-hPRL is hPRL fused at its N-terminus to
the C-terminus of a serum albumin binding peptide and has a molecular mass of
approximately 25.7 kDa. In contrast, hPRL-SA20 is hPRL fused at its C-terminus to the
N-terminus of a serum albumin binding peptide and has a molecular mass of
approximately 25.8 kDa. In addition to hPRL, SA20 derivatives of G129R, hGH and
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G120R were produced using a bacterial system. Chemically competent Rosetta™ (DE3)
pLysS E. coli cells (Novagen) were transformed with the constructs and propagated
overnight at 37°C with agitation in LB broth containing 100 µg/ml ampicillin. The next
morning 1 L baffled flasks containing 500 ml of Terrific Broth with 100 µg/ml ampicillin
were inoculated with 20 ml of each of the starter cultures. The cultures were grown to an
O.D.600 of 0.9 before induction of protein production with 1 mM isopropyl-βthiogalactoside (Alexis Biochemicals, San Diego, CA). After 4 h of induction the cells
were harvested by centrifugation at 5,000 x g for 5 min and resuspended in Solution 1 (50
mM Tris·HCl; 10 mM EDTA; 0.5% Triton X-100; pH adjusted to 8.0) to which 0.4
mg/ml lysozyme was added. The cells were incubated at room temperature for 1 h to
weaken the cell membranes before the cells were sheared on ice with five 1-min
ultrasonic pulses (30% duty at setting 7) using a 550 Sonic Dismembrator (Fisher
Scientific, Waltham, MA). The insoluble fraction containing the inclusion bodies was
recovered by centrifugation at 12,000 x g for 30 min at 4°C and resuspended in Solution
2 (50 mM Tris·HCl; 10 mM EDTA; 1 M urea; pH adjusted to 8.0). The inclusion bodies
were collected by centrifugation at 12,000 x g for 30 min at 4°C and were solubilized and
denatured in Solution 3 (50 mM Tris·HCl; 10 mM EDTA; 8 M urea; 1% v/v 2mercaptoethanol; pH adjusted to 12.0). The proteins were refolded by dialysis against baths of
50 mM Tris·HCl, pH 8.0 containing decreasing amounts of urea (4M urea, 2 M urea, 0 M urea,
0 M urea) at 4°C. The refolded proteins were filtered through 0.45 µm filters and purified by
anion-exchange chromatography using a 5 ml HiTrap Q Sepharose HP column (Amersham
Biosciences, Piscataway, NJ) on an ÄKTA fast protein liquid chromatography system
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(Amersham Biosciences). The concentration of the purified proteins was determined using the
Coomassie Plus™ Protein Assay Reagent (Pierce, Rockford, IL). The purified proteins were
separated by reducing SDS-PAGE along with hPRL standards on a 12% polyacrylamide gel
and stained with SYPRO® Orange (Molecular Probes, Eugene, OR) to confirm their size,
concentration and purity.
STAT5 and Erk1/2 Phosphorylation Assays
T-47D cells were resuspended in RPMI Medium 1640 supplemented with 10%
charcoal/dextran treated FBS (CSS; HyClone, Logan, UT) and 10 µg/ml gentamycin and
plated in twelve-well tissue culture plates.

The cells were grown overnight to

approximately 80% confluency and depleted for 1 h in RPMI Medium 1640
supplemented with 0.5% CSS. Cells were treated for the indicated amounts of times with
the indicated concentrations of hPRL, G129R, hGH, G120R or their albumin binding
counterparts. The cells were washed with ice cold phosphate buffered saline (PBS) and
lysed in 100 µl of Lysis Buffer (20 mM Tris·HCl, pH 7.4; 1% Igepal CA630; 6 mM
deoxycholic acid; 150 mM NaCl; 1 mM EDTA, pH 8.0) containing protease inhibitors (1
µg/ml aprotinin; 1 µg/ml leupeptin; 170 µg/ml PMSF; 180 µg/ml sodium orthovanadate).
The lysates were homogenized and incubated on ice for 20 minutes before clarification
by centrifugation at 12,000 x g at 4°C for 30 min.

Approximately 40 µg of the

supernatants were used for Western blot.
IM-9 cells were harvested by centrifugation and resuspended in DMEM
containing 0.5% CSS.

The volume was adjusted with medium to yield a final
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concentration of 1 x 106 cells per ml. The cells were aliquoted (1 mL) into Eppendorf
tubes and depleted for 1 h before addition of 111 μL of 10X treatments. Cells were
treated for 30 min at 37°C, pelleted, the medium aspirated and resuspend in 100 μL of
Lysis Buffer containing protease inhibitors. Approximately 80 µg of the supernatants
were used for Western blot.
Western Blot Analysis
The cell lysates were separated on 10% polyacrylamide gels by reducing SDSPAGE at 150 V for 1 h and transferred by Western blot to Hybond™ Enhanced
Chemiluminescence (ECL) nitrocellulose membranes (Amersham Biosciences) at 16
Watts for 90 min. The nitrocellulose membranes were blocked for 30 min at room
temperature in Tris buffered saline (TBS) containing 0.05% Tween 20 (TBS-T) and 5%
milk. The membranes were incubated at 4°C with agitation overnight in the blocking
solution containing the primary antibody. The blots were washed three times with TBST, and incubated for 2 h at room temperature with agitation in blocking solution
containing a secondary antibody conjugated to horseradish peroxidase.

Blots were

washed three times with TBS-T and incubated for 1 min with ECL™ Western Blotting
Detection Reagents (Amersham Biosciences). The blots were exposed to Biomax MR
film (Kodak, Rochester, NY) and the film was developed with a Konica SRX-101A
processor (Konica Minolta Medical Imagining, Wayne, NJ).
Blots were initially performed with a 1:1000 dilution of mouse anti-phospho
STAT5A/B antibody (Upstate Biotechnology, Inc. Lake Placid, NY) and 1:1333 dilution
of mouse anti-phospho ERK (sc-7383; Santa Cruz Biotechnology, Santa Cruz, CA)
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followed by a 1:2000 dilution of goat anti-mouse conjugated HRP (Bio-Rad, Hercules,
CA).

Blots were reprobed with a 1:1333 dilution of rabbit anti-STAT5 polyclonal

antibody (sc-835), 1:1000 dilution of rabbit anti-ERK1 (sc-93) and 1:1000 dilution of
rabbit anti-ERK2 (sc-154) from Santa Cruz Biotechnology followed by a 1:2000 dilution
of goat anti-rabbit conjugated HRP (Bio-Rad).
Nb2 Cell Proliferation Assay
Rat Nb2 cells were resuspended to a final concentration of 5.5 x 105 cells per ml
in RPMI 1640 supplemented with 10% low lactogen HS (Cat. 2921154; MP Biomedicals,
Irvine, CA), 10 µg/ml gentamicin and 0.1 mM 2-mercaptoethanol.

The cells were

depleted overnight and reseeded in flat bottom 96-well plates at a density of 20,000 cells
per well in 150 µl of medium. Treatments were added to each well in 50 µl volumes and
the cells were incubated for 72 h. The relative number of cells was determined by
incubating the cells for 4 h with 40 µl of 3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium/phenazine

methosulfate

(MTS/PMS) solution (CellTiter 96 AQueous non-radioactive cell proliferation kit;
Promega, Madison, WI) per well. The reduction of MTS by living cells was determined
by measuring the absorbance at 490 nm using a Benchmark microplate reader (Bio-Rad).
All assays were performed at least three times in quadruplicate.
Pharmacokinetic Studies in Mice
Female FVB/N mice (Charles River Laboratories, Wilmington, MA) eight weeks
of age and weighing 22-25 g were used for all pharmacokinetic studies. Mice were
acclimated to a 12 h light/dark cycle for at least one week prior to the start of the studies
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and provided LabDiet® Prolab® RMH 3000 feed (PMI Nutrition International; St. Louis,
MO) and water ad libitum. All animal studies were approved by the Animal Care and
Use Committee.

For pharmacokinetic studies, mice were administered a single

intraperitoneal (i.p.) injection of SA20-hPRL or hPRL-SA20 at 4 mg/kg body weight, or
an equimolar amount of hPRL using 27 gauge needles with a 0.4 mm bore and 13 mm
length. Blood drippings (10 to 50 µl) were collected via tail-sectioning in hematocrit
tubes at time points determined empirically. The samples were centrifuged and the
plasma was harvested and stored at -80 C until assayed.
Concentrations of hPRL or the fusion proteins were measured using a commercial
IRMA kit (Coat-A-Count® Prolactin IRMA; DPC, Los Angeles, CA) or ELISA kit
(Active® Prolactin ELISA; DSL, Webster, TX) determined to be insensitive to mouse
PRL. hPRL, hPRL-SA20 and SA20-hPRL standards (2 ― 200 ng/ml) were prepared in
the zero calibrator buffer provided with the kits and used to prepare standard curves.
Dilutions of the serum samples were determined empirically and were made in the zero
calibrator buffers. Plasma concentrations were extrapolated from the standard curves
prepared for each protein.
The plasma concentration (Cp) verses time (t) profiles were plotted and noncompartmental methods were used to estimate basic pharmacokinetic parameters. The
peak serum concentrations (Cmax) were measured. The terminal elimination rate constant
(k) was obtained from the terminal slope of the log-linear Cp versus t plots using the last
three data points within the linear portion of their elimination phases. The terminal halflife (t1/2) was calculated as ln2/k. The area under the serum concentration-time curve
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(AUC) and area under the first moment of serum concentration-time curve (AUMC) were
calculated by numerical integration using the trapezoidal rule. AUC0 was extrapolated
using the linear trapezoidal rule; whereas AUC∝ was determined by dividing the last
measurable concentration level by k. AUMC∝ was determined as Cplast·tlast/k + Cplast/k2.
The AUC and AUMC values were used to calculate the mean residence time (MRT),
apparent elimination rate constant (kel’) and total body clearance (CL).
Pharmacodynamic Studies
Starting at 60 days of age, mice (n=6) were injected i.p. with hPRL, SA20-hPRL
or PBS once daily for 12 consecutive days (days 1-12), every other day (days 1, 3, 5, 7, 9,
and 11), or every third day (1, 4, 7 and 10). Individual body weights of the mice were
determined using an analytical balance and the dose of hPRL administered was equimolar
with the amount of hPRL in a 4 mg/kg dose of SA20-hPRL. Blood samples were not
collected throughout the study because we did not want to stress the mice and potentially
compromise the study. Mice were euthanized by cervical dislocation on day 13 and the
right abdominal mammary glands were harvested to prepare whole-mounts to assess
mammary gland morphology. The mammary glands were spread onto glass slides and
fixed overnight in Carnoy’s fixative. The glands were then stained with alum carmine,
destained in water, dehydrated in xylene, and mounted with Permount (Fisher, Pittsburgh,
PA) and a glass cover slip. The whole mounts were scanned to obtain high resolution
images of the glands. The mammary glands were scored for lobulo-alveolar development
(LAD) on a scale of 1– 5. The scoring system used was: 1 = ducts with few side
branches and no lobulo-alveolar buds, 2 = ducts with end buds and few lobulo-alveoli,

93

3 = ducts with limited lobulo-alveolar development, 4= ducts with moderate lobuloalveolar development, 5 = ducts with extensive lobulo-alveolar development.
Pharmacodynamic studies were also carried out for hGH and SA20-hGH.
Starting at 23 days of age, mice (n=6) were injected i.p. with hGH, SA20-hGH or PBS
daily for 40 consecutive days. The dose of hGH was equimolar with the amount in a 8
mg/kg dose of SA20-hGH. Individual body weights of the mice were determined daily
until 44 days of age and three times a week thereafter. Body weight gain was evaluated
using repeated measures analysis of variance (ANOVA). Mice were euthanized by
cervical dislocation on day 63. Tail lengths were measured from anus to tail-tip. The
right posterior mammary glands were harvested, whole mounts were prepared, and
lobulo-alveolar development was scored as mentioned above.
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Results
Construction, Expression, and Purification of Serum Albumin Binding Derivatives
of hPRL, hGH, and Their Antagonists
SA20 derivatives of hPRL, G129R, hGH, and G120R were recombinantly
engineered by gene fusion. The cDNA encoding the mature form of hPRL, G129R,
hGH, or G120R were ligated with DNA encoding the SA20 peptide and cloned into an E.
coli expression vector. Expression of each of the fusion genes in E. coli resulted in a
single protein in which the SA20 moiety was connected to the N-terminus or C-terminus
of the hPRL, G129R, hGH, or G120R moiety via a Gly-Ser peptide linker. The proteins
were found to accumulate in the insoluble fraction as inclusion bodies. The inclusion
bodies

were

isolated,

denatured,

refolded,

and

purified

by

anion-exchange

chromatography to yield preparations of greater than 95% purity. Reducing SDS-PAGE
revealed that the purified fusion proteins had sizes corresponding to their predicted
molecular masses (not shown).
Serum Albumin Binding Derivatives of hPRL and hGH Induce Signal Transduction
Dose response and time course experiments were performed with hPRL, hGH and
their SA20 derivates to determine their potency and efficiency at inducing signal
transduction. Treatment of PRLR expressing T-47D cells with various concentrations of
hPRL (Fig. 3.1A) or hGH (Fig. 3.1B) resulted in the phosphorylation of STAT5 in a
dose-dependent manner. The potency of SA20-hPRL appeared to be equivalent to that of
hPRL; in contrast, the potency of hPRL-SA20 was reduced, requiring approximately 3fold higher molar concentrations to achieve the same degree of STAT5 phosphorylation
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observed for hPRL (Fig. 3.1A). The potency of SA20-hGH at activating STAT5 and
MAPKs, extracellular signal-regulated kinases 1 and 2 (Erk1/2), was reduced
approximately 3.3-fold in comparison to hGH; whereas, the potency of hGH-SA20 was
reduced approximately 10-fold (Fig. 3.1B). To determine if the SA20 derivatives of hGH
also retain the ability to bind to GHRs and activate signaling, we examined the
phosphorylation of STAT5 in IM-9 cells. Treatment with various concentrations of hGH
resulted in the phosphorylation of STAT5 in a dose-dependent manner (Fig. 3.1C). The
potency of SA20-hGH appeared to be approximately 10-fold less than that of hGH, and
hGH-SA20 appeared to be far less potent (Fig. 3.1C). Time course experiments were
also performed to examine the efficiency of signaling (Fig. 3.2). SA20-hPRL induced the
phosphorylation of Erk1/2 as efficiently as hPRL (Fig. 3.2A); in contrast, SA20-hGH
required a longer time course to achieve similar activation levels as hGH (Fig. 3.2B).
Serum Albumin Binding Derivatives of G129R and G120R Competitively Inhibit
hPRL and hGH-Induced Signal Transduction
To determine if the SA20 derivatives of G129R and G120R retain the ability to
bind and antagonize PRLR mediated signaling transduction, the phosphorylation of
signaling molecules associated with the JAK2/STAT5 and Ras/Raf/MEK/MAPK
signaling cascades were examined in T-47D cells. Treatment with various concentrations
of G129R (Fig. 3.3A) or G120R (Fig. 3.3B) resulted in the inhibition of hPRL and hGHinduced

STAT5

phosphorylation,

respectively,
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Fig. 3.1
Dose-dependent activation of STAT5 and Erk1/2 signaling induced by
hPRL, hGH, and their SA20 derivatives
T-47D cells (A and B) or IM-9 cells (C) were plated and serum starved as
described in the Materials and Methods. The cells were treated with increasing doses of
hPRL, SA20-hPRL or hPRL-SA20 (A) or increasing doses of hGH, SA20-GH or hGHSA20 (B and C) and response of the signaling molecules was examined after 30 min.
Cell lysates were harvested and 80 μg of lysate from each treatment was separated by
reducing SDS-PAGE using 10% polyacrylamide gels and transferred to nitrocellulose
membranes. The membranes were probed with anti-phospho-STAT5 (p-STAT5) and
anti-phospho-Erk1/2 (p-ERK1/2). Equal loading was confirmed by reprobing the
membranes with an anti-STAT5 antibody (STAT5).
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Fig. 3.2
Time course analysis of the activation of Erk1/2 in response to hPRL,
hGH, and their SA20 derivatives
T-47D cells were plated and serum starved as described in the Materials and
Methods. The cells were treated with hPRL (A), SA20-hPRL (B), hGH (C) or SA20hGH (D) for various durations (min). Cell lysates were harvested, and 80 μg of lysate
from each treatment was separated by reducing SDS-PAGE using 10% polyacrylamide
gels and transferred to nitrocellulose membranes. The membranes were probed with a
phospho-Erk1/2 antibody. Equal loading was confirmed by reprobing the membranes
with anti-Erk1/2 antibodies.
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Fig. 3.3
Comparison of the inhibitory effects of G129R, G120R, and their SA20
derivatives on hPRL and hGH-induced signaling
T-47D cells were plated and serum starved as described in the Materials and
Methods. The cells were treated with 5 nM hPRL and increasing doses of G129R, SA20G129R or G129R-SA20 (A) or 5 nM hGH and increasing doses of G120R, SA20-G120R
or G120R-SA20 (B) and the response of signaling molecules was examined after 30 min.
Cell lysates were harvested and 80 μg of lysate from each treatment was separated by
reducing SDS-PAGE using 10% polyacrylamide gels and transferred to nitrocellulose
membranes. The membranes were probed for activate Erk1/2 (p-ERK1/2), activate
STAT5 (pTyr-STAT5), inactive STAT5 (pSer-STAT5) and total STAT5 (STAT5).
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The potency of SA20-G129R was 5-fold less than that of G129R; in contrast, the potency
of G129R-SA20 was reduced more than 10-fold (Fig. 3.3A). The potency of SA20G120R at inhibiting STAT5 and Erk1/2 phosphorylation was reduced approximately 10fold in comparison to hGH; whereas, the potency of G120R-SA20 was reduced even
more so (Fig. 3.3B).
Serum Albumin Binding Derivatives of hPRL and G129R Induce Proliferation of
Rat Nb2 Cells in a Dose-Dependent Manner
To examine the biological activity of SA20-hPRL and hPRL-SA20, we measured
their ability to induce the proliferation of rat Nb2 cells, which proliferate in response to
lactogenic hormones such as hPRL. The relative number of viable cells was determined
after 72 h treatment by colorimetrically measuring the reduction of MTS by living cells.
Treatment of the cells with increasing doses of SA20-hPRL or hPRL-SA20 stimulated
cell proliferation in a dose-dependent manner (Fig. 3.4). SA20-hPRL was less potent
than hPRL but was more potent than hPRL-SA20 at stimulating cell proliferation. The
proliferation induced by these ligands in rat Nb2 cells correlated well with their ability to
activate signal transduction in T-47D cells, confirming that bioactivity of SA20-hPRL
was superior to that of hPRL-SA20. Rat Nb2 cells also proliferate in response to G129R
at concentrations more than 2-log higher than that of hPRL. This partial agonism has
been attributed to the rat PRLR forming a more stable interaction with binding Site 2 of
these ligands than the human PRLR. Interestingly, the residual agonism of SA20-G129R
was significantly higher than that of G129R. This may indicate that the addition of the
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SA20 moiety to the N-terminus enhances binding Site 2 affinity for the PRLR, an
attribute that is undesirable for an antagonist.
Bioanalysis
Before performing pharmacokinetic studies it was necessary to confirm that
SA20-hPRL and hPRL-SA20 could be detected using commercial immunoassays. The
IRMA and ELISA kits tested showed specificity for hPRL and no cross-reactivity with
mouse PRL. The IRMA kit was less sensitive at detecting hPRL when the SA20 peptide
was fused to the N-terminus; whereas, the ELISA kit recognized SA20-hPRL and hPRLSA20 equally well with sufficient sensitivity. Examination of the stability of hPRL,
SA20-hPRL, or hPRL-SA20 in plasma revealed negligible metabolism indicating that
plasma decay is not a major player in clearance. To ensure that the immunoassays were
detecting biologically active hPRL, SA20-hPRL, or hPRL-SA20 we attempted to
measure the proliferation of Nb2 cells in vitro in response to plasma samples. Plasma
was harvested from the serum of mice and spiked with different concentrations of hPRL,
SA20-hPRL, or hPRL-SA20.

Regardless of the volume of plasma used, the Nb2

bioassay had extremely low-sensitivity for measuring hPRL, SA20-hPRL and hPRLSA20 due to other components within the plasma.
Pharmacokinetics of hPRL, SA20-hPRL, and hPRL-SA20
To examine pharmacokinetic behavior, female FVB/N mice were i.p.
administered a single dose (4 mg/kg) of hPRL-SA20, SA20-hPRL, or the molar
equivalent amount of hPRL. The plasma concentrations (Cp) were monitored over time
(t) and a linear-plot of Cp versus t (Fig. 3.5A) was used to visually emphasize the initial
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absorption, distribution and elimination phases; a semi-logarithmic plot of Cp versus t
(Fig. 3.5B) was used to emphasize the terminal elimination phase and to derive
pharmacokinetic parameters. The pharmacokinetic parameters of hPRL, hPRL-SA20 or
SA20-hPRL were determined using non-compartmental methods and are summarized in
Table 3.2.
Absorption of hPRL and hPRL-SA20 into the bloodstream after i.p.
administration did not differ significantly, reaching their maximal observed concentration
after approximately 50 min and 1 h, respectively; however, the observed concentration
achieved by hPRL-SA20 was 3.5-fold higher than that of hPRL (Fig. 3.5A).

The

maximum observed concentration achieved by SA20-hPRL was slightly lower than that
of hPRL-SA20 but occurred after 3 h, indicating that SA20-hPRL was absorbed into the
blood stream more slowly (Fig. 3.5A). Differences were also observed in the elimination
of the SA20 derivatives of hPRL. The AUCs of hPRL-SA20 and SA20-hPRL were
increased approximately 7- and 10-fold in comparison to hPRL, respectively; with the
small difference between the two reflecting earlier distribution and elimination of hPRLSA20 (Fig. 3.5A). For the most part, the differences in AUC between hPRL and the
SA20 derivatives reflected alterations in their terminal elimination phase (Fig. 3.5B).
The elimination patterns for each protein had two distinct phases (α and β).
Elimination in the second phase occurred according to first-order kinetics, i.e. a linear
relationship was observed between the semi-log plot of drug concentration versus time
(Fig. 3.5B). This β phase was used to determine the elimination half-life of the proteins.
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Fig. 3.4
The effects of hPRL, G129R, and their SA20 derivatives on Nb2 cell
proliferation
Rat Nb2 cells were treated with various doses of hPRL, SA20-hPRL, hPRLSA20, G129R, SA20-G129R or G129R-SA20 for 72 h as described in the Materials and
Methods. Cell proliferation was assessed colorimetrically by measuring the reduction of
MTS. Each data point represents the mean ± SD of at least three independent
experiments performed in quadruplicate.
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Fig. 3.5
Mean plasma concentration-time profiles of hPRL, SA20-hPRL, and
hPRL-SA20 after administration to mice
A single dose of hPRL (3.59 mg/kg), SA20-hPRL (4 mg/kg) or hPRL-SA20 (4
mg/kg) was i.p. administered to female FVB/N mice and their plasma concentrations
were determined as described in Materials and Methods. (A) Linear-plot and (B) semilog plot of plasma concentration versus time profiles. Points, mean of two mice per time
point.
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The terminal elimination half-life of hPRL-SA20 and SA20-hPRL were nearly identical
and were increased approximately 4-fold in comparison to hPRL (Table 3.2). This
extension in terminal elimination half-life is reflected by a reduction in the clearance of
hPRL-SA20 and SA20-hPRL by approximately 7-fold and 9.5-fold, respectively (Table
3.2). The reduction in clearance from 535.72 ± 123.19 ml/h/kg to 56.70 ± 2.6 ml/h/kg by
addition of the serum albumin binding peptide to the N-terminus of hPRL is consistent
with an “effective” increase in molecular size as indicated in Figure 3.6. Distribution
studies using iodinated hPRL, hPRL-SA20, and SA20-hPRL were not performed;
however, the apparent volume of distribution of hPRL was observed to be much larger
than the plasma volume, indicating that hPRL readily left the bloodstream and entered
other tissues. In contrast, the apparent volume of distribution of hPRL-SA20 and SA20hPRL were reduced 1.75- and 2.4-fold, respectively, consistent with the serum albumin
binding peptide causing more hPRL to be retained in the plasma (Table 3.2). The steady
state volumes for hPRL-SA20 and SA20-hPRL were reduced 1.5- and 2.5-fold in
comparison to hPRL, respectively. Since steady state volume is inversely correlated with
molecular weight, the reduction in steady state volume likely reflects binding of SA20hPRL and hPRL-SA20 to serum albumin, which would effectively increase their
molecular size.
Pharmacodynamics of hPRL and SA20-hPRL
Since a reduction in volume of distribution generally results in a reduction in
biological half-life, we examined the biological activity of SA20-hPRL on mammary
gland lobulo-alveolar development in comparison to hPRL and PBS controls.
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Table 3.2
Pharmacokinetic parameters after a single treatment of mice (n = 2)
with hPRL, hPRL-SA20, or SA20-hPRL

hPRL

hPRL-SA20

(Mean)

(Mean)

(Mean)

IP

IP

IP

Dose (mg/kg)

3.59

4

4

AUC (mg•hr /L)

7.67

58.8

78.7

CL (mL/hr/kg)

535.7

77.4

56.7

Apparent Vd (mL/kg)

1302

745.9

544.6

t1/2 term (hr)

1.66

6.68

6.64

Observed Cmax (mg/L)

4.07

14.33

12.08

Observed Tmax (hr)

0.84

1.01

3.06

Administration Route

SA20-hPRL

Abbreviations: AUC = area under the concentration-time curve; CL = clearance; Vd =
volume of distribution; t1/2term = terminal elimination half-life; Cmax = maximum plasma
concentration; Tmax = time to maximum plasma concentration.
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hPRL

SA20-hPRL

Figure 3.6
The rate of hPRL and SA20-hPRL clearance in mice and their effective
molecular size
The clearance of hPRL and SA20-hPRL were calculated as described in the
Materials and Methods. Based on the calculated clearance values the “effective”
molecular size was extrapolated. Clearance of hPRL (23 kD) was similar to that reported
for hGH (22 kD) and had an “effective” molecular size deduced to be 23 kD (blue circle);
in contrast, clearance of SA20-hPRL (26 kD) was reduced and had an “effective”
molecular size deduced to be 54 kD (green circle). Adapted from Clark et al. (Clark et
al., 1996), with modifications.
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FVB/N female mice (n = 6) were i.p. administered 4 mg/kg SA20-hPRL, an equimolar
amount of hPRL or PBS everyday, every other day, or every third day over a period of 12
days. No adverse side effects were observed in the mice after administration of hPRL or
its serum albumin binding derivative. Both hPRL and SA20-hPRL increased the number
of lobulo-alveoli in the mammary glands in a dosing-dependent manner (Fig. 3.7), the
more often they were treated, the greater the extent of lobulo-alveolar development. The
group receiving SA20-hPRL consistently had more lobulo-alveoli than the group
receiving hPRL. Mice receiving SA20-hPRL every other day exhibited more lobuloalveoli than mice receiving hPRL every other day (Fig. 3.7).
Pharmacodynamics of hGH and SA20-hGH
Female FVB/N mice (n=6) were i.p. administered 8 mg/kg SA20-hGH, an
equimolar amount hGH, or PBS in a volume of 200 μl for 40 consecutive days. No
adverse side effects were observed in the mice after administration of hGH or its serum
albumin binding derivative.

Extremely significant alterations were observed in the

number of lobulo-alveoli and extent of side-branching in the mammary glands of mice
treated with hGH or SA20-hGH in comparison to mice treated with PBS (Fig. 3.8). Sidebranching and the number of lobulo-aveoli were consistently and significantly elevated in
the mammary glands of mice treated with SA20-hGH in comparison to hGH (Fig. 3.8).
Extremely significant changes were also observed in the length of the tails (Fig. 3.9) and
overall body weight (Fig. 3.10) of mice treated with hGH or SA20-hGH in comparison to
PBS. After the 6th and 7th day of treatment with SA20-hGH and hGH, respectively, a
significant weight gain was observed in the mice in comparison to mice receiving PBS.
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A significant difference in the body weights of mice treated with SA20-hGH in
comparison to hGH was eventually observed after 20 days of treatment (Fig. 3.10).
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Figure 3.7
Lobulo-alveolar response in the mammary glands of mature nulliparous
mice treated with PBS, hPRL, or SA20-hPRL
Eight-week old nulliparous FVB/N female mice (n = 6) were treated (i.p.) with
hPRL (3.59 mg/kg), SA20-hPRL (4 mg/kg) or PBS everyday, every other day, or every
third day over a period of 12 days. The mammary glands were isolated and the whole
mounts were prepared and scored for lobulo-alveolar development.
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Fig. 3.8
Lobulo-alveolar response in the mammary glands of young nulliparous
mice treated with PBS, hGH, or SA20-hGH
Nulliparous FVB/N female mice (n = 6) were treated (i.p.) with hGH (7.15
mg/kg), SA20-hGH ( 8 mg/kg) or PBS daily beginning at 24 days of age and ending at 63
days of age. Mammary gland whole mounts were prepared and scored for lobuloalveolar development.
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Fig. 3.9

Tail length measurements after treatment with PBS, hGH, or SA20-hGH

Nulliparous FVB/N female mice (n = 6) were treated (i.p.) with hGH (7.15
mg/kg), SA20-hGH (8 mg/kg) or PBS daily beginning at 24 days of age and ending at 63
days of age, at which time the the tail lengths were measured. Points, mean tail length of
five mice; bars, SE; symbols, indicate a P ≤ 0.001 by t test after 5.5 wk of treatment
compared with PBS controls (**).
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Body weight measurement after treatment with PBS, hGH, or SA20-hGH

Nulliparous FVB/N female (n = 6) mice were treated (i.p.) with PBS, hGH (7.15
mg/kg), or SA20-hGH (8 mg/kg) beginning at 23 days of age and ending at 63 days of
age. Points, mean weight of six mice per time point; bars, SE; symbols, indicate a P ≤
0.0001 by t test after 5.5 wk of treatment compared with PBS controls (*) or SA20-hGH
vs. hGH (†).
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Discussion
A potential indication for rhPRL is the support and sustainment of lactation. PRL
is critical for milk production in humans (Kauppila et al., 1987) and its secretion from
lactotrophs in the anterior lobe of the pituitary gland is under the stimulatory and strong
inhibitory control of thyrotropin releasing hormone (TRH) and dopamine, respectively.
Administration of dopamine receptor agonists, such as Cabergoline, prevent postpartum
lactation (Melis et al., 1988); whereas, administration of TRH significantly increases milk
production in postpartum women (Tyson et al., 1975; Peters et al., 1991). Approximately
15% of newly lactating women suffer from lactation insufficiencies (Powers, 1999).
Milk production can be compromised by low hPRL response to suckling in women
whom are overweight or obese before conception (Rasmussen and Kjolhede, 2004) and
difficulty maintaining milk production can arise due to premature birth (Ehrenkranz and
Ackerman, 1986) but is most often associated with inadequate breast-feeding rates
(Delvoye et al., 1977).
Breast-feeding is important and beneficial for both the infant and mother
(Williams, 1995). Breast milk contains maternal macrophages and antibodies that protect
the infant against illness, benefits not afforded by formulations, and numerous studies
have shown that breast-feeding reduces the risk of developing breast cancer (Beral et al.,
2002). Unfortunately, there are no drugs approved by the FDA for enhancing breast milk
production in women suffering from lactation insufficiency. Dopamine antagonists, such
as Metoclopramide, have been used to increase pituitary hPRL secretion (Brouwers et al.,
1980; Brown et al., 2000) and milk production (Kauppila et al., 1981; Ehrenkranz and
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Ackerman, 1986); however, they can have severe side-effects, can be transferred by
breastfeeding to infants where their effects are unknown, and can inadvertently increase
the secretion of other hormones (Massara et al., 1985).
Rather than use drugs to modulate hPRL levels, rhPRL is a more logical choice to
treat lactation insufficiencies. It can be administered with fewer side effects and is safe
for infants since hPRL is naturally transferred via milk during breast feeding.
Preliminary studies have shown that rhPRL actually causes the secretion of milk in nonpostpartum woman (Page-Wilson et al., 2007), indicating that it should support and
sustain lactation in postpartum woman. Evidence also indicates that rhGH can improve
breast milk volume in normal lactating women (Milsom et al., 1992) and in women
suffering from lactational insufficiency due to premature birth (Gunn et al., 1996; Milsom
et al., 1998); but also increases the level of IGF-I in the breast milk (Breier et al., 1993).
Another potential indication for rhPRL is the enhancement or reconstitution of the
lymphopoietic portion of the immune system when under dysregulation (Richards and
Murphy, 2000). SCID mice engrafted with normal human peripheral blood lymphocytes
are perhaps the best model to study the effects of rhPRL on the human immune system.
Using this model, rhPRL was shown to increase the number of human natural killer (NK)
cells, T lymphocytes, and B lymphocytes (Sun et al., 2004b); to improve the anti-tumor
effects of normal human NK cells by enhancing their proliferation and cytotoxicity
(Zhang et al., 2005a); and to promote human B-cell secondary Ig responses following
rechallenge (Zhang et al., 2007). These findings provide further support that rhPRL may
be useful for recovering from myelosuppression caused by chemotherapy (Woody et al.,
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1999b; Zhang et al., 2005b), bone marrow transplant (Woody et al., 1999a; Sun et al.,
2003), burn injury (Dugan et al., 2002; Dugan et al., 2004) or immunosuppressive disease
(Richards et al., 1998); may have adoptive immunotherapeutic value for cancer
(Oberholtzer et al., 1996; Matera et al., 1999; Matera et al., 2000; Majumder et al., 2002;
Sun et al., 2002; Sun et al., 2004a) or pathogen-induced infection (Di Carlo et al., 1993;
Meli et al., 1996); and may be of potential use as a B-cell adjuvant in vivo (Richards et
al., 1998). Evidence suggests that rhGH may have similar effects on multilineage human
hematopoiesis (Hanley et al., 2005) and may be useful for recovering from
myleosuppression (Chen et al., 2003; Carlo-Stella et al., 2004).
A more recently proposed indication for rhPRL is for the treatment of type 1
diabetes mellitus (Labriola et al., 2007b).

Type 1 diabetes mellitus results from a

deficiency in insulin production in the pancreas caused by the autoimmune destruction of
beta cells in the islets of Langerhans. rhPRL increases the proliferation of beta cells, islet
cell mass, and insulin synthesis and secretion in primary cultures of human pancreatic
islets (Labriola et al., 2007a), much like is observed in during pregnancy. Consistent
with this, hyperprolactinemia has been associated with hyperinsulinemia and insulin
resistance (Bahceci et al., 2003). Like rhPRL, rhGH has been shown to increase insulin
secretion in human islets in vitro (Brelje et al., 1993). These findings indicate that rhPRL
administration could prevent the destruction of beta cells or could be used to expand
primary islets for transplantation back into the pancreas.
Currently, administration of rhPRL is not practical due to its short half-life, the
necessity for continuous maintenance, and the high cost of production. This would
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undoubtedly create problems with compliance and discomfort at the site of injection. In
this study, we examined the potential of fusing a serum albumin binding peptide to hPRL
and hGH to enhance their serum half-life. Serum albumin is the most common protein in
serum; it has a long half-life and has the ability to reversibly bind proteins. As a
transporter it prevents the renal clearance of small molecules, thereby increasing their
serum half-life.

Recently, a series of unique peptides were developed using phage

display which bind to serum albumin in an apparently non-competitive manner (Dennis et
al., 2002). In this study, we genetically fused one of these serum albumin binding
peptides, SA20, to the N-terminus or C-terminus of hPRL, hGH, and their antagonists in
an effort to increase their plasma half-life by reducing renal clearance.
SA20-hPRL was found to be as efficient as hPRL at inducing signal transduction
and was 3.3-fold more efficient than hPRL-SA20 (Fig. 3.1). Similarly, SA20-hPRL was
superior to hPRL-SA20 at inducing the proliferation of Nb2 cells (Fig. 3.4). Three
parameters were used to determine which version of the fusion protein would be used for
in vivo bioactivity studies. The observed peak height concentration (Cmax) achieved; the
time to reach this peak concentration (Tmax) and the area under the blood concentrationtime curve which reflects absorption, distribution, metabolism and excretion. The rate of
absorption of SA20-hPRL was slower than hPRL-SA20 in mice as indicated by the larger
Tmax and smaller Cmax, the AUC was greater, and the duration during the first 24 h
appeared more favorable than for hPRL-SA20. In addition, SA20-hPRL had a lower
apparent volume of distribution and reduced clearance, consistent with binding to serum
albumin and slower renal elimination.
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Based on these observations we examined the pharmacodynamics of SA20-hPRL
and SA20-hGH in comparison to hPRL and hGH, respectively, after being i.p.
administered to mice. Drugs administered to the peritoneum are absorbed only four times
slower than when administered intravenously (Morton et al., 2001) due to the large
surface area and vasculature of the peritoneum. Once in the peritoneum drugs rapidly
enter circulation via the colic, the intestinal, and the mesenteric veins and are delivered
via the inferior and superior mesenteric veins to the portal vein and enter the liver (Lukas
et al., 1971). In the liver, drugs may be subject to metabolism before being carried with
deoxygenated blood by the inferior vena cava into the right atrium of the heart. From the
right atrium the blood enters the right ventricle and is pumped into the pulmonary artery
to the lungs before returning via the pulmonary vein into the left atrium and left ventricle
into the circulatory system.
This route of administration undoubtedly subjects hPRL, hGH, and their
derivatives to first pass hepatic metabolism, meaning they pass through the liver before
they reach systemic circulation. Since hepatic blood flow is much higher in mice than
man, hepatic extraction is very high in mice and hPRL, hGH, and their derivatives are
subject to rapid metabolism in the liver, which expresses high levels of PRLR and GHR.
Previously, we have demonstrated that i.p. administered G129R is cleared rapidly from
the blood of mice primarily by the liver and kidneys with less than 1% of the injected
dose per gram of tissue remaining after one hour. Although the SA20 peptide should
reduce kidney clearance by allowing hPRL or hGH to interact with serum albumin; this
interaction probably has little effect on metabolism in the liver. Thus, although the route
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of administration is convenient in mice it is less than ideal due to first pass hepatic
metabolism.
To partially overcome this problem we treated mice with relatively high doses of
hPRL, hGH, and their SA20 derivatives. Still we observed an increase in the number of
lobulo-alveoli-like structures in the mammary glands of mice treated with hPRL, hGH
and their SA20 derivatives. In contrast to hPRL and hGH, SA20-hPRL and SA20-hGH
consistently increased the number of lobulo-alveoli in all mammary glands to a greater
extent, indicating that serum albumin binding effectively increased the efficacy of hPRL
and hGH in vivo. The half-life of mouse serum albumin is only 1 day (Stevens et al.,
1992); in contrast the half-life of human serum albumin is 19 days (Sterling, 1951).
Since mice metabolize proteins much faster than humans the circulating half-lives of
SA20-hPRL and SA20-hGH should be increased substantially in humans.
In summary, genetic fusion of a serum albumin binding peptide to hPRL and hGH
caused it to associate with serum albumin and extended their plasma half-life in vivo.
This strategy didn’t require downstream conjugation and therefore provided an
economically feasible alternative to PEGylation or HESylation.

In contrast to

PEGylation and HESylation, the fusion of the small serum albumin binding peptide to the
N-terminus of hPRL and hGH had minimal deleterious effects upon signal transduction
and bioactivity in vitro and in vivo. Most importantly, SA20-hPRL or SA20-hGH can be
combined with existing sustained release formulations to further enhance their
effectiveness.
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CHAPTER FOUR
IMPROVING THE PHARMACOKINETIC PROPERTIES OF
PROLACTIN AND GROWTH HORMONE RECEPTOR
AGONISTS BY FUSION IN TANDEM
Abstract
Human (h) prolactin (PRL) and growth hormone (GH) have two distinct binding
sites (Site 1 with high affinity; Site 2 with low affinity) that each interact with a prolactin
receptor (PRLR) to form a functional receptor dimer that activates signal transduction.
The G129R mutation in hPRL and the G120R mutation in hGH disrupt the structural integrity
of Site 2 such that the ligands retain the ability to bind to the first receptor with high affinity,
but act as receptor antagonists. In this study, we examined the ability of monomeric and
dimeric forms of hPRL, hGH, hPRL-G129R (G129R), and hGH-G120R (G120R) to (1)
bind to PRLRs; (2) induce conformational changes in PRLRs; (3) activate signaling
pathways associated with the PRLR; and (4) mediate cell proliferation in vitro. In
contrast to monomeric G129R, homodimeric G129R induced PRLR dimerization;
activated Janus-activated kinase 2/signal transducer and activator of transcription 5,
Ras/Raf/MAPK kinase/Erks, and phosphatidylinositol 3-kinase/Akt signaling cascades;
and stimulated Nb2 cell proliferation.

Similarly, homodimeric G120R was able to

mediate signaling via the PRLR and to stimulate Nb2 cell proliferation.

These

experiments demonstrate that a ligand must have two functional binding sites, but that
these may be Site 1 plus Site 2 or two Site 1s, to elicit receptor mediated signal
transduction. The size of the ligand plays less of a role in receptor activation, suggesting
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that the extracellular portion of the PRLR (and possibly the growth hormone receptor) is
rather flexible and can accommodate larger ligands.

These findings may have

implications for designing multi-functional therapeutics that target this class of cytokine
receptors.
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Introduction
Prolactin (PRL) and growth hormone (GH) are members of the hematopoietin
family of cytokines. Despite their low amino acid sequence identity they have similar
tertiary structures (de Vos et al., 1992; Keeler et al., 2003), as do the extracellular regions
of the receptors to which they bind (Forsyth and Wallis, 2002). These peptide hormones
have four α-helical segments that are connected via loops which provide flexibility and
allow the helices to be bundled in an anti-parallel (up-up-down-down) manner. Two
separate asymmetric receptor binding regions have been identified in these hormones,
each of which interacts with the equivalent region of a receptor to form a one ligand two
receptor complex. Due to differences in affinity between the two receptor binding sites,
binding occurs sequentially with the higher affinity site (Site 1) interacting with the first
receptor before the lower affinity site (Site 2) can interact with a second receptor
(Cunningham et al., 1991; Ultsch et al., 1991; Fuh et al., 1993; Goffin et al., 1994; Fuh
and Wells, 1995). Recently, this sequential binding process has been shown to be due to
the functional coupling of the receptor binding sites. The interaction of Site 1 with the
first receptor induces conformational changes in the ligand that create a functional Site 2
(Sivaprasad et al., 2004; Walsh et al., 2004).
Studies of human (h) GH, PRL, and placental lactogen (PL) have shown that the
third α-helix is important to their structure and the function of Site 2. Substitution of a
Gly residue in this region with an Arg residue results in antagonists (hGH-G120R, hPRLG129R, hPL-G120R) with little or no biological activity (Chen et al., 1991a; Fuh et al.,
1993; Chen et al., 1994; Fuh and Wells, 1995; Goffin et al., 1996; Chen et al., 1999).
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Comparative studies of the interaction of hGH-G120R and hGH with the extracellular
domain (ECD) of the hGH receptor (hGHR-ECD) have shown that the mutation has
minimal effects upon initial hormone-receptor interactions at Site 1 but disrupts the
critical hormone-receptor-interactions at Site 2 (de Vos et al., 1992; Sundstrom et al.,
1996; Clackson et al., 1998); thereby preventing proper receptor dimerization.
Proper ligand-induced receptor dimerization induces conformational changes in
the receptors that bring about the activation of receptor associated Janus-activated kinase
2 (JAK2) (Carter-Su et al., 1989; Campbell et al., 1994; Dusanter-Fourt et al., 1994;
Lebrun et al., 1994; Rui et al., 1994a), which stimulates signal transducer and activators
of transcription 5 (STAT5) signaling. Receptor activation also leads to the activation of
Ras/Raf/MAPK kinase/Erks (Das and Vonderhaar, 1996) and phosphatidylinositol 3kinase/Akt signaling pathways. It is primarily via these pathways that the receptors for
these ligands induce cell differentiation, proliferation, and/or survival (Socolovsky et al.,
2001; Shillingford et al., 2002).
In addition to the monomeric forms of these ligands, dimeric and oligomeric
forms have been identified in plasma of mammals and within pituitary extracts
(Schneider et al., 1975a; Stolar et al., 1984; Smith and Norman, 1990; Sinha, 1995;
Fahie-Wilson et al., 2005). Dimeric forms may arise from interchain disulfide-linkages
or non-covalent aggregation; oligomeric forms exist and larger forms may also arise from
immunoglobulin G (IgG) covalent and non-covalent complexes with monomeric or
dimeric forms of these ligands (Schneider et al., 1977; Brostedt et al., 1990; Baumann,
1991; Sinha, 1995). The significance of these larger forms with reduced affinities for the
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PRLR remains largely unknown. In addition to these natural ligands of the PRLR,
bivalent monoclonal antibodies (mAbs) have been developed that exhibit various degrees
of agonistic activity (Djiane et al., 1985; Okamura et al., 1989; Elberg et al., 1990) which
correlates with their ability to induce the phosphorylation of JAK2 (Rui et al., 1994b).
To better understand the molecular interactions between ligands and the PRLR,
we prepared dimeric forms of hGH, hPRL, hGH-G120R (G120R), and hPRL-G129R
(G129R), including homodimers (PRL-PRL, GH-GH) with four potentially functional
binding sites, heterodimers (PRL-G129R, G129R-PRL) with three potential binding sites
and homodimers (G129R-G129R, G120R-G120R) with two potential binding sites. We
demonstrate that the fusion of two antagonists (G129R or G120R) together restores some
biological activity, even though the two functional binding sites are located in separate
moieties. This suggests that the PRL/GH receptor family exhibits a considerable degree
of flexibility in accommodating ligands and transducing their signals. This finding may
have implications for designing ligand-based therapeutics that target this family of
receptors.
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Materials and Methods
Cell Lines and Reagents
T-47D human breast cancer cells and transformed human embryonic kidney cells
(HEK293) were obtained from the American Type Culture Collection (Manassas, VA).
Nb2-11 rat pre-T lymphoma cells (Nb2) were kindly provided by Dr. Arthur Buckley.
All reagents were purchased from Invitrogen (Carlsbad, CA) unless otherwise stated. T47D cells were maintained in RPMI Medium 1640 supplemented with 10% fetal bovine
serum (FBS) and 10 µg/ml gentamicin. HEK293 cells were maintained in Dulbecco's
Modified Eagle Medium (DMEM) containing high glucose, 1 mM sodium pyruvate, 1
mM pyridoxine hydrochloride, and 2 mM L-glutamine; the medium was further
supplemented with 10% FBS, 100 U/ml penicillin, and 0.7 µM streptomycin. Nb2 cells
were maintained in Minimum Essential Medium (MEM) supplemented with 10% FBS,
10% horse serum (HS), 0.1 mM non-essential amino acids, 50 µg/ml streptomycin, 50
U/ml penicillin, and 0.1 mM 2-mercaptoethanol. The cell lines were incubated at 37°C
with humidity and 5% CO2.
Construction of hPRL and G129R Homo- and Heterodimer Expression Vectors
Previously, hPRL and G129R were cloned by inserting their cDNAs between the
Nde I and Xho I sites of the expression vector pET22b(+) (Novagen; Madison, WI).
These plasmids were used as DNA templates for PCR amplification of each moiety of the
recombinant dimers. The first moiety of hPRL or G129R was amplified using the
oligonucleotide

primers

5’-TCATATGTTGCCCATCTGTCCCGGCG-3’

and

5’-

TGGATCCGCAGTTGTTGTTGTGGATG-3’; which incorporate an Nde I site at the N-
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terminus and replace the C-terminal stop codon with a BamH I site. The second moiety
of

hPRL

or

G129R

was

amplified

using

the

primers

5’-

TGGATCCTTGCCCATCTGTCCCGGCG-3’ and 5’-TCTCGAGTTAGCAGTTGTTGT
TGTGG-3’; which incorporate a BamH I site at the N-terminus and an Xho I site after the
stop codon.

The PCR products were ligated with pCR2.1 T/A cloning vector and

transformed into E. coli TOP10 cells obtained from Invitrogen. Positive clones were
identified by plating the cells on Luria-Bertani (LB) agar plates containing 100 µg/ml
ampicillin and 80 µg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside.

The

plasmids were isolated using the QIAprep® Spin Miniprep Kit (Qiagen, Valencia, CA)
and the Nde I-PRL-BamH I, Nde I-G129R-BamH I, BamH I-PRL-stop-Xho I and BamH
I-G129R-stop-Xho I DNA fragments were isolated by restriction digestion and separated
by electrophoresis. The DNA fragments were purified from the agarose gel using the
QIAquick® Gel Extraction Kit (Qiagen) and ligated with Nde I and Xho I cut pET22b(+)
to create pET22b-PRL-PRL, pET22b-G129R-G129R, pET22b-PRL-G129R and pET22bG129R-PRL.

A similar strategy was used to create pET22b-GH-GH and pET22b-

G120R-G120R. All oligonucleotides were synthesized by Integrated DNA Technologies
(Coralville, IA), restriction and modifying enzymes were purchased from New England
BioLabs (Beverly, MA), and PCR reactions were performed using the Advantage-HF™
Kit (BD Biosciences, Palo Alto, CA).
Production and Purification of hPRL and G129R Homo- and Heterodimers
Chemically competent Rosetta™(DE3) pLysS E. coli cells (Novagen) were
transformed with the constructs and propagated overnight at 37°C with agitation in LB
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broth containing 100 µg/ml ampicillin. The next morning 40 ml of each of the starter
cultures was used to inoculate one liter of Terrific Broth in baffled flasks and the cultures
were grown to an O.D.600 of 0.9 before induction of protein production with 1 mM
isopropyl-β-thiogalactoside (Alexis Biochemicals, San Diego, CA).

After 4 h of

induction the cells were harvested by centrifugation at 5,000 x g for 5 min at 4°C and
resuspended in Solution 1 (20 mM Tris·HCl; 10 mM EDTA; 0.5% Triton X-100; pH
adjusted to 8.0) to which 0.4 mg/ml lysozyme was added. The cells were incubated at
room temperature for 1 h to weaken the cell membranes before the cells were sheared on
ice with five 1-min ultrasonic pulses (30% duty at setting 7) using a 550 Sonic
Dismembrator (Fisher Scientific, Waltham, MA). The insoluble fraction containing the
inclusion bodies was recovered by centrifugation at 12,000 x g for 30 min at 4ºC and
resuspended in Solution 2 (20 mM Tris·HCl; 10 mM EDTA; 1 M urea; pH adjusted to
8.0). The inclusion bodies were collected by centrifugation at 12,000 x g for 30 min at
4ºC and were solubilized and denatured in Solution 3 (20 mM Tris·HCl; 10 mM EDTA; 8
M urea; 1% v/v 2-mercaptoethanol; pH adjusted to 8.0). The proteins were refolded by dialysis
against baths of 20 mM Tris·HCl; 10 mM EDTA, pH 8.0 containing decreasing amounts of
urea (4M urea, 2 M urea, 0 M urea, 0 M urea). The refolded proteins were filtered through 0.45
µm filters and purified by anion-exchange chromatography using a 5 ml HiTrap Q Sepharose
HP column (Amersham Biosciences, Piscataway, NJ) on an ÄKTA fast protein liquid
chromatography system (Amersham Biosciences). The concentration of the purified proteins
was determined using the Coomassie Plus™ Protein Assay Reagent (Pierce, Rockford, IL).
The purified proteins were separated by non-reducing and reducing SDS-PAGE along with
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BSA standards (Pierce, Rockford, IL) and stained with SYPRO® Orange (Molecular Probes,
Eugene, OR) to confirm their concentration and purity. The identity of the proteins was
confirmed by Western blotting.
Western Blot Analysis
Purified monomers, homodimers and heterodimers of hPRL and G129R were
separated on a 12% polyacrylamide gel by reducing SDS-PAGE. The proteins were
transferred by Western blot to a Hybond™ Enhanced Chemiluminescence (ECL)
nitrocellulose membrane (Amersham Biosciences) at 25 V overnight. The nitrocellulose
membrane was blocked for 1 h at room temperature in Tris buffered saline (TBS)
containing 0.05% Tween 20 (TBS-T) and 5% milk. The membrane was incubated at
room temperature with agitation for 4 h in the blocking solution containing a 1:5000
dilution of rabbit anti-hPRL antiserum (National Hormone and Pituitary Program, NIH,
Bethesda, MD). The blots were washed three times with TBS-T, and incubated for 2 h at
room temperature with agitation in blocking solution containing a 1:2000 dilution of goat
anti-rabbit conjugated HRP (Bio-Rad, Hercules, CA). Blots were washed three times
with TBS-T and incubated for 1 min with ECL™ Western Blotting Detection Reagents
(Amersham Biosciences).

The blots were exposed to Biomax MR film (Kodak,

Rochester, NY) and the film was developed with a Konica SRX-101A processor (Konica
Minolta Medical Imagining, Wayne, NJ).
Radio-Receptor Binding Assay
One million cells per well of T-47D human breast cancer cells were seeded in sixwell tissue culture plates and grown to confluency. Cells were starved in serum-free
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RPMI Medium 1640 for 1 h, and incubated for 2 h at room temperature in serum-free
medium containing 5 x 104 cpm of 125I-labeled hPRL (specific activity, 40 µCI/µg; NEN
Perkin-Elmer, Boston, MA) with or without various concentrations of monomeric or
homodimeric hPRL and G129R. An excess of hPRL was used to determine non-specific
binding. Cells were washed three times with serum-free RPMI Medium 1640 and lysed
in 0.5 ml of 0.1 N NaOH/1% SDS.

Bound radioactivity was determined using a

Beckman LS6500 Liquid Scintillation Counter calibrated to detect

125

I using a wide

spectrometer window. The percentage of specific binding was calculated and compared
among the samples.
BRET2 Assay (Performed by Dunyong Tan at the University of California,
Riverside)
Bioluminescence resonance engegy transfer (BRET2) assays were performed
precisely as described by Tan et al. (Tan et al., 2005). Briefly, HEK293 cells were
seeded in six-well tissue culture plates at a density of 5 x 105 cells per well and grown
overnight to 90-95% confluency. Eukaryotic expression vectors encoding the long form
(LF) or short forms (SF1a and SF1b) of the human PRLR tagged with a variant of green
fluorescent protein (GFP2) [LF-GFP2, SF1a-GFP2, SF1b-GFP2] and Renilla reniformis
luciferase (Rluc) [LF-Rluc, SF1a-Rluc, SF1b-Rluc] at the C-terminus were transiently
transfected into the cells. After 48 h incubation the transfected cells were washed,
detached, and resuspended in BRET2 buffer at a density of 2 x 106 cells per ml. After
incubation at 37°C for at least 1 h, the relative expression levels of the GFP2- and Rluctagged PRLR constructs were estimated by comparing their fluorescence and
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bioluminescence to that of cells transfected with a GFP2-Rluc fusion plasmid.
Bioluminescence scanning and BRET2 signal detection were carried out immediately
after the addition of the ligand (45.7 nM) and 5 µM of DeepBlueC™.

The

bioluminescence from the oxidation of the DeepBlueC™ by Rluc has a peak emission at
390–405 nm and the fluorescence from the GFP2 acceptor has a peak emission at 500–
520 nm. Energy transfer from Rluc to GFP2 was defined as the BRET ratio, which was
determined by calculating the ratio of light emitted by receptor-GFP2 (500-520 nm) over
the light emitted by receptor-Rluc (385-420 nm). Values were corrected by subtracting
the BRET background signal detected in nontransfected cells (Emission500

nm-520 nm-

background500 nm-520 nm)/(Emission385 nm-420 nm-background385 nm-420 nm).
STAT5, Erk1/2, and Akt Phosphorylation Assays
T-47D cells were resuspended in RPMI Medium 1640 supplemented with 10%
charcoal/dextran treated FBS (CSS; HyClone, Logan, UT) and 10 µg/ml gentamycin and
plated in twelve-well tissue culture plates.

The cells were grown overnight to

approximately 80% confluency and depleted for 1-72 h in RPMI Medium 1640
supplemented with 0.5% CSS to determine which condition best achieved the lowest
background activation of signaling molecules. Since prolonged depletion produced no
improvement in this regard, 1 h depeletions were used. Cells were treated for the
indicated amounts of time with the indicated concentrations of monomeric, homodimeric,
or heterodimeric hPRL, G129R, hGH, or G120R. The cells were washed with ice cold
phosphate buffered saline (PBS) and lysed in 100 µl of Lysis Buffer (20 mM Tris·HCl,
pH 7.4; 1% Igepal CA630; 6 mM deoxycholic acid; 150 mM NaCl; 1 mM EDTA, pH
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8.0) containing protease inhibitors (1 µg/ml aprotinin; 1 µg/ml leupeptin; 170 µg/ml
PMSF; 180 µg/ml sodium orthovanadate). The lysates were homogenized and incubated
on ice for 20 minutes before clarification by centrifugation at 12,000 x g at 4°C for 30
min. Approximately 40 µg of the supernatants were used for Western blot analysis as
described above using 10% or 4-15% polyacrylamide gels.
Blots were initially performed with a 1:1000 dilution of mouse anti-phospo
STAT5A/B antibody (Upstate, Lake Placid, NY) and a 1:2000 dilution of goat antimouse-HRP conjugate (Bio-Rad). Blots were reprobed with a 1:1333 dilution of rabbit
anti-STAT5 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and a
1:2000 dilution of goat anti-rabbit HRP conjugate (Bio-Rad); a 1:1333 dilution of mouse
anti-phospho ERK (Santa Cruz Biotechnology), and a 1:2000 dilution of goat antimouse-HRP conjugate; and lastly with a 1:200 dilution of rabbit anti-phospo Akt
antibody (Santa Cruz Biotechnology) and a 1:2000 dilution of goat anti-rabbit HRP
conjugate.
Rat Nb2 Cell Proliferation Assay
Rat Nb2 cells were resuspended to a final concentration of 5.5 x 105 cells per ml
in MEM supplemented with 0.1 mM non-essential amino acids, 10% low lactogen HS
(Cat. 2921154; MP Biomedicals, Irvine, CA), 50 µg/ml streptomycin, 50 U/ml penicillin,
and 0.1 mM 2-mercaptoethanol. The cells were depleted overnight and reseeded in flat
bottom 96-well plates at a density of 20,000 cells per well in 150 µl of medium.
Treatments were added to each well in 50 µl volumes and the cells were incubated for 72
h. The relative number of cells was determined by incubating the cells for 4 h with 40 µl
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of

3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-

tetrazolium/phenazine methosulfate (MTS/PMS) solution (CellTiter 96 AQueous nonradioactive cell proliferation kit; Promega, Madison, WI) per well. The reduction of
MTS by living cells was determined by measuring the absorbance at 490 nm using a
Benchmark microplate reader (Bio-Rad). Preliminary experiments demonstrated that cell
plating densities up to 45,000 showed a linear relationship to OD 490. All assays were
performed at least three times in quadruplicate.
In Vivo Pharmacokinetics
Two groups of four BALB/C mice were injected intraperitoneally with 200 µg of
monomeric or dimeric hPRL.

Blood was collected by tail-vein bleeding 1 h after

injection and collected hourly for an additional 3 h. Plasma samples were diluted when
necessary with the zero calibrator and subject to an immunoradiometric assay (IRMA) for
hPRL (Coat-A-Count® Prolactin IRMA; DPC, Los Angeles, CA). The concentrations of
monomeric and dimeric hPRL were extrapolated and plotted versus time and the areas
under the curve were calculated. Human PRL and dimeric hPRL standards of known
concentration were detected equally using the IRMA kit since the standard curve was in
nanograms per milliliter and not molar concentrations.

Blood from control mice

indicated that the IRMA kit was insensitive to endogenous mouse PRL.
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Fig. 4.1
Non-reducing SDS-PAGE, reducing SDS-PAGE, and Western blot
analysis of purified monomeric and dimeric hPRL derivatives
Monomers, homodimers, and heterodimers of hPRL and G129R were separated
by non-reducing SDS-PAGE (A) or reducing SDS-PAGE (B) on 12% polyacrylamide
gels and stained with SYPRO® Orange to confirm their size and purity. M, BenchMark
Ladder (Invitrogen); Lane 1, PRL; Lane 2, G129R; Lane 3, PRL-PRL; Lane 4, G129RG129R; Lane 5, PRL-G129R; and Lane 6, G129R-PRL. The identity of the proteins was
confirmed by Western blotting with an antibody that detects the hPRL and G129R
moieties (C).
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Results
Construction, Expression, and Purification of Dimeric Derivatives of hPRL and
hGH
Homodimers and heterodimers of hPRL and G129R were recombinantly
engineered by gene fusion. The cDNAs encoding the mature form of the proteins were
ligated together via a small linker (GGATCC), and cloned into an E. coli expression
vector. Expression of the fusion gene in E. coli resulted in a single fusion protein in
which the C-terminus of the first moiety was connected to the N-terminus of the second
moiety by a Gly-Ser peptide linker. The proteins were found to accumulate in the
insoluble fraction as inclusion bodies.

The inclusion bodies were isolated, denatured,

refolded, and purified by anion-exchange chromatography to yield preparations of greater than
95% purity. The dimeric fusion proteins were analyzed by non-reducing (Fig. 4.1A) and
reducing SDS-PAGE (Fig. 4.1B) along with hPRL and G129R. Human PRL and G129R were
predominantly monomeric (20 kDa) under non-reducing conditions with only a small portion
remaining unfolded (25 kDa) or forming covalently linked dimers via interchain disulfide
linkages (40 kDa) (Fig. 4.1A, lanes 1 and 2). No covalently linked multimeric forms were
observed for the recombinantly engineered homodimers and heterodimers of hPRL and G129R
after purification; however, multiple bands were observed which would suggest some improper
intrachain disulfide linkages (Fig. 4.1A, lanes 3-6). This was anticipated since the C-terminal
cysteines of the first moiety (Cys191, Cys199) are separated from the N-terminal cysteines
(Cys4, Cys11) of the second moiety by only a small linker (Gly-Ser). Reducing SDS-PAGE
revealed that purified dimers have sizes corresponding to their predicted molecular mass of 46
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kDa (Fig. 4.1B, lanes 3-6) and Western blotting with an antibody that detects hPRL and G129R
confirmed the identity of purified dimers (Fig. 4.1C, lanes 3-6).
Homodimers of hPRL and G129R Retain the Ability to Bind to PRLRs
To examine if the homodimers of hPRL and G129R retain the ability to bind to
PRLRs, we measured their ability to compete with

125

I-labeled hPRL for binding to

PRLRs expressed on the surface of T-47D human breast cancer cells. Monomers and
homodimers of hPRL and G129R effectively displaced the binding of

125

I-hPRL (Fig.

4.2), confirming that the dimers retain the ability to specifically bind to PRLRs. The
effective concentrations necessary to displace 50% of the

125

I-labeled hPRL (EC50) were

calculated. There was no statistical difference between the EC50 of dimeric hPRL (0.97 ±
0.23 nM), dimeric G129R (1.17 ± 0.1 nM), and monomeric hPRL (0.96 ± 0.29 nM);
however, there were statistical differences between the EC50 of these ligands and
monomeric G129R (1.96 ± 0.25 nM).
Homodimeric G129R Induces a BRET Signal Consistent with Receptor
Dimerization
To determine if dimeric G129R truly has a second functional binding site, we
examined whether or not it could induce conformational changes in PRLRs consistent
with dimerization. Figure 4.3A shows representative luminescence scans in the absence
or presence of monomeric hPRL, monomeric G129R, and homodimeric G129R. In the
absence of ligand or the presence of monomeric G129R there is minimal emission of a
BRET signal from HEK293 cells cotransfected with tagged human PRLRs.
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Fig. 4.2
Competitive binding of monomeric and homodimeric hPRL derivatives to
PRLRs on T-47D cells
The ability of monomeric and homodimeric hPRL and G129R to bind to PRLRs
was determined by measuring their ability to compete with 125I-labeled hPRL for binding
to the surface of T-47D cells as described in the Materials and Methods. Each data point
represents the mean ± SD of at least three independent experiments. The EC50 for
monomeric hPRL, homodimeric hPRL, homodimeric G129R, and monomeric G129R
were determined to be 0.96 ± 0.29 nM, 0.97 ± 0.23 nM, 1.17 ± 0.1 nM, and 1.96 ± 0.25 nM,
respectively. **, p<0.005, for difference in EC50 from that of monomeric hPRL.
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Fig. 4.3
PRLRs

Monomeric hPRL and homodimeric G129R-induced homodimerization of

BRET2 assays were performed within 48 h after transfection of HEK 293 cells in
the presence of 5 µM DeepBlueC™ (DBC) with or without monomeric hPRL, monomeric
G129R, or homodimeric G129R as described in the Materials and Methods.
Representative bioluminescence scans from the DBC reaction in the absence of ligand
and after the addition of monomeric hPRL (45.7 nM), monomeric G129R (45.7 nM), or
homodimeric G129R (45.7 nM) to cells transiently transfected with SF1a-GFP2/SF1aRluc (A). Note the absence of a BRET signal in the absence of monomeric hPRL or
homodimeric G129R. Averaged BRET ratios from four or more separate determinations
on different preparations of cells transfected with LF, SF1a, or SF1b (B). The BRET
ratio was calculated as (Emission500–520 nm – Background500–520 nm)/(Emission385–420 nm –
Background385–420 nm). *, p<0.05; **, p<0.01, for difference with and without monomeric
hPRL or dimeric G129R.
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In contrast, the addition of monomeric hPRL or homodimeric G129R induces a
significant BRET signal in HEK 293 cells cotransfected with tagged human PRLRs,
SF1b-Rluc/SF1b-GFP2 (Fig. 4.3A). The BRET ratios for HEK293 cells cotransfected
with LF-Rluc/LF-GFP2, SF1a-Rluc/SF1a-GFP2, or SF1b-Rluc/SF1b-GFP2 increased
approximately 4, 3, and 3-fold, respectively, upon treatment with dimeric G129R (Fig.
4.3B).
Dimerization of G129R Restores Human PRLR Mediated Signal Transduction
To determine if the receptor dimers induced by homodimeric G129R are
functional we examined its ability to activate signaling molecules associated with these
pathways. We also produced homodimeric G120R, a GHR as well as PRLR antagonist,
to test whether dimerization of this antagonist would also produce an agonist. Treatment
of T-47D cells with various concentrations of hPRL or hGH resulted in the
phosphorylation of STAT5, Erk1/2, and Akt (Fig. 4.4, A and B). Monomeric G129R and
G120R, which block the conformational changes necessary for the formation of a
functional receptor dimer, did not elicit phosphorylation of any of these signaling
molecules (Fig. 4.4, A and B).

In contrast to the monomeric PRLR antagonists,

homodimers of G129R and G120R activated STAT5, Erk1/2, and Akt in a dosedependent manner (Fig. 4.5, A and B).
Dose response and time course experiments were performed to examine the
potency (Fig. 4.6) and efficiency (Fig. 4.8) of dimeric G129R in the activation of STAT5
in comparison to hPRL. Dimeric G129R was able to induce STAT5 phosphorylation
(Fig. 4.6B), but required approximately 3- fold higher molar concentrations (Fig. 4.6A).
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Fig. 4.4
Western blot analysis of the phosphorylation status of Akt, Erk1/2, and
STAT5 in response to monomeric hPRL and hGH derivatives
T-47D cells were plated as described in the Materials and Methods and serum
starved overnight. The cells were treated for 30 min with 5 nM, 50 nM, or 500 nM of
monomeric hPRL or G129R (A) or treated with monomeric hGH or G120R (B). Cell
lysates were harvested and 40 µg of lysate from each treatment was separated by
reducing SDS-PAGE using 4-15% polyacrylamide gels and transferred to nitrocellulose
membranes. The membranes were probed with antibodies recognizing phosphoAkt1/2/3, phospho-Erk1/2 and phospho-STAT5A/B. Equal loading was confirmed by
reprobing for STAT5.
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Fig. 4.5
Western blot analysis of the phosphorylation status of Akt, Erk1/2, and
STAT5 in response to dimeric hPRL and hGH derivatives
T-47D cells were plated as described in the Materials and Methods and serum
starved overnight. The cells were treated for 30 min with 5 nM, 50 nM, or 500 nM of:
homodimeric hPRL or G129R (A); homodimeric hGH or G120R (B); or heterodimers of
hPRL and G129R (C). Cell lysates were harvested and 40 µg of lysate from each
treatment was separated by reducing SDS-PAGE using 4-15% polyacrylamide gels and
transferred to nitrocellulose membranes. The membranes were probed with antibodies
recognizing phospho-Akt1/2/3, phospho-Erk1/2 and phospho-STAT5A/B. Equal loading
was confirmed by reprobing for STAT5.
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Fig. 4.6
Dose-dependent activation of STAT5 phosphorylation induced by
monomeric and dimeric hPRL derivatives
T-47D cells were plated as described in the Materials and Methods and serum
starved overnight. The cells were treated with increasing doses of monomeric (A),
homodimeric (B, C), or heterodimeric (D, E) hPRL or G129R and the efficiency of
STAT5 phosphorylation was examined after 20 min. Cell lysates were harvested and 40
µg of lysate from each treatment was separated by reducing SDS-PAGE using 4-15%
polyacrylamide gels and transferred to nitrocellulose membranes. The membranes were
probed with anti-phospho-STAT5. Equal loading was confirmed by reprobing the
membranes with an anti-STAT5 antibody.
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The difference in potency between dimeric G129R and monomeric hPRL may be
explained in part by the difference in their relative binding affinity to human PRLRs (Fig.
4.2), but may also be related to the adjustments in the receptor that are necessary to bind
two Site 1s. We also compared the efficiency of dimeric G120R and monomeric hGH at
activating STAT5, Erk1/2, and Akt (Fig. 4.7).

Dimeric G120R induced the

phosphorylation of these signaling molecules in a dose-dependent manner (Fig. 4.7B),
but required approximately 30-fold higher concentrations to achieve similar levels of
activation induced by monomeric hGH (Fig. 4.7A).
Consistent with having a lower affinity, the efficiency of signal transduction
induced by 10 nM dimeric G129R (Fig. 4.8B) or dimeric G120R (Fig. 4.9B) were lower
than that of 10 nM of hPRL (Fig. 4.8A) and hGH (Fig. 4.9A), requiring a longer time
course to achieve similar activation levels. The phosphorylation of STAT5 induced by
10 nM dimeric G129R (Fig. 4.8A) was detectable after 20 min whereas it was detectable
after 10 min for hPRL (Fig. 4.8B). The phosphorylation of STAT5 by dimeric G120R
(Fig. 4.9B) required 30 min to achieve the same level as hGH (Fig. 4.9A) after 2 min;
similarly, it took much longer for dimeric G120R to stimulate phosphorylation of Erk1/2.
We further examined the signaling induced by homodimers of hPRL, homodimers
of hGH, and heterodimers of hPRL and G129R. We show that these dimers activate the
same signaling pathways as hPRL and hGH (Fig. 4.5). Heterodimers of hPRL and
G129R (Fig. 4.6, D and E, and Fig. 4.8, D and E) exhibited slightly lower signaling
efficiencies than monomeric hPRL (Figs. 4.6A and 4.8A); whereas, homodimers of hPRL
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(Figs. 4.6C and 4.8C) and hGH (Figs. 4.7C and 4.9C) activated STAT5 nearly as well as
monomeric hPRL (Figs. 4.6A and 4.8A) and hGH (Figs. 4.7A and 4.9A).
Dimeric G129R and G120R Induce Proliferation of Rat Nb2 Cells in a DoseDependent Manner
To examine the biological activity of homodimeric G129R, homodimeric G120R,
and the other dimeric derivatives we measured their ability to induce the proliferation of
rat Nb2 cells which proliferate in response to lactogenic hormones. The relative number
of viable cells was determined after 72 h treatment by colorimetrically measuring the
reduction of MTS by living cells. Treatment of the cells with increasing doses of
homodimeric G129R (Fig. 4.10A) or homodimeric G120R (Fig. 4.10C) stimulated cell
proliferation in a dose-dependent manner.

Homodimers of hPRL (Fig. 4.10B),

homodimers of hGH (Fig. 4.10D), and heterodimers of hPRL and G129R (Fig. 4.10, E
and F) were more potent agonists than homodimers of G129R (Fig. 4.10A) and
homodimers of G120R (Fig. 4.10C). The proliferation induced by these ligands in rat
Nb2 cells correlated well with the ability of the ligands to bind receptors (Fig. 4.2) and
induce signaling in human T-47D cells (Figs. 4.5-4.7). Dimeric G129R appeared to be a
more potent agonist than dimeric G120R.
To provide further evidence that the agonism observed for homodimeric G129R
was due to the presence of two functional Site 1s, we made a series of deletions to the Cterminus of the second moiety of G129R (Fig. 4.11). Removal of a portion of helix IV by
deleting the last 25 amino acid residues (G129R2ΔC25) reduced the agonism by
approximately 10-fold. Further removal of helix IV by deleting 40 amino acid residues
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(G129R2ΔC40) resulted in further reduction in agonist activity to a level similar to
monomeric G129R, strongly suggesting that helix IV in the second moiety of G129R
plays an important role in forming the second functional binding site. Interestingly,
truncations into and beyond helix III (G129R2ΔC80 thru G129R2ΔC160, with the
exception of G129R2ΔC180) abolished all residual agonistic activity.
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Fig. 4.7
Dose-dependent induction of STAT5, Erk1/2 and Akt phosphorylation
induced by monomeric and dimeric hGH derivatives
T-47D cells were plated as described in the Materials and Methods and serum
starved overnight. The cells were treated with increasing doses of monomeric hGH (A),
homodimeric G120R (B) or homodimeric hGH (C) and the efficiency of activation was
examined after 30 min. Cell lysates were harvested and 40 µg of lysate from each
treatment was separated by reducing SDS-PAGE using 10% polyacrylamide gels and
transferred to nitrocellulose membranes. The membranes were probed with antibodies
that recognize phospho-Akt1/2/3, phospho-Erk1/2, and phospho-STAT5A/B. Equal
loading was confirmed by reprobing the membranes with an anti-STAT5 antibody.
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Fig. 4.8
Time course of Erk1/2 and STAT5 phosphorylation in T-47D cells in
response to monomeric and dimeric hPRL derivatives
T-47D cells were plated as described in the Materials and Methods and serum
starved overnight. The cells were treated with 10 nM of monomeric hPRL (A),
homodimeric G129R (B), homodimeric hPRL (C) or heterodimeric hPRL and G129R (D
and E) for various durations (0, 2, 5, 10, 20, 30, 40, 50, and 60 min). Cell lysates were
harvested and 40 µg of lysate from each treatment was separated by reducing SDS-PAGE
using 4-15% polyacrylamide gels and transferred to nitrocellulose membranes. The
membranes were probed with antibodies that recognize phospho-Erk1/2 and phosphoSTAT5A/B. Equal loading was confirmed by reprobing the membranes with an antiSTAT5 antibody.
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Fig. 4.9
Time course of STAT5, Akt, and ERK1/2 phosphorylation in T-47D cells
in response to monomeric and dimeric hGH derivatives
T-47D cells were plated as described in the Materials and Methods and serum
starved overnight. The cells were treated with 10 nM of monomeric hGH (A),
homodimeric G120R (B) or homodimeric hGH (C) for various durations (0, 2, 5, 10, 20,
30, 40, 50, and 60 min). Cell lysates were harvested and 40 µg of lysate from each
treatment was separated by reducing SDS-PAGE using 10% polyacrylamide gels and
transferred to nitrocellulose membranes. The membranes were probed with antibodies
that recognize phospho-Akt1/2/3, phospho-Erk1/2, and phospho-STAT5A/B. Equal
loading was confirmed by reprobing the membranes with an anti-STAT5 antibody.
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Fig. 4.10
Rat Nb2 cell proliferation in response to monomeric and dimeric hPRL
and hGH derivatives
Rat Nb2 cells were treated with various doses of monomeric, homodimeric, or
heterodimeric hPRL, G129R, hGH, or G120R for 72 h as described in the Materials and
Methods. Cell proliferation was assessed by colorimetrically measuring the reduction of
MTS. Each data point represents the mean ± SD of at least three independent
experiments performed in quadruplicate. Rat Nb2 cells proliferate in response to
picomolar concentrations of hPRL and hGH; G129R and G120R exhibit partial agonism
at concentrations more than 2-log higher than that of hPRL and hGH. This partial
agonism has been attributed to the rat PRLR forming a more stable interaction with
binding site 2 of these ligands than the human PRLR.
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Fig. 4.11
Examination of rat Nb2 cell proliferation in response to truncated forms of
dimeric G129R
Rat Nb2 cells were treated with various doses of hPRL, G129R, or truncated
forms of dimeric G129R (G129R2) for 72 h as described in the Materials and Methods.
Cell proliferation was assessed by colorimetrically measuring the reduction of MTS.
Each data point represents the mean ± SD of at least two independent experiments
performed in quadruplicate.
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Discussion
Human PRL and hGH share limited amino acid sequence identity, yet they both
can bind to PRLRs with high affinity to form functional receptor dimers. These ligands
have two separate and different binding sites that each interact with a PRLR in a
sequential manner to form a 1:2 ligand-receptor complex that activates signal
transduction (Cunningham and Wells, 1989, 1991; Ultsch et al., 1991; de Vos et al.,
1992; Fuh et al., 1993). Although the interactions of hPRL and hGH with the PRLR
overlap they are not identical (Rozakis-Adcock and Kelly, 1992), hGH requires the
presence of zinc to bind with high affinity (Cunningham et al., 1990b). The ability of
hGH to adapt to both the GHR and PRLR has largely been attributed to the local
conformational flexibility of its binding loops (Kossiakoff et al., 1994). Studies have
shown that the second half of the long loop between helices I and II is important to the
structure and/or function of both GH and PRL (Cunningham et al., 1989; Goffin et al.,
1992). Conformational changes in this region of the loop were observed for a high
affinity hGH variant (Ultsch et al., 1994) and amino acid changes to this region were
necessary to engineer PRL to bind to the GHR (Cunningham et al., 1990a). These studies
suggest that the natural ligands of the PRLR exhibit local conformational flexibility.
The ability of the PRLR and GHR to be activated by ligands other than the
monomeric forms suggests that the ECD of the PRLR and GHR also exhibit flexibility.
In addition to monomers, dimeric and oligomeric forms of PRL, GH, and PL have been
identified in the circulation of mammals and account for a small portion of the total
plasma levels of these ligands (Stolar et al., 1984; Smith and Norman, 1990; Sinha, 1995;

150

Fahie-Wilson et al., 2005). Dimeric forms may arise from interchain disulfide linkages,
linkages between glycosylated monomers, or be due to non-covalent interactions.
Purified disulfide-linked dimers of hPL have been shown to retain the ability to bind to
mammary glands with high affinity and to be biologically active in vitro (Schneider et al.,
1975b; Schneider et al., 1977). A natural dimeric form of hGH with an extremely stable
disulfide-linkage (MER-45-kDA hGH) has been characterized (Grigorian et al., 2005)
which binds to both the GHR and PRLR with high affinity (Grigorian et al., 2002). It has
been shown to stimulate Nb2 cell proliferation (Grigorian et al., 2003), but to inhibit the
proliferation of breast cancer cell lines (Muñoz et al., 2004), suggesting either that it acts
as an antagonist in the presence of autocrine PRL or that it antagonizes the GHR, or both
(Muñoz et al., 2005). In addition to these natural ligands, mAbs developed against the
ECD of the PRLR have been shown to be weak agonists (Djiane et al., 1985; Okamura et
al., 1989; Elberg et al., 1990), with activities approximately 100-fold lower than natural
monomeric ligands in the rat Nb2 assay (Rui et al., 1994b). These bivalent mAbs were
inactive as monovalent Fab fragments, confirming that the dimerization and activation of
PRLRs occurs only when a ligand has two functional binding sites. Whether or not these
mAbs recognize epitopes involved in PRL binding remains to be determined.
To specifically address whether or not the ligand-binding sites of the PRLR are
flexible enough to accommodate larger ligands, we recombinantly engineered dimeric
forms of the ligands (hPRL, hGH) and their antagonists (G129R, G120R). Previous
studies have shown that mutations in helix III of GH and PRL disrupt the integrity of
binding Site 2, resulting in mutants with little or no biological activity (Chen et al.,

151

1991a; Fuh et al., 1993; Chen et al., 1994; Fuh and Wells, 1995; Goffin et al., 1996; Chen
et al., 1999). This Gly to Arg mutation reportedly has minimal effects upon initial
hormone-receptor interactions at Site 1 but disrupts the critical hormone-receptorinteractions at Site 2 (de Vos et al., 1992; Sundstrom et al., 1996; Clackson et al., 1998),
preventing proper receptor dimerization from occurring. We reasoned that the fusion of
two molecules of G129R or G120R together would create a bivalent ligand with only two
potentially functional binding Site 1s located in different moieties. Dimerization and
activation of PRLR by these dimers would provide further evidence that the PRLR
exhibits considerable flexibility in accommodating ligands of larger size (Fig. 4.13).
Using a radio-receptor binding assay we examined the overall affinity of hPRL
derivatives for human PRLRs expressed on the surface of T-47D cells. Since ligand
binding occurs sequentially and because ligand binding is transient in nature, the radioreceptor binding assay reflects 1:1 ligand-receptor interactions to a larger extent than 1:2
interactions. We observed that higher concentrations of G129R were needed to compete
with 125I-labeled hPRL than were necessary for hPRL (Fig. 4.2) (Chen et al., 1999). This
lower affinity may reflect the inability of G129R to interact with a second receptor due to
the disruption of binding Site 2. Homodimers of G129R were found to have an affinity
greater than that of monomeric G129R (Fig. 4.2), indicating that the addition of a second
G129R moiety was able to improve the interaction of the ligand with a second receptor.
Homodimeric hPRL was found to have an affinity for PRLRs similar to that of
monomeric hPRL, suggesting that the fusion of two hPRL molecules together had
minimal effect on 1:1 ligand-receptor interactions.
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To determine if dimeric G129R truly has a second functional binding site, we
examined whether or not it could induce the dimerization of human PRLRs. Ligandinduced dimerization causes conformational changes that bring the cytoplasmic domains
of the two PRLRs into close proximity to each other. To examine the conformational
changes induced by dimerization we fused Renilla luciferase (Rluc) or a mutant of green
fluorescent protein (GFP2) to the C-terminus of the long (LF) and short (SF1a and SF1b)
forms of the human PRLR and cotransfected the fusions of each isoform into HEK 293
cells. Upon addition of DeepBlueC™ (DBC), Rluc catalytically degrades the substrate
and releases bioluminescence resonance energy (peak ~395 nm). If receptor dimerization
occurs, Rluc is brought into close proximity to GFP2 and the bioluminescence resonance
energy is transferred to GFP2 which emits fluorescence at a higher wavelength (peak
~515 nm) referred to as a bioluminescence resonance energy transfer (BRET) signal.
Previously, it has been demonstrated that hPRL induces a BRET signal in this system and
that G129R does not; additionally, it has been shown that G129R can competitively
inhibit hPRL-induced BRET (Tan et al., 2005). In contrast to monomeric G129R, we
demonstrate that the addition of homodimeric G129R to the transfected cells results in
the emission of a BRET signal similar to that of monomeric hPRL (Fig. 4.3A). The
BRET ratios for HEK293 cells cotransfected with LF-Rluc/LF-GFP2, SF1a- Rluc/SF1aGFP2, or SF1b-Rluc/SF1b-GFP2 and treated with homodimeric G129R increased
approximately 4, 3, and 3-fold, respectively (Fig. 4.3B); which are comparably less than
that of monomeric hPRL which increased the BRET ratios approximately 9, 4, and 4fold, respectively (Tan et al., 2005).

The lower efficiency of BRET induction by
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homodimeric G129R in comparison to monomeric hPRL may reflect alterations in the
conformation of the receptor homodimers formed. These findings indicate that dimeric
G129R is able to induce conformational changes in the long and short isoforms of the
PRLR which are consistent with receptor dimerization. It also indicates that the second
G129R moiety provides the second functional receptor binding site necessary for receptor
dimerization to occur (Fig. 4.13).
To determine whether the receptor dimers induced by dimeric G129R were
functional we examined the ability of dimeric G129R to activate signaling molecules.
The conformational changes induced by the formation of a functional PRLR dimer
activate receptor-associated JAK2 tyrosine kinase which stimulates the phosphorylation
of STAT5. Activation of PRLRs by hPRL or hGH also leads to the activation of the
Ras/Raf/MAPK kinase/Erk and phosphatidylinositol 3-kinase/Akt signaling pathways.
We demonstrate that dimeric G129R and dimeric G120R are able to activate these three
different intracellular signaling pathways in a manner qualitatively similar to that of
hPRL and hGH (Fig. 4.5). The magnitude of response induced by the dimers was similar
to that of monomeric hPRL and hGH (Figs. 4.6 and 4.7); however, activation of signaling
by homodimeric G129R was slightly less efficient than hPRL, whereas homodimeric
G120R was significantly less efficient than hGH. These finding suggest that dimeric
G129R acts as a substantial agonist and that G120R acts as a weak agonist at the PRLR.
One explanation for the reduced efficiency of homodimeric G129R and homodimeric
G120R is that the receptor homodimers formed upon ligand binding have an altered
conformation that reduces the efficiency of signal transduction.
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The even lower

efficiency of signaling induced by homodimeric G120R may be attributed to the
signaling of hGH and its derivatives being mediated primarily via the PRLR and not the
GHR in T-47D cells (data not shown) (Tsunekawa et al., 1999). Studies have shown that
His18 and Glu 174 located within binding Site1 of hGH and Asp187 and His188 of the
human PRLR interact with a single zinc cation to enhance the affinity of hGH for the
PRLR approximately 8000-fold (Cunningham et al., 1990b). Presumably, homodimeric
hGH would require the coordination of two zinc cations to dimerize PRLRs (one for each
binding Site 1) since the two binding Site 2s are not functional. This would suggest that
the interactions of homodimeric G120R with PRLRs may be more stringent and less
flexible than would be necessary for this ligand to interact with the GHR.
The quantitatively similar signaling activation observed for monomeric hPRL
(Figs. 4.4A, 4.6A, and 4.8A) and heterodimers of hPRL and G129R (Fig. 4.5A, Fig. 4.6,
D and E, and Fig. 4.8, D and E) suggests that fusion of two ligands together has little
effect on their ability to interact with the first receptor, a finding in agreement with the
binding data. The decreased agonism observed for homodimeric G129R (Figs. 4.5A,
4.6B, and 4.8B) as opposed to heterodimers likely reflects the fact that both moieties are
required for activity, requiring some accommodation in the receptors.

These data

indicate that the receptor dimerization induced by dimeric derivatives of hPRL and hGH
are functional and capable of activating the signaling pathways necessary for biological
activity.
hPRL-mediated signaling can induce cell differentiation, proliferation, and/or
survival (Socolovsky et al., 2001; Shillingford et al., 2002). We examined the bioactivity

155

of the dimers using rat Nb2 cells which proliferate in response to lactogens.

The

bioactivity of the dimers on rat Nb2 cells (Fig. 4.10) correlated well with their ability to
transduce signals in human T-47D cells.

This suggests that the restoration of the

biological activities of G129R and G120R was most likely due to the addition of a second
functional binding site (Site 1). This conclusion is further supported by our examination
of truncated forms of dimeric G129R in which a large portion of the second Site 1 (helix
IV) was deleted (Fig. 4.11). It is noteworthy that three types of responses were observed
in the Nb2 cell proliferation assay in response to these truncated mutants including: full
or near full agonism (PRL, G129R2 and G129R2∆C25), partial agonism (G129R,
G129R2∆C40, G129R2∆C60, and G129R2∆C180), and minimal agonism (G129R2∆C80,
G129R2∆C100, G129R2∆C120, G129R2∆C142, and G129R2∆C160). With the exception
of G129R2∆C180, truncations into and beyond helix III completely abolished the partial
agonism, suggesting that helix III in the second G129R moiety is involved in the partial
agonism observed in G129R2ΔC25, G129R2ΔC40 and G129R2ΔC60. One possibility is
that the role of helix III is just to maintain the integrity of the second G129R moiety.
Loss of helix III may prevent the formation of a helical bundle and the remnants of the
second moiety may take on a structure that sterically hinders the ability of the first
G129R moiety to interact with the PRLR. Radio-receptor binding assays were not
performed for these truncated variants of dimeric G129R because of low production
yields.
In addition to studying homodimeric G129R, we demonstrate that homodimeric
hPRL binds to human PRLRs (Fig. 4.2), activates PRLR associated signaling pathways
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(Fig. 4.8C), and exhibits bioactivity in vitro (Fig. 4.10B) similar to that of monomeric
hPRL (Figs. 4.2, 4.8A, and 4.10B). Similar results were observed for homodimeric hGH
(Figs. 4.9C and 4.10D) when compared to monomeric hGH (Figs. 4.9A and 4.10D). To
examine if the pharmacokinetic behavior of homodimers differs from that of monomers,
we injected mice with monomeric and homodimeric hPRL and measured the plasma
concentrations over time. We demonstrate that homodimeric hPRL has twice the area
under the serum concentration-time curve as monomeric hPRL (Fig. 4.12), indicating that
the larger size of the ligand enhances its pharmacokinetic behavior. This suggests that
homodimers of ligands in this cytokine family could be more clinically efficacious. The
presence of four potential binding sites, and the necessity for only two sites, suggests that
chemical modification to further improve their pharmacokinetics may be possible.
Chemical modifications such as polyethylene glycol, dextran chains, or fusion to albumin
or albumin binding peptides can affect the size and ability of a ligand to bind to a
receptor; use of homodimers of a ligand for derivatization may decrease the probability
of affecting crucial receptor binding sites. Conversely, it is clear that homodimerization
of antagonists would produce the opposite of what was intended. The findings in this
study also suggest the possibility that the different degree of partial agonism reported by
different laboratories for G129R and other antagonists may be reflective of the number of
dimeric or larger aggregates in the preparation.
Studies of the erythropoietin (EPO) have yielded similar results to our study. An
EPO receptor (EPOR) antagonist (EPO-R103A) was shown to regain its biological
activity when homodimerized (Qiu et al., 1998). Similarly, dimeric forms of EPO have
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been shown be fully active and to have beneficial pharmacokinetic behavior different
from that of monomeric EPO (Sytkowski et al., 1999; Dalle et al., 2001). These findings
suggest that this class of hematopoietin receptors exhibits considerable plasticity and that
modifications to their cognate ligands may have therapeutic value.
In summary, we demonstrate that the ligand binding sites of the PRLR are capable
of interacting with larger molecules to induce receptor dimerization. We confirm that
larger ligands with at least two functional binding sites can act as agonists and that a
second receptor binding Site 1 can replace the need for a receptor binding Site 2 (Fig.
4.13).

The recent implications of autocrine hPRL and hGH in cancers and the

overexpression of their cognate receptors in certain cancers make the PRLR and GHR
targets of interest for the development of therapeutics. The results of this study suggest
the feasibility of designing novel multi-functional therapeutics that target the PRL/GH
receptor family as we have demonstrated using G129R fused with other proteins (G129RIL2, G129R-Endostatin, and G129R-PE40-KDEL) (Zhang et al., 2002; Beck et al., 2003;
Langenheim and Chen, 2005).
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Pharmacokinetics of monomeric and dimeric forms of hPRL in vivo

Two groups of four BALB/C mice were injected intraperitoneally with 200 µg of
monomeric (triangles) or dimeric (squares) hPRL. Blood was collected by tail-vein
bleeding at 1 h intervals after injection and the serum was subjected to an
immunoradiometric assay for hPRL. The concentrations of monomeric and dimeric
hPRL were extrapolated and plotted vs. time and the difference in the area under the
plasma concentration curves was calculated. Monomeric and dimeric hPRL standards of
known concentration were detected equally well. Endogenous mouse PRL was not
detected at all by the IRMA kit.
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Illustration of monomeric and homodimeric G129R and G120R binding to

Substitution of a Gly residue with an Arg residue in helix 3 (X) of hPRL or hGH
prevents functional receptor dimerization and activation of signal transduction from
occuring. Fusion of two antagonists in tandem restores receptor dimerization and signal
transduction via the two functional binding Site 1s (composed of helix 1 and 4) each
interacting with a receptor.
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CHAPTER FIVE
DEVELOPMENT OF NOVEL LIGANDS THAT ACTIVATE JAK2/
STAT5 SIGNALING EXCLUSIVELY THROUGH THE
HETERODIMER OF A PROLACTIN RECEPTOR
AND GROWTH HORMONE RECEPTOR
Abstract
Prolactin (PRL), growth hormone (GH), and placental lactogen (PL) have two
binding sites, Site 1 and Site 2, which each interact with a receptor to form a trimeric
complex that stimulates signal transduction.

In ruminants, PRL binds to prolactin

receptors (PRLRs), GH to growth hormone receptors (GHRs) and PL to PRLRs or to
heterodimerized GHR and PRLR. In humans, GH binds to PRLRs in addition to GHRs
and PL has only been reported to bind PRLRs. To examine if a heterodimer of PRLR
and GHR is formed in humans, we designed two novel ligands composed of G129R and
B2036 in tandem (G129R-B2036 and B2036-G129R). G129R and B2036 are antagonists
of human (h) PRL and GH, respectively, with their binding Site 2 disrupted.
Furthermore, B2036 has its binding Site 1 altered to reduce its affinity towards PRLR.
Therefore, these novel fusion proteins should contain a single PRLR and single GHR
binding site. The data presented in this study demonstrates that these ligands do not
activate Janus-activated kinase 2/signal transducer and activator of transcription 5
(JAK2/STAT5) signaling in cells that express only GHR or PRLR, but rather behave as
receptor antagonists. No biological activity was observed for these ligands in rat Nb2
cells, which predominately express PRLRs. When tested in human cell lines that co-
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express PRLR and GHR, both B2036-G129R and G129R-B2036 activated JAK2/STAT5
signaling. These findings indicate that a functional heterodimer of PRLR and GHR may
be formed in humans and that these novel ligands may be used to modulate heterodimer
signaling.
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Introduction
Prolactin (PRL) (Keeler et al., 2003; Teilum et al., 2005), growth hormone (GH)
(de Vos et al., 1992; Chantalat et al., 1995; Clackson and Wells, 1995) and placental
lactogen (PL) (Walsh and Kossiakoff, 2006) are long-chain four α-helical cytokines.
They each have two distinct binding sites, Site 1 and Site 2, that bind to homodimeric
type 1 cytokine receptors and stimulate Janus-activated kinase 2/signal transducer and
activator of transcription 5 (JAK2/STAT5) signaling (Nicola and Hilton, 1998). PRL and
PL mediate their effects via prolactin receptor (PRLR) homodimers; whereas, GH
mediates its effects via growth hormone receptor (GHR) homodimers. Binding to the
receptor homodimers occurs sequentially with the higher affinity Site 1 interacting with
the first receptor before the lower affinity Site 2 interacts with a second receptor to form a
functional trimeric complex.
A recent finding in ruminants challenges the paradigm that that these peptide
hormones only bind to receptor homodimers and indicates that ovine and bovine PL may
also bind a heterodimer of PRLR and GHR. Like PRL, PL induces the formation of a
functional PRLR homodimer in ovines and bovines (Byatt et al., 1994; Sakal et al.,
1997), but in contrast to GH, forms an inactive complex with GHR (Staten et al., 1993;
Herman et al., 2000) that competitively inhibits the action of GH (Herman et al., 1999;
Warren et al., 1999). Since receptor binding Site 2 of PL binds a PRLR, the possibility
that PL might heterodimerize a GHR via Site 1 and PRLR via Site 2 was explored.
Using homologous systems, it was demonstrated that ovine (o) PL transiently
heterodimerizes a oPRLR and oGHR (Biener et al., 2003; Gertler et al., 2005) and that
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the cytoplasmic domains of heterodimerized receptors induce STAT5-responsive
transcriptional activity (Biener et al., 2003). The transcriptional response to oPL was
better in cells with both oPRLR and oGHR than in cells with only oPRLR (Gertler and
Djiane, 2002). Consistent with the existence of receptor heterodimers, binding of oPL in
the endometrial gland was displaced completely by oPL and oPRL but only partially by
oGH (Noel et al., 2003). Also, in contrast to bovine (b) PRL, bPL was shown to
stimulate DNA synthesis in the bovine mammary gland (Byatt et al., 1994). These
observations suggest that receptor heterodimers activated by PL may have a
physiological role in mammary, placental, and fetal tissues of ruminants.
There is no direct evidence that a PRLR can heterodimerize with a GHR in
humans. In contrast to ruminants, human (h) PL is more closely related to hGH than
hPRL (Dietz et al., 1992; Gootwine and Yossafi, 1998), sharing 93% and 42% sequence
identity, respectively. Also, the two binding sites of hGH (Cunningham et al., 1991; de
Vos et al., 1992; Clackson and Wells, 1995; Sundstrom et al., 1996) can interact with
PRLRs (Kleinberg and Todd, 1980) in addition to a GHRs (Cunningham et al., 1989;
Cunningham et al., 1991; de Vos et al., 1992). The binding sites of hGH for PRLRs
(Somers et al., 1994) and GHRs (Ultsch et al., 1994) overlap but are not identical
(Cunningham and Wells, 1991; Kossiakoff et al., 1994). Zinc influences the binding of
hGH to PRLRs but not to GHRs (Cunningham et al., 1990b) and increases its bioactivity
(Dattani et al., 1993; Fuh et al., 1993) by increasing the affinity of Site 1 for the PRLR
(Somers et al., 1994; Duda and Brooks, 2003). Since hGH can readily homodimerize
PRLRs or GHRs, it may potentially heterodimerize a PRLR via Site 1 and GHR via Site
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2 or vice versa.
Rather than speculate which ligands might heterodimerize a PRLR and GHR in
humans and have to utilize elaborate systems in which the extracellular or intracellular
portions of the receptors are modified, we chose to design novel ligands that retain a
single functional PRLR binding site and a single functional GHR binding site. To do this
we utilized a well characterized PRLR antagonist, hPRL-G129R (G129R); PRLR/GHR
antagonist, hGH-G120R (G120R); and pure GHR antagonist, B2036. Previously, we
have demonstrated that the fusion of two PRLR antagonist (G129R-G129R) or two
PRLR/GHR antagonist (G120R-G120R) in tandem results in ligands able to activate
STAT5 signaling via PRLRs (Langenheim et al., 2006) and that G120R-G120R also
induces STAT5 signaling via GHRs (Yang et al., 2007). Based upon these findings we
wanted to determine if G129R and G120R linked in tandem (G129R-G120R and G120RG129R), or G129R and B2036 linked in tandem (G129R-B2036 and B2036-G129R)
could heterodimerize a PRLR and GHR. To do this we examined the ability of the fusion
proteins to induce the tyrosine phosphorylation of STAT5 using cell lines determined to
express human GHR, PRLR, or both receptors.
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Materials and Methods
Cell Lines and Reagents
T-47D human breast cancer cells, IM-9 Epstein-Barr virus-transformed human Blymphoblastoid cells and human embryonic kidney (HEK) 293 cells transformed by
sheared human adenovirus type 5 DNA were obtained from the American Type Culture
Collection (Manassas, VA). PRL-dependent Nb2-11 rat pre-T lymphoma cells (Nb2)
were kindly provided by Dr. Ameae Walker and are now available from Sigma-Aldrich
(St. Louis, MO). All reagents were purchased from Invitrogen (Carlsbad, CA) unless
otherwise stated. T-47D cells were maintained in RPMI Medium 1640 supplemented
with 10% fetal bovine serum (FBS) and 10 µg/ml gentamicin. For IM-9 cells, the
medium was further supplemented with 10 mM HEPES and 1.0 mM sodium pyruvate.
For Nb2 cells, the medium was further supplemented with 10% horse serum (HS) and 0.1
mM 2-mercaptoethanol. HEK293 cells were maintained in Dulbecco's Modified Eagle
Medium (DMEM) containing high glucose, 1 mM sodium pyruvate and 2 mM Lglutamine; the medium was supplemented with 10% FBS and 10 µg/ml gentamicin. The
cell lines were incubated at 37°C with humidity and 5% CO2.
Construction of Prokaryotic Expression Vectors with G129R and G120R or B2036
Linked in Tandem
Previously, a PRLR antagonist (G129R), a PRLR/GHR antagonist (G120R), and
a pure GHR antagonist (B2036) were cloned between the Nde I and Xho I sites of the
expression vector pET22b(+) (Novagen; Madison, WI). These plasmids were used as
templates for PCR to modify and amplify the DNA encoding G129R, G120R or B2036
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so that the genes could be linked in tandem to create recombinant fusion proteins. The
first moiety of G120R or B2036 was amplified using the oligonucleotide primers 5’TCATATGTTCCCAACCATTCCCTTATC-3’ and 5’-TGGATCCGAAGCCACAGCTG
CCCTCC-3’; which incorporate an Nde I site at the N-terminus and replace the Cterminal stop codon with a BamH I site. The second moiety of G120R or B2036 was
amplified using the primers 5’-TGGATCCTTCCCAACCATTCCCTTATC-3’ and 5’TCTCGAGCTAGAAGCCACAGCTGCCC-3’; which incorporate a BamH I site at the
N-terminus and an Xho I site after the stop codon. The primers used to create the first
and second moieties of G129R were reported in Chapter 4. The PCR products were
ligated with pCR2.1 T/A cloning vector and transformed into E. coli TOP10 cells
obtained from Invitrogen. Positive clones were identified by plating the cells on LuriaBertani (LB) agar plates containing 100 µg/ml ampicillin and 80 µg/ml 5-bromo-4chloro-3-indolyl-β-D-galactopyranoside. The plasmids were isolated using the QIAprep®
Spin Miniprep Kit (Qiagen, Valencia, CA) and the Nde I-G129R-BamH I, Nde I-G120RBamH I or Nde I-B2036-BamH I DNA fragments were isolated by restriction digestion
and separated by electrophoresis as were the BamH I-G129R-stop-Xho I, BamH IG120R-stop-Xho I and BamH I-B2036-stop-Xho I DNA fragments. The DNA fragments
were purified from the agarose gel using the QIAquick® Gel Extraction Kit (Qiagen) and
the appropriate combinations were ligated with Nde I and Xho I cut pET22b(+) to create
pET22b-G129R-G120R, pET22b-G129R-G120R, pET22b-G129R-B2036 and pET22bB2036-G129R. All oligonucleotides were synthesized by Integrated DNA Technologies
(Coralville, IA), restriction and modifying enzymes were purchased from New England
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BioLabs (Beverly, MA) and PCR reactions were performed using the Advantage-HF™
Kit (BD Biosciences, Palo Alto, CA).
Production and Purification of the Fusion Proteins
Chemically competent Rosetta™(DE3) pLysS E. coli cells (Novagen) were
transformed with the constructs and propagated overnight at 37°C with agitation in LB
broth containing 100 µg/ml ampicillin. The next morning 40 ml of each of the starter
cultures was used to inoculate one liter of Terrific Broth in baffled flasks and the cultures
were grown to an O.D.600 of 0.8 before induction of protein production with 1 mM
isopropyl-β-thiogalactoside (Alexis Biochemicals, San Diego, CA).

After 3 h of

induction the cells were harvested by centrifugation at 5,000 x g for 5 min at 4°C and
resuspended in Solution 1 (50 mM Tris·HCl; 10 mM EDTA; 0.5% Triton X-100; pH
adjusted to 8.0) to which 0.4 mg/ml lysozyme was added. The cells were incubated at
room temperature for 1 h to weaken the cell membranes before the cells were sheared on
ice with five 1-min ultrasonic pulses (30% duty at setting 7) using a 550 Sonic
Dismembrator (Fisher Scientific, Waltham, MA). The insoluble fraction containing the
inclusion bodies was recovered by centrifugation at 12,000 x g for 30 min at 4ºC and
resuspended in Solution 2 (50 mM Tris·HCl; 10 mM EDTA; 1 M urea; pH adjusted to
8.0). The inclusion bodies were collected by centrifugation at 12,000 x g for 30 min at
4ºC and were solubilized and denatured in Solution 3 (50 mM Tris·HCl; 10 mM EDTA; 8
M urea; 1% v/v 2-mercaptoethanol; final pH after protein addition was adjusted to 11.0).
The proteins were refolded by dialysis against baths of 50 mM Tris·HCl, pH 8.0
containing decreasing amounts of urea (4 M urea, 2 M urea, 0 M urea, 0 M urea). The
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refolded proteins were filtered through 0.45 µm filters and purified by anion-exchange
chromatography using a 5 ml HiTrap Q Sepharose HP column (Amersham Biosciences,
Piscataway, NJ) on an ÄKTA fast protein liquid chromatography system (Amersham
Biosciences).

The concentration of the purified proteins was determined using the

Coomassie Plus™ Protein Assay Reagent with BSA standards (Pierce, Rockford, IL).
The purified proteins were separated by reducing SDS-PAGE along with BenchMark
Protein Ladder (Invitrogen) and stained with SYPRO® Orange (Molecular Probes,
Eugene, OR) to confirm their concentration and purity.
STAT5 Phosphorylation Assays
T-47D cells were resuspended in RPMI Medium 1640 supplemented with 10%
charcoal/dextran treated FBS (CSS; HyClone, Logan, UT) and 10 µg/ml gentamycin and
plated in twelve-well tissue culture plates.

The cells were grown overnight to

approximately 80% confluency and depleted for 3 h in RPMI Medium 1640
supplemented with 0.5% CSS. L-cells were resuspended in DMEM supplemented with
10% FBS and 10 µg/ml gentamycin and plated in twelve-well tissue culture plates. The
cells were grown overnight to approximately 80% confluency and depleted for 3 h in
DMEM supplemented with 0.5% CSS. Cells were treated for the indicated amounts of
time with the indicated concentrations of monomeric hPRL, hGH, B2036-REV, G129R,
G120R, or B2036; or with heterodimeric G129R-G120R, G120R-G129R, G129R-B2036,
or B2036-G129R.

The cells were washed with ice cold phosphate buffered saline

containing 0.4 mM sodium vanadate and lysed in 100 µl of Lysis Buffer (20 mM
Tris·HCl, pH 7.4; 1% Igepal CA630; 6 mM deoxycholic acid; 150 mM NaCl; 1 mM
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EDTA, pH 8.0) containing protease inhibitors (1 µg/ml aprotinin; 1 µg/ml leupeptin; 170
µg/ml PMSF; 180 µg/ml sodium orthovanadate). The lysates were homogenized and
incubated on ice for 20 minutes before clarification by centrifugation at 12,000 x g at 4°C
for 30 min. Approximately 80 µg of the supernatants were used for Western blot analysis
as described below.
IM-9 cells were harvested by centrifugation and resuspended in DMEM
containing 0.5% CSS.

The volume was adjusted with medium to yield a final

concentration of 1 x 106 cells per ml. The cells were aliquoted (1 mL) into Eppendorf
tubes and depleted for 1 h before addition of 111 μL of 10X treatments. Cells were
treated for 30 min at 37°C, pelleted, the medium aspirated and resuspend in 100 μL of
Lysis Buffer. Approximately 80 µg of the supernatants were used for Western blot
analysis as described below.
HEK293 cells stably transfected with human GHR or PRLR were trypsinized and
resuspended in selection medium at a final concentration of 5 x 105 cells per ml. For
each treatment, 10 ml of the cell suspension was seeded into a 100 mm2 tissue culture
dish and incubated overnight at 37°C with 5% CO2 and humidity. The medium was
aspirated and the cells were depleted in 9 ml of DMEM containing 0.5% CSS for 3 h.
Treatments (1 ml) were added directly to the cells and incubated for 15 min. The
medium was aspirated and the cells were lysed in 1 ml of modified RIPA Buffer (50 mM
Tris-HCl, pH 7.4; 150 mM NaCl; 1% IGEPAL CA-6305; 0.25% sodium deoxycholate)
to which protease inhibitors (1 mM EGTA; 1 mM NaF, 1 mM Na3VO4; 1 mM
phenylmethylsulfonyl fluoride; 5 µg/ml aprotinin; 1 µg/ml pepstatin A; 2 µg/ml
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leupeptin) were added. Cells lysate was collected into eppendorf tubes, centrifuged at
18,000 x g for 30 min at 4°C and the supernatant was subject to immunoprecipitation.
Immunoprecipitation
The concentrations of the clarified cell lysates were determined using the
Coomassie Plus™ Protein Assay Reagent with BSA standards (Pierce). Approximately
500 μg of cell lysate was incubated with 5 μg of anti-STAT5 (sc-835, Santa Cruz
Biotechnology, Santa Cruz, CA ) and 25 μl of protein A-sepharose (GE Healthcare
Sciences,

Piscataway,

NJ)

overnight

at

4°C

on

a

slowly

rotating

wheel.

Immunoprecipitates were washed in 1 ml of washing buffer (50 mM HEPES, pH 7.5; 150
mM NaCl; 5 mM EDTA; 50 mM Tris-HCl, pH 7.5; 0.05% Triton X-100), centrifuged
briefly and the liquid was aspirated. Washing was repeated twice before Sample Buffer
(1% SDS; 100 mM DTT; 50 mM Tris, pH 7.5; 0.05% bromophenol blue) was added to
the beads and the samples were denatured at 98°C for 5 min. The immunoprecipitated
products were then subject to Western blotting as described below.
Western Blot Analysis
Cell lysates or immunoprecipitate were separated on 10% polyacrylamide gels by
reducing SDS-PAGE.

The proteins were transferred by Western blot to Hybond™

Enhanced Chemiluminescence (ECL) nitrocellulose membranes (Amersham Biosciences)
at 16 W for 1 h. The nitrocellulose membranes were blocked for 20 min at room
temperature in Tris buffered saline (TBS) containing 0.05% Tween 20 (TBS-T) and 5%
milk. The blocking solution was replaced with solution containing a 1:500 dilution of
mouse anti-phospo STAT5A/B antibody (Upstate, Lake Placid, NY) and incubated
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overnight at 4°C with agitation. The blots were washed three times with TBS-T, and
incubated for 2 h at room temperature with agitation in blocking solution containing a
1:2000 dilution of goat anti-mouse-HRP conjugate (Bio-Rad, Hercules, CA). Blots were
washed three times with TBS-T and incubated for 1 min with ECL™ Western Blotting
Detection Reagents (Amersham Biosciences). The blots were exposed to Biomax MR
film (Kodak, Rochester, NY) and developed with a Konica SRX-101A processor (Konica
Minolta Medical Imagining, Wayne, NJ). Blots were stripped and reprobed with a
1:1333 dilution of rabbit anti-STAT5 polyclonal antibody (Santa Cruz Biotechnology)
and a 1:2000 dilution of goat anti-rabbit HRP conjugate (Bio-Rad).
Rat Nb2 Cell Proliferation Assay
Rat Nb2 cells were resuspended to a final concentration of 5.5 x 105 cells per ml
in RPMI 1640 Medium supplemented with 10% low lactogen HS (Cat. 2921154; MP
Biomedicals, Irvine, CA), 10 µg/ml gentamicin and 0.1 mM 2-mercaptoethanol. The
cells were depleted overnight, counted and reseeded in flat bottom 96-well plates at a
density of 20,000 cells per well in 150 µl of medium. Treatments were added to each
well in 50 µl volumes and the cells were incubated for 72 h. The relative number of cells
was determined by incubating the cells for 4 h with 40 µl of 3-(4,5-dimethylthiazol-2-yl)5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium/phenazine methosulfate
solution (CellTiter 96 AQueous non-radioactive cell proliferation kit; Promega, Madison,
WI) per well. The reduction of the substrate by living cells was determined by measuring
the absorbance at 490 nm using a GENios Pro microplate reader (Tecan, Durham, NC).
All assays were performed at least three times in quadruplicate.
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Fig. 5.1
Reducing SDS-PAGE analysis of purified agonists, antagonists, and
fusions of the antagonists
One microgram of the agonists (hPRL, hGH, and B2036-REV), their antagonists
(G129R, G120R, and B2036) and the fusions of the antagonists (G129R-G120R, G120RG129R, G129R-B2036, and B2036-G129R) were separated by reducing SDS-PAGE on
12% polyacrylamide gels and stained with SYPRO® Orange to confirm their size and
purity.
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Results
Construction, Expression, and Purification of Antagonist-Based Fusion Proteins
A PRLR antagonist (G129R) was covalently fused to the N-terminus or Cterminus of a PRLR/GHR antagonist (G120R) or a pure GHR antagonist (B2036)
through gene fusion. Expression of the fusion genes in E. coli resulted in a protein in
which the C-terminus of the first moiety was connected the N-terminus of the second
moiety by a Gly-Ser peptide linker. The fusion proteins were found to accumulate in the
insoluble fraction as inclusion bodies. The inclusion bodies were isolated, denatured and
the fusion proteins were refolded and purified by anion-exchange chromatography to
yield preparations greater than 95% purity (Fig. 5.1).
The Fusion Proteins Do Not Activate STAT5 Signaling Via GHRs
Before examining the ability of the fusion proteins to induce the STAT5 tyrosine
phosphorylation it had to be determined if the cell lines respond to stimulus via GHRs,
PRLRs or both receptors. IM-9 cells did not respond to hPRL but responded equally well
to hGH or an analog of hGH which doesn’t bind to PRLRs, B2036-REV (Fig. 5.2A). We
also show that hGH-induced STAT5 activation was completely inhibited by GHR
antagonists, G120R and B2036, but not by a PRLR antagonist, G129R (Fig. 5.3A). This
indicates that hGH-induced STAT5 signaling in IM-9 cells was mediated entirely via
GHRs and not PRLRs. Since all four of the fusion proteins contain only a single GHR
binding site, we suspected that the ligands would not induce signal transduction in IM-9
cells, and if their affinity was high enough, would behave as antagonists in the presence
of hGH. We demonstrated that fusions of G129R and G120R or B2036 do not activate
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STAT5 signaling in IM-9 cells (Fig. 5.2, C and D), and therefore do not induce the
formation of a functional GHR homodimer.
The Fusion Proteins Behave as GHR Antagonists
To confirm that the fusion proteins retain the ability to bind a single GHR, we
examined their ability to competitively inhibit hGH-induced STAT5 signaling. The
fusion proteins competitively inhibited hGH-induced STAT5 signaling to different
degrees (Fig. 5.3, B and C). Ligands in which the GHR binding site was located within
the C-terminal moiety (G129R-G120R, G129R-B2036) were more potent than ligands in
which the GHR binding site was located within the N-terminal moiety (G120R-G129R,
B2036-G129R) at inhibiting hGH-induced signaling (Fig. 5.3, B and C). Compared to
monomers of G120R and B2036, the potency of the G129R-G120R and G129R-B2036
fusion proteins was reduced only two-fold; in contrast, the potency of the G120R-G129R
and B2036-G129R fusion proteins was reduced over sixteen-fold (Fig. 5.3, A versus B
and C). These findings are consistent with our rudimentary 3D-models of the fusion
proteins, which indicate that the receptor binding site within the N-terminal moiety is
sterically hindered; whereas, the receptor binding site within the C-terminal moiety is not.
The Fusion Proteins Are Inactive in the Nb2 Cell Proliferation Assay
Having confirmed that the fusion proteins bind to a GHR but are unable to induce
the formation of a functional GHR homodimer, we wanted to examine their behavior in
PRLR system. Rat Nb2 cells proliferate in response to extremely low concentrations of
hPRL and hGH, but not readily in response to a PRLR antagonist (G129R), a
PRLR/GHR antagonist (G120R) or a pure GHR antagonist (B2306) (Fig. 5.4A).
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Fig. 5.2
Fusions of a PRLR antagonist (G129R) and a PRLR/GHR antagonist
(G120R) or pure GHR antagonist (B2036) do not activate STAT5 signaling in cells
expressing only GHRs
IM-9 cells were prepared as described in the Materials and Methods and serum
starved for 1 h prior to assay. Cells were treated for 30 min with increasing doses of the
agonists (hGH, B2036-REV, or hPRL) to confirm that the cells respond via GHR and not
PRLR; increasing doses of the antagonists (G120R, B2036, or G129R) to confirm that
they retain no residual agonistic activity (B); increasing doses of the heterodimers
containing G129R and G120R (C) or the heterodimers containing G129R and B2036 (D)
to confirm that they do not acquire the ability to activate GHR homodimers. Cell lysates
were harvested and 80 μg of lysate from each treatment was separated by reducing SDSPAGE using 10% polyacrylamide gels and transferred to nitrocellulose membranes. The
membranes were probed with antibodies that recognize tyrosine phosphosphorylated
STAT5A/B (p-STAT5). Equal loading was confirmed by reprobing the membranes with
anti-STAT5 antibody.
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Fig. 5.3
Fusions of a PRLR antagonist (G129R) and a PRLR/GHR antagonist
(G120R) or pure GHR antagonist (B2036) inhibit STAT5 signaling in cells expressing
only GHRs
IM-9 cells were prepared as described in the Materials and Methods and serum
starved for 1 h prior to assay. Cells were treated with 5 nM of hGH in the absence or
presence of increasing doses of GHR antagonists or a PRLR antagonist (A), fusion
proteins containing G129R and G120R in tandem (B), or G129R and B2036 in tandem
(C). Cell lysates were harvested and 80 μg of lysate from each treatment was separated
by reducing SDS-PAGE using 10% polyacrylamide gels and transferred to nitrocellulose
membranes. The membranes were probed with an antibody that recognizes tyrosine
phosphorylated STAT5A/B (p-STAT5). Equal loading was confirmed by reprobing the
membranes with anti-STAT5 antibody.
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When G129R and G120R were linked in tandem the ability to induce proliferation was
restored due to the presence of a PRLR binding site within each moiety of the fusion
proteins (Fig. 5.4B). However, when the PRLR/GHR antagonist (G120R) moiety was
replaced with a pure GHR antagonist (B2036) moiety, proliferation was once again lost
(Fig. 5.4B). This observation is consistent with the G129R-B2036 and B2036-G129R
fusion proteins having only one PRLR binding site and that they are unable to induce the
formation of a functional PRLR homodimer.
The Fusion Proteins Retain the Ability to Interact with PRLR
To confirm that G129R-B2036 and B2036-G129R still retain a functional PRLR
binding moiety we examined their effect on STAT5 phosphorylation using mouse Lcells. L-cells do not respond to hPRL and respond poorly but equally to hGH and
B2036-REV (Fig. 5.5A), indicating that they endogenously express low levels of mouse
GHR, but not PRLR. Treatment of L-cells with G129R-B2036 or B2036-G129R did not
result in STAT5 activation (not shown). However, transfection of the L-cells with human
PRLR enabled STAT5 activation in response to hPRL and enhanced STAT5 activation
induced by hGH but not by B2036-REV (Fig. 5.5A). In addition, a small but significant
activation of STAT5 was induced by B2036-G129R (Fig. 5.5B); however, it is unclear if
G129R-B2036 was able to activate STAT5 (Fig. 5.5B). Since G129R-B2036 is at best a
weak agonist we examined if it could antagonize hPRL-induced signaling via PRLRs.
Consistent with G129R-B2036 being a very weak agonist, at best, it behaved as an
antagonist at the concentrations examined (Fig. 5.5C); whereas, B2036-G129R, which
has weak agonism (Fig. 5.5B), was a poor antagonist (Fig. 5.5C).
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Fig. 5.4
Proliferation of rat Nb2 cells in response to monomers or fusions of
G129R and G120R or B2036 in comparison to hGH, hPRL, and B2036-REV
Rat Nb2 cells were treated for 72 h with various doses of the ligands indicated
above as described in Materials and Methods. Cell proliferation was assessed by
colorimetrically measuring the reduction of MTS. Each data point represents the mean ±
SD of at least three independent experiments performed in quadruplicate.
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These findings are consistent with our model of activation. The affinity of the
receptor binding sites within the N-terminal moiety and the C-terminal moiety of the
fusion proteins is not equal due to steric hindrance caused by the linkage of the two
ligands together. The potency of the fusion proteins at activating STAT5 appears to be
determined by the receptor binding site in its C-terminal moiety and the abundance of its
cognate receptor. In the L-cells stably transfected with the PRLR the levels of PRLR
were higher than GHR; therefore, the fusion protein with its PRLR binding moiety on the
C-terminus, B2036-G129R, was more potent at activating STAT5 than G129R-B2036.
The Fusion Proteins Induce STAT5 Signaling in Human Cells Co-Expressing PRLR
and GHR
Having confirmed that G129R-B2036 and B2036-G129R retain the ability to bind
a GHR and PRLR but are unable to induce the formation of functional PRLR or GHR
homodimers, we wanted to examine if they behave as agonists in human cells that
naturally express both the GHR and PRLR. Treatment of T-47D cells with various
concentrations of hPRL or hGH readily resulted in the phosphorylation of STAT5 (Fig.
5.5A). In contrast to hGH, a pure GHR agonist (B2036-REV) only slightly induced the
activation of STAT5 (Fig. 5.5A), suggesting that hGH mediates its effects primarily via
PRLRs in T-47D cells. The effects of hPRL could be completely blocked by a PRLR
antagonist (G129R) and a PRLR/GHR antagonist (G120R) but were not affected by a
pure GHR antagonist (B2036) (Fig. 5.5C). The effects of a pure GHR agonist (B2036REV) could be completely blocked by a pure GHR antagonist (B2036) and a PRLR/GHR
antagonist (G120R) but were not affected by a PRLR antagonist (G129R) (Fig. 5.6D).

180

A

CCL1.4
CCL1.4 PRLR
- PRL GH B2036-REV - PRL GH B2036-REV

p-STAT5
STAT5

B

nM:

PRL
0 10

(B2036-G129R)
0
5 50 500

(G129R-B2036)
0 5 50 500

PRL
- 5 nM

PRL :
PRL :
(G129R-B2036)
(B2036-G129R)
0 :50 :100 :150 :10 :50 :100 :150
1
:
1 1
1
1
1 1 1
1

p-STAT5
STAT5

C

p-STAT5
STAT5
Fig. 5.5
Fusions of B2036 and G129R retain the ability to bind PRLR as indicated
by the activation of or competitive inhibition of STAT5 signaling in L-cells transfected
with human PRLR
L-cells or L-cells transfected with human PRLR cells were plated as described in
Materials and Methods and incubated overnight. The cells were depleted for 3 h before
treatment for 30 min with 20 nM of the indicated ligands (A). L-cells transfected with
the PRLR were treated with increasing concentrations of the B2036 and G129R fusion
proteins in the absence of hPRL (B) or presence of hPRL (C). Cell lysates were
harvested and 80 μg of lysate from each treatment was separated by reducing SDS-PAGE
using 10% polyacrylamide gels and transferred to nitrocellulose membranes. The
membranes were probed with an antibody that recognizes tyrosine phosphosphorylated
STAT5A/B (p-STAT5). Equal loading was confirmed by reprobing the membranes with
anti-STAT5 antibody.
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These findings clearly indicate that T-47D cells express both PRLR and GHR.
In T-47D cells, monomers of the receptor antagonists (G129R, G120R and
B2036) did not induce STAT5 activation (Fig. 5.6B). When G129R and G120R were
linked in tandem, regardless of orientation, they equally and robustly induced the
activation of STAT5 (Fig. 5.7A). When G129R and B2036 were linked in tandem, they
differentially induced the activation of STAT5 (Fig. 5.7B). G120R-G129R and G129RG120R had similar potency to hPRL since both moieties can bind to PRLRs (Fig. 5.7A).
B2036-G129R, which has a single PRLR binding site in the C-terminal moiety, had
potency similar to that of hPRL (Fig. 5.7B); likewise, G129R-B2036 which has its GHR
binding site in the C-terminal moiety had potency similar to that of a pure GHR agonist,
B2036-REV (Fig. 5.7B).

These results suggest that the potency of each ligand

corresponds with the receptor binding site located in the C-terminal moiety of the fusion
protein and reflects the abundance of its cognate receptor. Since B2036-G129R has its
PRLR binding moiety on the C-terminus and PRLRs are more prevalent in T-47D cells, it
was more potent at activating STAT5 signaling than G129R-B2036.
Since G129R-B2036 has its GHR binding site in the C-terminal moiety, it would
be expected to be more potent at activating STAT5 when GHRs were more prevalent
than PRLRs. To create this scenario we transfected HEK293 cells with either PRLR or
GHR and initially examined there response to hPRL and B2036-REV (Fig. 5.8, A and B).
HEK293 cells endogenously express low levels of PRLR and even lower levels of GHR.
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Fig. 5.6
Western blot analysis of the phosphorylation status of STAT5 in T-47D
cells in response to PRLR and GHR agonists and antagonists
T-47D cells were plated as described in Materials and Methods and incubated
overnight. The cells were depleted for 3 h before treatment for 30 min with: (A)
increasing doses of agonists (hPRL, hGH, B2036-REV); (B) increasing doses of
antagonists (G129R, G120R, B2036-K120G); or 5 nM of (C) hPRL or (D) B2036-REV
in the absence or presence of increasing doses of a PRLR antagonist (G129R), a
PRLR/GHR antagonist (G120R), or a pure GHR antagonist (B2036). Cell lysates were
harvested and 80 μg of lysate from each treatment was separated by reducing SDS-PAGE
using 10% polyacrylamide gels and transferred to nitrocellulose membranes. The
membranes were probed with antibodies that recognize tyrosine phosphosphorylated
STAT5A/B (p-STAT5). Equal loading was confirmed by reprobing the membranes with
anti-STAT5 antibody.

183

A
nM:
p-STAT5

GH PRL
- 5 5

(G120R-G129R)
0
5 50 500

(G129R-G120R)
0
5 50 500

STAT5

B

B2036-REV PRL
5
5
nM: p-STAT5

(B2036-G129R)
0 5 50 500

(G129R-B2036)
0
5 50 500

STAT5
Fig. 5.7
Western blot analysis of the phosphorylation status of STAT5 in T-47D
cells in response to PRLR and GHR agonists and antagonist fusions
T-47D cells were plated as described in Materials and Methods and incubated
overnight. The cells were depleted for 3 h before treatment for 30 min with increasing
doses of fusions of G129R and G120R (A) or fusions of G129R and B2036 (B). Cell
lysates were harvested and 80 μg of lysate from each treatment was separated by
reducing SDS-PAGE using 10% polyacrylamide gels and transferred to nitrocellulose
membranes. The membranes were probed with an antibody that recognizes tyrosine
phosphosphorylated STAT5A/B (p-STAT5). Equal loading was confirmed by reprobing
the membranes with anti-STAT5 antibody.
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In the HEK293 PRLR cell line, STAT5 was activated more readily by hPRL than B2036REV (Fig. 5.8A) as observed in T-47D cells (Fig. 5.6A). In the HEK293 GHR cell line,
STAT5 was activated more robustly by B2036-REV than hPRL (Fig. 5.8B). We next
examined their responses to the B2036 and G129R fusion proteins (Fig. 5.8, C and D).
STAT5 was activated more robustly in the PRLR cell line by B2036-G129R than
G129R-B2036 (Fig. 5.8C) and was similar to the response seen in T-47D cells (Fig.
5.7B). In contrast to T-47D cells (Fig. 5.7B) and HEK293 PRLR cells (Fig. 5.8C),
STAT5 was activated as readily by G129R-B2036 as B2036-G129R in HEK293 GHR
cells (Fig. 5.8D). By increasing the level of GHR, the potency of G129R-B2036 at
activating STAT5 was increased.
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Fig. 5.8
Western blot analysis of the phosphorylation status of STAT5 in
transfected HEK293 cells in response to hPRL, B2036-REV, and fusions of a PRLR
antagonist (G129R) and GHR antagonist (B2036)
HEK293 cells transfected with PRLR or GHR were plated as described in
Materials and Methods and incubated overnight. The cells were depleted for 3 h before
treatment for 15 min with increasing doses of a PRLR agonist (hPRL) or GHR agonist
(B2036-REV (A and B); or fusions of B2036 and G129R (C and D). For each treatment
the cell lysate was harvested and STAT5 was immunoprecipitated from 500 μg of lysate.
Immunoprecipitate was separated by reducing SDS-PAGE using 10% polyacrylamide,
transferred to nitrocellulose membranes, and probed with an antibody that recognizes
tyrosine phosphosphorylated STAT5A/B (p-STAT5). Equal loading was confirmed by
reprobing the membranes with anti-STAT5 antibody.
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Discussion
hPRL (Keeler et al., 2003; Teilum et al., 2005), hGH (de Vos et al., 1992;
Chantalat et al., 1995; Clackson and Wells, 1995) and hPL (Walsh and Kossiakoff, 2006)
are structurally similar to one another. They have 190 to 199 amino acids; a folded
conformation of a four α-helix bundle; two disulfide bridges at homologous positions;
and two asymmetric receptor binding sites that provide receptor specificity. The two
binding sites of hPRL, hGH, and hPL can each interact with a PRLR to form a one ligand
two receptor complex; in addition, hGH can also interact with GHRs to form a one ligand
two receptor complex.
The PRLR and GHR are glycoproteins which belong to the type 1 cytokine
receptor family and are characterized as forming homodimers and as having no intrinsic
kinase activity. The long form of PRLR and GHR are similar in size and are composed
of 598 and 620 amino acids, respectively.

Topologically, each receptor has an N-

terminal extracellular domain that binds ligand, or in the absence of ligand, prevents the
formation of active receptor homodimers; a single-pass transmembrane/juxtamembrane
domain involved in membrane anchorage and dimer formation; and a C-terminal
intracellular domain involved in signal transduction.
Although the PRLR and GHR exhibit little overall sequence identity, they have
highly conserved sequences in both their extracellular and intracellular domains. The
tertiary structure of the extracellular domain of the PRLR (Ultsch and de Vos, 1993;
Kossiakoff et al., 1994; Somers et al., 1994) and GHR (de Vos et al., 1992; Kossiakoff et
al., 1994; Sundstrom et al., 1996) contain two fibronectin-like type III subdomains (S1
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and S2) (Thoreau et al., 1991; de Vos et al., 1992) which are connected via a hinge region
(de Vos et al., 1992). A portion of the N-terminal S1 domain, which is stabilized by four
positionally conserved Cys residues, and the hinge region are involved in ligand binding;
whereas, the membrane proximal S2 domain, which contains a Trp-Ser-X-Trp-Ser
(WSXWS) motif near its C-terminus, is thought to stabilize the ligand recognition site
(Somers et al., 1994). Much less is known about the structure of their cytoplasmic
domain. At the membrane proximal region of these receptors there is a conserved Box 1
motif which is the binding site for the intracellular non-receptor tyrosine kinase, JAK2,
which is proceeded by a Box 2 motif.
Evidence suggests that the PRLR (Gadd and Clevenger, 2006) and GHR (Gent et
al., 2002; Brown et al., 2005; Waters et al., 2006) exist as preformed homodimers and
that ligand binding occurs sequentially with the higher affinity binding Site 1 interacting
with the first receptor before the lower affinity binding Site 2 interacts with the second
receptor. Due the asymmetric nature of the receptor binding sites, minor alterations in
the conformation of the second receptor are necessary (Mellado et al., 1997; Clackson et
al., 1998; Kossiakoff, 2004).

These ligand-induced alterations lead to the optimal

alignment and binding of the extracellular receptor dimerization domain residues
(Behncken et al., 2000) and lead to a rotation in the transmembrane domain that bring
cytoplasmic receptor-associated JAK2 molecules into close proximity, allowing their
kinase domains to transphosphorylate each other.

Activated JAK2 catalyzes the

phosphorylation of the receptors and receptor-associated proteins and can lead to: STAT
1, 3, and 5 signaling; phosphoinositide 3-kinase/3-phosphoinositide-dependent protein
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kinase 1/Akt signaling; Ras/Raf/mitogen-activated protein kinase (MAPK) kinase/MAPK
signaling by interacting with the SHC/Grb2/SOS complex; and protein kinase C/MAPK
signaling by activating phospholipase C-gamma.
In ruminants it has been demonstrated that PL can interact with a GHR via
binding Site 1 and a PRLR via binding Site 2 leading to the stimulation of JAK2/STAT5
signaling (Biener et al., 2003; Gertler et al., 2005). There is no evidence that a PRLR can
heterodimerize with a GHR in humans; however, the structural similarity between the
PRLR and GHR and the ability of hGH to homodimerize PRLRs or GHRs raises some
interesting questions.

Can a functional PRLR and GHR heterodimer be formed in

humans? If so, what ligand(s) would induce the formation of a functional heterodimer?
In what tissue would this heterodimer occur? And would the receptor heterodimers have
any physiological or pathological relevance in humans?
In this study we provide evidence that a PRLR and GHR can heterodimerize and
transduce STAT5 signaling in human cells. To do this we designed novel fusion proteins
using well characterized receptor antagonists (G129R, G120R and B2036) which retain a
single functional PRLR and/or GHR binding Site 1 (Fig. 5.9).

Previously, we

demonstrated that fusions of two PRLR antagonists together (G129R-G129R) or
PRLR/GHR antagonists together (G120R-G120R) were able to activate STAT5 signaling
via PRLRs (Langenheim et al., 2006) and that G120R-G120R also induced STAT5
signaling via GHRs (Yang et al., 2007). In this study we demonstrate that fusions of
G129R and G120R in either orientation (G129R-G120R and G120R-G129R) are able to
activate STAT5 signaling (Fig. 5.7A) and induce cell proliferation (Fig. 5.4B).
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Fig. 5.9
Illustration of the binding of G129R, B2036, or fusions of the two in
tandem to homodimers or heterodimers of PRLR and GHR
(A) G129R can only bind to one PRLR and B2036 to one GHR due to the
substitution of a Gly residue in helix 3 (X), preventing functional receptor dimerization
and activation of signal transduction from occuring. Fusion of the two antagonists in
tandem (G129R-B2036 or B2036-G129R) results in a ligand with one PRLR and one
GHR binding site. (B) In a pure PRLR or GHR signaling system, G129R-B2036 and
B2036-G129R behave as antagonists because they are unable to find a second receptor to
partner with; in a heterologous signaling system, they can dimerize a PRLR and GHR via
the two functional binding Site 1s (composed of helix 1 and 4) leading to signal
transduction.
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Table 5.1 Effect of hGH and hPRL analogs on receptor dimers

PRLR
Homodimer

GHR
Homodimer

PRLR/GHR
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xxx

xxx

xxx

-
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xxx

xxx

-
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+++
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GH and PRL Analogs
Antagonists
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B2036 (Somavert)
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G129R-G129R(2)
G120R-G120R

(2,3)

++

x

nd
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(1)
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x

++
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(1)

xx
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+

+ Behaves as receptor agonist.
x Behaves as receptor antagonist.
- Does not bind receptor.
nd Behavior towards receptor not determined.
+ Unique profile of receptor agonistic activity.

(1)

Characterized in this study.
Characterized by Langenheim et al., 2006.
(3)
Characterized by Yang et al., 2007.
(2)
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However, since G120R is able to bind a PRLR or GHR, it was impossible to differentiate
if G129R-G120R and G120R-G129R mediated their effects via PRLR homodimers or a
PRLR and GHR heterodimer.
To overcome this problem we used a pure GHR antagonist, B2036, which
combines an amino acid substitution at position 120 of hGH (Fuh et al., 1992) with an
additional eight amino acid substitutions to reduce the affinity of binding Site 1 towards
the PRLR (Goffin et al., 1999) without negatively affecting its affinity towards the GHR
(Maamra et al., 1999). Thus, fusion of B2036 and G129R resulted in two novel ligands
(G129R-B2036 and B2036-G129R) which retain a single functional PRLR binding site
and a single functional GHR binding site. These ligands provided the molecular tools
necessary to address the simple question: can a functional PRLR and GHR heterodimer
be formed in human tissues?
By examining the response to receptor agonists (hPRL, hGH, and B2036-REV) in
the absence or presence of receptor antagonists (G129R, G120R, B2036) we were able to
determine that IM-9 cells can be stimulated via GHRs (Fig. 5.2A and 5.3A), Nb2 cells
via PRLRs (Fig. 5.4A), and T-47D cells via PRLRs or GHRs (Fig. 5.6, A, C and D). As
monomers, the receptor antagonists did not exhibit any significant agonistic effects in
IM-9 cells (Fig. 5.2B), Nb2 cells (Fig. 5.4A) or T-47D cells (Fig. 5.6B). Linkage of a
PRLR antagonist (G129R) to a PRLR/GHR antagonist (G120R) resulted in a ligand
capable of inducing proliferation in a PRLR system (Fig. 5.4B) but unable to induce
STAT5 signaling in a GHR system (Fig. 5.2C). Linkage of a PRLR antagonist (G129R)
to a pure GHR antagonist (B2036) resulted in ligands (G129R-B2036 and B2036-
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G129R) which no longer were capable of inducing proliferation in a PRLR system (Fig.
5.4B) and did not activate STAT5 in a GHR system (Fig. 5.2D), suggesting that these
ligands are inactive in pure receptor systems.
Although the fusions of G129R and B2036 could not activate receptor
homodimers, the ligands retained the ability to bind to GHRs on IM-9 cells (Fig. 5.3C) or
PRLRs on transfected L-cells (Fig. 5.5C) as indicated by their ability to competitively
inhibit GHR and PRLR mediated signal transduction, respectively. More importantly,
the fusions of G129R and B2036 behaved as agonists when examined in T-47D cells
(Fig. 5.7B) and transfected HEK293 cells expressing both PRLR and GHR (Fig. 5.8, C
and D). Since these ligands behaved as antagonists in cells predominantly expressing
either GHR or PRLR, it is concluded that these novel ligands elicit STAT5 activation via
the formation of a functional PRLR and GHR heterodimer.
When the novel fusion proteins were designed it was assumed that the affinities of
each moiety would differ depending upon their location in the fusion protein. Based
upon rudimentary 3D models of the fusion proteins, it was predicted that the moiety on
the C-terminus would have higher affinity than the moiety on the N-terminus due to steric
hindrance, and that binding might occur sequentially with the higher affinity C-terminal
moiety interacting with its cognate receptor before the lower affinity N-terminal moiety
interacted with its cognate receptor. G129R-B2036 was expected to sequentially bind to
a GHR followed by a PRLR and B2036-G129R was expected to sequentially bind to a
PRLR followed by a GHR. In agreement with the two receptor binding sites having
different affinities, a bell-shaped pattern for STAT5 activity in response to increasing
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doses of the B2036-G129R and G129R-B2036 was observed in the transfected HEK293
cells (Fig. 5.8, C and D). It was also observed that B2036-G129R was a better agonist in
cell lines that expressed higher levels of PRLR than GHR (Fig. 5.7B and 5.8C). We also
expected that the agonistic activity of G129R-B2036 could be improved by elevating the
level of GHR (Fig. 5.8C versus 5.8D). It is interesting to point out that there was
remarkable improvement in terms of the potency of G129R-B2036 in the STAT5 assay;
however, a better activation by G129R-B2036 than B2036-G129R in GHR transfected
cells was never achieved (Fig. 5.8D), even when GHR levels were in excess of PRLRs.
It was not taken into consideration that receptor heterodimers formed in the
absence of ligand might differ fundamentally from receptor homodimers. In the absence
of ligand, the interactions between the extracellular domains of PRLR homodimers and
GHR homodimers are likely to be symmetrical in nature; whereas, PRLR/GHR
heterodimers are more likely to be asymmetrical.

Also, it was not taken into

consideration that the flexibility of the extracellular domains of the PRLR and GHR may
differ. In Chapter 4, we demonstrated that the PRLR in addition to being promiscuous is
quite flexible and can readily accommodate dimeric forms of ligand, such as G129RG129R. The asymmetry in preexisting PRLR/GHR heterodimers and the variability in
receptor flexibility may favor the initial binding to one receptor (likely the PRLR) over
that of another, which can explain the potency difference between G129R-B2036 and
B2036-G129R.

B2036-G129R would be a better agonist of human PRLR/GHR

heterodimers because its PRLR binding moiety is fully accessible on the C-terminus. On
the other hand, G129R-B2036 would not be a better agonist than B2036-G129R, even
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when GHR levels were elevated, because it’s PRLR binding moiety on the N-terminus is
sterically hindered, reducing its ability to initially interact with a PRLR.
In summary, we have created novel ligands and demonstrated that they only
activate a PRLR and GHR heterodimer (Table 5.1). B2036-G129R was a superior
agonist of PRLR/GHR heterodimers (Figs. 5.5B and 5.7B, and Fig. 5.8, C and D);
whereas, G129R-B2036 was a weaker agonist of PRLR/GHR heterodimers (Fig. 5.7B
and Fig. 5.8, C and D) and exhibited strong antagonism towards PRLR (Fig. 5.5C) and
GHR homodimers (Fig. 5.3C). Using these ligands we have provided evidence that a
functional PRLR and GHR heterodimer either preexists or can be formed in response to
ligands in humans, resulting in STAT5 activation. In addition, B2036-REV was created
which unlike hGH does not readily activate PRLR homodimers. These novel ligands
provide the molecular tools to differentiate signaling events induced via PRLR and GHR
homodimers or heterodimers in human tissue.
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CHAPTER SIX
CONCLUSIONS
In this dissertation, the following conclusions can be drawn from the experiments.
From the experimental results presented in Chapter 2, we conclude that the G129RPE40KDEL fusion toxin drastically increased the cytotoxicity of G129R; however, it was
not nearly as potent as we anticipated. Nevertheless, the cytotoxicity was abolished by
anti-PE, could be blocked by hPRL or G129R, and was only observed in human breast
cancer cell lines expressing PRLR. We were unaware of it at the time, but hPL had been
fused to both diphtheria fragment A and the ricin A-beta subunit. The diphtheria based
fusion protein was non-functional and the ricin A based fusion protein only worked at
high concentrations. Since hPRL and hPL are similar in structure and both bind to the
PRLR, we believe that the reduced toxicity is likely a problem with endocytosis.
From the experimental results presented in Chapter 3, we conclude that the fusion
of the serum albumin binding peptide (SA20) to the ligands extended their serum half-life
as expected. Furthermore, fusion of SA20 to the N-terminus of hGH and hPRL was
superior to fusion to their C-terminus. SA20-hGH and SA20-hPRL were superior to
hGH and hPRL at inducing lobulo-alveolar development, respectively. It should also be
noted that these proteins are amendable to slow-releasing formulations since the serum
albumin binding peptide is only twenty amino acids in length.
From the experimental results presented in Chapter 4, we conclude that the
intrinsic activity of PRL-PRL and GH-GH are unaffected and that the plasma half-life of PRLPRL was extended. Surprisingly, G129R-G129R and G120R-G120R exhibited agonistic
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activity. By making a series of trunctations in G129R-G129R we were able to show that
binding Site 1 within each moiety was responsible for receptor homodimerization and
activation. This indicates that PRL-PRL and GH-GH can activate PRLRs in three different
manners (Site1 and Site2 of the 1st moiety; Site 1 and Site 2 of the 2nd moiety; and the Site 1s
from each moiety). For this reason we believe that the PRL-PRL and GH-GH molecules will
be more amendable to chemical modifcations such as HESylation and PEGylation.
From the experimental results presented in Chapter 5, we conclude that that there
are functional PRLR/GHR heterodimers in humans.

These results were obtained by

extending the findings of Chapter 4 (i.e. that the fusion of two antagonists together results in an
agonist). We believe that hGH is capable of binding to receptor heterodimers. Also we were
able to make a pure GH agonist which will be quite useful for studying how hGH mediates its
effects. We have examined different cell lines that respond to hGH and found that the effects
are mediated almost completely through PRLRs in many breast cancer cell lines. This may
indicate that hGHs effects are primarily mediated via PRLRs in breast cancer.
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